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I. Introduction 
 
1. Pathogenesis of atherosclerosis  
Atherosclerosis is one of the main causes of death in Western societies and may well 
account for over 50% of the mortalities in the UK and USA which may affect about 500 
individuals/day or 170,000 annually. 
Atherosclerosis is a multifactorial process which goes along with the formation of 
atherosclerotic lesions isolated in large and medium-sized arteries, the brain, the heart and 
the legs. The atherogenic process starts at an early age with the deposition in blood-vessel 
walls of lipids such as cholesterol, derived from lipoproteins circulating in the bloodstreams, 
which leads to the formation of the characteristic “fatty streaks”, the earliest lesion in the 
atherosclerotic process. Over time and with continued irritation these streaks progress into 
protruding and more complicated lesions containing an accumulation of lipids and necrotic 
cells (1). Fatty streaks consist mainly of macrophage foam cells that have taken up massive 
amounts of cholesterol. The formation of fatty streaks is initiated by the adherence of 
circulating monocytes to activated endothelial cells at lesion-prone sites within large arteries. 
Adherent monocytes subsequently migrate into the subendothelial space in response to 
locally produced chemoattractant molecules, where they further differentiate into 
macrophages and develop into foam cells by lipid uptake (Fig.1). The lipid taken up by 
macrophages is believed to originate predominantly from oxidized low density lipoproteins 
(Ox-LDL) (2). Myocardial infarctions occur frequently as a result of plaque rupture, a late-
stage complication seen in vulnerable plaques. These plaques are characterized by large, 
necrotic, highly thrombogenic lipid cores with a high content of lipid and necrotic debris. A 
thin fibrous cap contains increased numbers of macrophages and T lymphocytes in shoulder 
regions where plaque rupture clinically occurs (3). Evidence suggests that matrix 
metalloproteinases (MMPs) contribute to plaque destabilization by degrading the matrix in 
the fibrous cap, thus contributing to the weakness and ultimate rupture of the plaque (4). 
Mechanical forces are also thought to be involved. The MMPs are a large, complex, highly 
regulated family of matrix (collagen)-degrading enzymes produced by vascular smooth 
muscle cells (VSMCs) and macrophages (1). An alternative mechanism contributing to lesion 
formation is that of superficial erosion of the endothelium (5).  
As a result of atherogenesis, thrombosis, coronary heart disease, myocardial infarct and 
stroke may occur. Surgical treatment is sometimes effective, but there is no specific cure. A 
low-cholesterol diet combined with cholesterol synthesis and absorption inhibitors as well as 
control of predisposing factors, such as hypertension, smoking, diabetes and obesity, are 
usually recommended. 
 
Introduction 
 
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Glass C. and Witztum J. Atherosclerosis: The Road Ahead; Cell, Vol. 104, 503-516, Feb. 23, 2001 
Fig. 1: Role of lipoproteins and monocytes/macrophages in lesion formation and progression 
Monocytes attach to endothelial cells that have been induced to express cell adhesion molecules by 
mmLDL and inflammatory cytokines. Adherent monocytes migrate into the subendothelial space and 
differentiate into macrophages. Uptake of Ox-LDL via scavenger receptors leads to foam cell 
formation. Ox-LDL cholesterol taken up by scavenger receptors is subject to esterification and storage 
in lipid droplets, is converted to more soluble forms or is exported to extracellular HDL acceptors via 
cholesterol transporters, such as ABCA1. 
 
1.1. Response to injury hypothesis 
The modified response to injury hypothesis of atherosclerosis emphasizes endothelial 
dysfunction rather than denudation as the first step in atherosclerosis (2). This hypothesis 
stated that the endothelium helped to regulate homeostasis of the cardiovascular system. 
This was supported by the fact that an intact endothelium is capable of releasing 
antithrombic and fibrinolytic factors in addition to the potent vasodilator nitric oxide. In normal 
blood vessels, nitric oxide and acetylcholine induce vasodilatation, but with endothelial 
damage, disruption of cell state negates normal function and the actions of potent 
vasodilators. The damaged endothelium causes abnormal responses from acetylcholine by 
increasing the production of vasoconstricting agents such as thromboxane A2 and 
prostaglandins. In addition to eliciting the development of abnormal intracellular signalling 
mechanisms which augment an increase of intracellular Ca2+ and endothelin-derived 
vasoconstricting factors. Endothelial damage also triggers platelets to adhere and aggregate 
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at the site of the damage, this enhances monocytes to enter the tunica intima, and induces 
SMC-proliferation within the tunica-media junction of the artery. This effect causes the 
arterial wall to be injured at this site. With increased monocyte invasion into arteries, and 
continual lesion development and fibrosis the lumen of the artery can become progressively 
reduced. This combination of biochemical and anatomical alterations contributes to oxidative 
stress and increased vascular damage; the so-called precursors for atherogenic changes 
within arteries.  
 
1.2. Response to retention hypothesis 
This hypothesis proposes that the retention and modification of atherogenic lipoproteins in 
the arterial lining is one of the initiating events that triggers the inflammatory response (6). 
The atherogenic apolipoprotein B100 (apoB100)-containing lipoproteins enter the 
subendothelial space and are bound and retained through ionic interactions between 
positively charged residues on the atherogenic lipoproteins, and negatively charged residues 
in the extracellular matrix molecules. Of these extracellular matrix components, 
proteoglycans in particular appear to play an important role. Proteoglycans are 
macromolecules composed of a core protein and complex, long-side-chain carbohydrates, 
called glycosaminoglycans (GAGs), which consist of repeating disaccharide units, all bearing 
negatively charged, usually sulphate or carboxylate, groups (7). The interaction between LDL 
and proteoglycans involves positively charged amino acids arginine and lysine in apoB100, 
the protein moiety of LDL, that bind ionically with the negatively charged GAGs of the 
proteoglycans (8). 
The consequence of the retention of atherogenic lipoproteins is not only a net accumulation 
of lipid, but also prolonged exposure to local oxidants and other non-oxidative enzymes in 
the vessel wall resulting in a variety of modified lipoproteins and their constituents which 
trigger an inflammatory reaction that accelerates lesion development (6) 
 
2. Cellular constituents of atherosclerosis 
The pathobiology of atherosclerosis may be determined by numerous cellular entities 
involved in the atherosclerotic process. These cells can be broadly organized into structural 
elements of the arterial wall, inflammatory cells that enter the arterial wall and circulating 
elements (e.g., platelets, leukocytes) (3). Vascular cells with important, well-defined roles in 
atherosclerosis include the endothelial cell and the VSMC (1). Endothelial responses include 
the induction of adhesion molecules, a decisive step early in atherogenesis and the change 
in the production of nitric oxide, a critical, short lived molecule that helps to maintain normal 
endothelial reactivity while limiting thrombosis and inflammation (9). 
The VSMCs are integral to many processes implicated in normal vessel function as well as to 
atherosclerosis and hypertension (10). Atherosclerosis can be characterized by the migration 
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of VSMCs from the media to the intima and their subsequent proliferation in this location 
(11). Also, VSMCs provide the main source for the extracellular matrix, which forms the 
fibrous cap overlying the lipid core atherosclerotic plaques (1). In this role, VSMCs provide 
an essential function, albeit a reaction to a pathologic state. 
Inflammatory cells, including monocytes, macrophages, and lymphocytes (predominantly T 
cells), are critical to the development of atherosclerosis (2). Circulating monocytes and 
lymphocytes are attracted to arterial sites of endothelial injury by the stimulation of 
chemoattractant cytokines (chemokines), a large, complex family of small proteins that signal 
through specific chemokine receptors on the surface of inflammatory cells (12).  Endothelial 
adhesion molecules-including vascular cell adhesion molecule-1 (VCAM-1), intracellular 
adhesion molecule-1 (ICAM-1), P-selectin and E-secletin (13-18), have specific roles leading 
to rolling, firm adhesion, and ultimate entry of these cells into the arterial wall (19) (Fig.1). 
These adhesion molecules and also monocyte chemoattractant protein (MCP-1), interleukin-
1 (IL-1) and tumor necrosis factor-alpha (TNFa) as well as degraded collagens and elastins 
(2) are highly up-regulated by the elevation of the levels of atherogenic lipoproteins (Ox-LDL 
and Lp(a)) and cytokines in vitro (5;13).  
Among all the mediators reported thus far, MCP-1 and Lysophosphatidylcholine (a 
component of Ox-LDL) may be the most important and are the best characterized 
chemoattractants in the lesions (20).  
Macrophages appear at a very early stage in the development of atherosclerotic lesions and 
persist throughout their evolution, indicating a pivotal role for these cells in the disease 
process. T lymphocytes also provide important signals to the process. For example, T-cell-
derived inflammatory cytokines are thought to contribute to monocyte, VSMC, and 
endothelial cell activation (21-23). 
 
2.1. Differential expression of the monocyte innate immunity receptor complex 
defining monocyte subpopulations 
Following adherence to endothelial cells, defined subpopulations of circulating monocytes 
that express the lipopolysaccharide (LPS) receptor CD14, the Fcg-receptor IIa/CD32 and the 
Fcg-receptor IIIa/CD16a (CD14bright CD16+) might extravasate into the subendothelial space 
(24-26). 
In normal subjects, five different subpopulations of blood monocytes have been discriminated 
by cell expression densities of various antigens involved in extravasation, uptake of 
atherogenic lipoproteins, differentiation and inflammation. The Fcg receptors (FcgRs), in 
particular CD16a/FcgRIII, together with the LPS receptor CD14, appear to be key players in 
defining monocyte subpopulations. Their heterogeneous expression suggested a different 
capacity for IgG-dependent phagocytosis (24). The pool size of CD14dim CD16+ monocytes 
Introduction 
 
 5 
correlates with plasma lipids and lipoprotein metabolism as well as inflammation and the 
acute phase reaction stressing a link between peripheral blood monocyte heterogeneity and 
cardiovascular risk factors (27). Monocytic CD14 expression is reduced in systemic 
inflammation (28) and an atherogenic lipoprotein profile is associated with an expansion of a 
more differentiated monocyte subpopulation with a lower expression of CD14 and Fcg-
RIIIa/CD16a (24;26). Moreover, a functional genetic polymorphism of CD14 is associated 
with myocardial infarction (29), suggesting a role of CD14 in inflammation and atherogenesis. 
As described by Pfeiffer et. al. (30) results the binding of lipopolysaccharide and ceramide, a 
constituent of atherogenic lipoproteins in ligand-specific receptor clustering in rafts (detergent 
resistant membrane microdomains). Lipid rafts on monocytes/macrophages provide a 
dynamic microenvironment for an integrated CD14-dependent clustering of a set of receptors 
involved in innate immunity and clearance of atherogenic lipoproteins (31). In resting cells, 
CD14 was associated with CD55, the Fcg-receptors FcgRIIA/CD32 and FcgRI/CD64 and the 
pentaspan CD47. Cer further recruited the complement receptor 3 (CD11b/CD18) and the 
scavenger receptor CD36 into proximity of CD14. LPS, in addition, induced co-clustering with 
Toll-like receptor 4, Fcg-RIIIa/CD16a and the tetraspanin CD81 while CD47 was dissociated 
(Fig.2). Thus clustering of signalling competent receptors to a common recognition platform 
in rafts may provide an interesting mechanism by which different ligands induce distinct 
cellular processes in systemic inflammation (SIRS or sepsis) and cardiovascular disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: The innate immunity receptor complexes in inflammation and cardiovascular disease 
The basic cluster includes specific and non-specific opsonin recognition sites (ex vivo, control) 
whereas ligand induced clustering is dependent of ligand surface composition (LPS/LTA or  
ceramide/HSP70) and atherogenic LDL 
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2.2. Foam-cell formation 
After monocytes bind to the surface of the arterial wall, they migrate into the subendothelial 
space, where they differentiate to macrophages and are transformed by lipid uptake into 
foam cells (Fig.1). They are called foam cells because, by light microscopy, the lipid deposits 
make the cells look foamy. Low density lipoproteins which have become modified are the 
major source of lipid for foam cell formation. These altered lipoproteins are taken up into the 
cell via receptor-mediated endocytosis and delivered to lysosomes. The cholesterol 
accumulating in foam cells is known to be ultimately derived from circulating plasma 
lipoproteins. However, incubation of neither monocytes and macrophages nor arterial smooth 
muscle cells with native LDL, even at very high concentrations, increases their cellular 
cholesterol content substantially (32;33). These cells, like other cells, protect themselves 
against cholesterol overloading by decreasing the number of LDL receptors on their surface 
when overloaded with cholesterol (34). Therefore LDL must be somehow modified before it 
can induce foam-cell formation (33) and the binding and internalization of these modified 
lipoproteins are mediated by receptors, principally scavenger receptors, on macrophages 
(35). Unlike the LDL receptor, scavenger receptors are not significantly down-regulated and 
they potentially can produce large amounts of cholesterol accumulation. Among the possible 
candidate scavenger receptors involved in atherosclerosis, CD36 is currently a leading 
candidate (36). Chemical modifications that induce uptake by scavenger receptors and other 
poorly regulated receptors include acetylation and oxidation of LDL (37). The resulting 
cholesterol–filled “foam cell” macrophages are a characteristic feature of atherosclerotic 
lesions and contribute to lesion development in a number of ways. The large cholesterol-rich 
core of advanced lesions appears to be substantially derived from necrosis and/or apoptosis 
of foam cells (38) and cholesterol enrichment of macrophages also affects the expression 
and secretion of several proteins and enzymes (39). Foam cells also contain small but 
significant amounts of various lipid oxidation products, which are potent mediators of 
macrophage function. 
 
3. Cholesterol Transport 
 
3.1. Cholesterol efflux from macrophages to prevent foam cell formation  
When cholesterol acceptors such as high density lipoprotein (HDL) are present, cholesterol 
efflux from macrophages is accelerated, which prevents foam cell formation. To produce this 
efflux, neutral cholesteryl ester hydrolase catalyzes the intracellular hydrolysis of cholesteryl 
esters (CE) into free cholesterol in the lysosome. The mobilization of cholesterol from late 
endosomes and lysosomes requires functional Niemann-Pick type C 1 (NPC1) and NPC2 
proteins, originally identified as an important secreted protein from human epididymis (HE1) 
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(40). Excess free cholesterol is esterified by acyl-coenzyme A:cholesterol acyltransferase 1 
(ACAT1,SOAT), an enzyme that localizes to the ER to form CE which are stored in cytosolic  
lipid droplets. Free cholesterol respectively unesterified cholesterol/phospholipids complexes 
(UC/PL) are transported via the ATP-binding cassette transporters (ABCs) ABCA1 and 
ABCG1 through cell membranes and are accepted on the membranes by apolipoprotein A-I  
(apoA-I), which generates preb (nascent)-HDL particles (Fig.3). In humans and mice, apoA-I 
is produced primarily in the liver and intestine. Extracellular sources of apoA-I have been 
shown to increase cholesterol efflux from macrophages in vitro,(41) and the presence of 
apoA-I in the extracellular space is considered to be necessary for the activation of 
cholesterol efflux through the ABCA1 pathway (23). The Rho family GTPase Cdc42 directly 
interacts with ABCA1 to control filopodia formation, actin organization and intracellular lipid 
transport (Fig.3) (42;43). Also vesicular transport processes involving different interactive 
proteins like β-2 syntrophin are involved in cellular lipid homeostasis controlled by ABCA1 
(44) (Fig.3). It could be shown by Drobnik et al. (45) that ABCA1 and Cdc42 were partially 
localized in Lubrol- but not in Triton-X (TX) detergent resistant membrane microdomains 
(rafts) and that apoA-I preferentially depleted UC/PL from Lubrol rafts, whereas HDL3 
additionally decreased the cholesterol content of TX rafts (Fig.3).  
Mutations in the ABCA1 transporter gene cause a disorder of cholesterol efflux known as 
Tangier disease (TD), a familial HDL deficiency syndrome, which leads to the development 
of either coronary artery disease or splenomegaly dependent on ABCA1 mutations (46).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: ABCA1 a regulator of lipid rafts, vesicular transport and filipodia formation 
GIRK3
apoAI
apoAI
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3.2. Further cholesterol transport candidates 
NPC1 and 2 are involved in the exit of cholesterol and/or other lipids from the endosomal or 
lysosomal membranes. NPC1 may function as a permease to allow phospholipids and 
cholesterol to exit the endosomal system. This activity may depend on NPC2 wich may 
function as a chaperone for sterol insertion into the endosomal/lysosomal membrane by 
acting as a bridge to allow free cholesterol, released from its fatty-acid moiety by the action 
of lysosomal acid lipase, to insert into the inner membrane of the organelle (Fig.4). MLN64, a 
protein which was initially identified as an upregulated transcript in malignant cells has been 
colocalized with NPC1 in the membrane of the late endosome, indicating that it might play a 
role in cholesterol egress together with NPC1. MLN64 however could also act independently 
of NPC1 to facilitate shuttling of cholesterol between the endosomal membrane and an 
acceptor (47). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Cholesterol binding and transport proteins  
NPC1, MLN64 and NPC2 reside in the endosomal-ysosomal system.  
(MLN64, malignancy antigen 64; NPC1 and 2, Niemann-Pick disease Type C 1 and 2) 
(figure from Ioannou 2001(47)) 
 
 
3.3. Niemann-Pick Disease Type C- a cholesterol storage disease 
Niemann-Pick Disease Type C (NPC) is caused by mutations in the NPC1 or NPC2 gene. 
NPC is a rare autosomal-recessive lipidosis, characterized by the accumulation of 
unesterified cholesterol in late endosomes, lysosomes and the Golgi apparatus (48;49). 
Further cholesterol relocation to and from the plasma membrane is delayed. Patients show 
progressive neurodegeneration and hepatosplenomegaly, which leads to death during early 
childhood. Although it has been assumed that NPC is primarily a cholesterol-storage 
disorder, sphingolipids like lactosylceramide (LacCer) or globotriaosylceramide (Gb3Cer) also 
accumulate to similar degrees in peripheral organs (Fig.5) (50). 
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Fig. 5: Model for altered sorting in NPC 
In the normal state (left picture) LacCer is transported to the trans-Golgi network (TGN) following by 
exocytosis to the plasma membrane. 
In the diseased state (right picture) LacCer is predominantly transported to the lysosome where it 
accumulates.  
(Abbreviations: ER, endoplasmatic reticulum; LE/SE, late or sorting endosome) 
(figure from Sillence, Platt 2003(50)) 
 
 
4. Role of lipoproteins in the development of atherosclerosis 
Lipids are transported between the intestine, liver and periphery in soluble complexes 
defined as lipoproteins. These circulate as spherical lipoprotein particles and comprise a core 
of neutral lipids, such as cholesteryl esters (CE) and triglycerides, and a surface shell of 
polar phospholipids, cholesterol, other polar lipids and apolipoproteins (apos). Apos are 
specific lipid-binding proteins that are integral constituents or attach to the surface of the 
particle, to stabilize it and to function as ligands for cell membrane receptors or as enzyme 
activators. Lipoproteins can be separated by density centrifugation and electropheretic 
mobility. The largest and least dense lipoproteins, those that contain the most lipid relative to 
protein, are the chylomicrons (d=<0.96g/ml). In order of increasing density because of 
escalating percent protein composition and smaller particle size, are the other major 
lipoproteins: very low density lipoprotein (VLDL) (d=0.96-1.006g/ml), low density lipoprotein 
(LDL) (d=1.019-1.063), and high density lipoprotein (HDL) (d=1.063-1.210). In addition, there 
are subfractions of these major classes of lipoproteins, for example, intermediate density 
lipoproteins (IDL), which lie between VLDL and LDL in density (d=1.006-1.019). 
Chylomicrons and VLDL carry the greatest proportion of their lipid as triacylglycerol, while CE 
is the lipid in highest concentration in LDL. Relative to other lipoproteins, HDL carry the least 
percentage of lipid as triacylglycerol, but is rich in CE and phospholipid.  
After the uptake of various lipoproteins by macrophages through various routes of 
endocytosis, most of the lipoproteins are finally transported into lysosomes, digested therein 
and degraded into amino acids and free cholesterol. Within late endosomes and lysosomes, 
NPC1+/+ NPC1-/-
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CE is hydrolyzed by acid lipase (CE hydrolase) into free cholesterol, which is released into 
the cytosol and further into the extracellular space. 
 
4.1. Chylomicrons 
These are large particles composed mainly of triglyceride, synthesised in the small intestinal 
mucosa and transported from dietary fat. Chylomicrons contain phospholipid, cholesterol, 
apos, for example apoB48, apoA-I, apoA-I, C-apolipoproteins (C-I, C-II, C-III) and apoE. The 
presence of apoC-II surface protein activates the capillary endothelial enzyme lipoprotein 
lipase that is responsible for the conversion of chylomicrons into chylomicron remnants and 
VLDL into IDL and to deliver fatty acids and cholesterol to peripheral cells. Both of these 
products circulate in peripheral tissues to be later absorbed by hepatic apoB and apoE 
receptors. 
 
4.2. VLDL 
VLDLs are the products of endogenous triglyceride synthesis within the liver. A major 
function of this lipoprotein is to transport endogenously synthesized triacylglycerol from the 
liver to extrahepatic tissues. They contain the apoB100 and apoE proteins which are 
catabolised by lipoprotein lipase within peripheral tissues. VLDL upon reaching capillaries of 
adipose tissue or muscle extract the triglyceride units leaving enriched CE with two 
apoprotein units. VLDL are broken down with small apos and transferred to HDL which 
produce smaller fragments or IDL. The VLDL pathway, including its metabolism to IDL and 
LDL, is the endogenous pathway of triacylglycerol and CE transport. 
 
4.3. IDL 
As triacylglycerol molecules are lost from the VLDL particle, apoC-II and apoE are 
transferred back to HDL. This results in formation of an IDL that contains apoB100 and some 
remaining apoE. IDL, like HDL and chylomicron remnants can be cleared by the apoE 
receptor on liver. Genetic defects in the apoE ligand or its receptor elicit Type III 
hyperlipidemia, in which IDL, as well as chylomicron remnants and HDL, are elevated. 
Further hydrolysis of triacylglycerol in IDL by lipoprotein lipase and transfer of the remaining 
apoE to HDL results in formation of LDL.  
 
4.4. LDL 
LDL is the major cholesterol carrying lipoprotein in normal plasma. It has been shown that 
the higher the concentration of LDL, the higher the risk of developing atherosclerosis. (51). 
LDL is composed of a core of 1500 molecules of cholesterol enclosed in layers of 
phospholipid and unesterified cholesterol molecules. CE in LDL may originate from 
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cholesterol directly synthesized by the liver (endogenous pathway), or indirectly from the diet 
via the clearance of chylomicron remnants by the liver (exogenous pathway). The hydrophilic 
portions of the molecule are arranged on the outside which allows LDL to dissolve in blood or 
extracellular fluid. ApoB-100 is embedded in this hydrophilic layer. This protein is recognised 
and binds to the LDL receptor, a transmembrane glycoprotein, which spans the full thickness 
of cell’s plasma membrane in clusters within specialised regions referred to as “clathrin 
coated pits”. These pits pinch inward to allow LDL to be carried into the cell, a process called 
receptor mediated endocytosis. Endocytosed vesicles containing LDL rapidly lose clathrin 
and fuse with a vesicle that has an internal pH of about 5.0, to form a sorting endosome. The 
acidity induces LDL to dissociate from its receptor. LDL and its CE accumulate inside a 
transport vesicle, while the LDL receptors recycle to the plasma membrane. When the 
transport vesicle fuses with a lysosome, apoB100 is degraded to its component amino acids 
and CE are hydrolyzed by acid cholesterol ester hydrolase (ACEH) to free cholesterol and 
fatty acids (Fig. 6). After cholesterol leaves the lysosome, it is transported to the 
endoplasmatic reticulum (ER) and to the plasma membrane by means of an intermediate 
step through the Golgi apparatus. Excess free cholesterol is esterified by acyl-coenzyme 
A:cholesterol acyltransferase 1 (ACAT1), an enzyme that localizes to the ER, and is stored 
as cytosolic droplets of CE. The most important mechanism in order to regulate cholesterol 
synthesis by the cell is to adjust the number of LDL receptors in order to meet the demands 
of cholesterol but not the excesses. If the demand exceeds the supply, then an accumulation 
of receptors will occur and vice versa. Lipoprotein disorders in which LDL receptors, or their 
capacity to bind the apoB100 ligand, are defective, result in an increased level of cholesterol 
in LDL remaining in circulation, causing hypercholesterolemia and atherosclerosis. Because 
of this and its potential to become oxidized to an atherogenic form, LDL is called the “bad” 
cholesterol carrier. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Receptor mediated 
endocytosis of LDL (from 
Garland publishing 1998) 
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4.5. HDL 
HDL has essentially the opposite function of LDL: it takes up cholesterol from peripheral 
cells. HDL is synthesized in liver and secreted into plasma as nascent HDL, which are 
discoidal pre-b-migrating complexes of phospholipid and apoA-I. Mature HDL contains 
lecithin, CE, lecithin:cholesterol acyl transferase (LCAT), and apoA-I, apoC-II, and apoE. 
Circulating HDL acquires cholesterol by using LCAT to extract cholesterol from the plasma 
membranes of peripheral cells. This process of cholesterol removal by HDL is facilitated by 
ABCA1, an ATP-binding cassette protein transporter. ABCA1 is activated by apoA-I and flips 
unesterified cholesterol and lecithin to the outer layer of cell membranes. ABCA1 delivers 
free cholesterol and lecithin as substrates for LCAT on HDL. ApoA-I activates LCAT in the 
nascent HDL, and also functions as a ligand for a cell surface receptor that exists on 
peripheral cells. CE, the product of LCAT catalysis, move to the core of nascent HDL. The 
entire process of LCAT extraction of cell cholesterol and incorporation into HDL for liver 
clearance is called "reverse cholesterol transport." The CE moiety of HDL is taken up 
selectively by the liver via SR-BI (52). HDL functions as a cholesterol scavenger, facilitating 
the transport of cholesterol to the liver for conversion to bile acids and secretion into the bile 
for elimination or recycling in the enterohepatic bile acid cycle. It is this cholesterol-removing 
property that renders HDL the "good" cholesterol carrier. Of course another major function of 
HDL is to serve as a depository for apoA-I, apoC-II and apoE. Transfer of apoC-II is required 
for the metabolism of chylomicrons and VLDL, and apoE is crucial for clearance of 
chylomicron remnants, IDLs and HDLs. Therefore, HDL contributes to both the exogenous 
and endogenous pathways of lipid transport. HDL as an anti-atherogenic lipoprotein protects 
against atherogenesis via reverse cholesterol transport and plays an important role as an 
antiinflammatory factor. Several beneficial functions of HDL have been documented (table 1) 
and it is expected that the therapeutic use of HDL elevation may open avenues for the 
treatment of atherosclerosis in the future (53). 
 
Table 1: Possible anti-atherogenic effects of HDL 
Effects Possible mechanisms 
Inhibition of lesion formation ¯  Reverse cholesterol transport 
Adhesion of monocytes to endothelial cells ¯ Inhibition of adhesion molecules and 
decreased cytokine production 
Thrombosis ¯ Modulation of endothelial antithrombotic and 
profibrinolytic properties 
Antioxidant effects ­ Modulation of paraoxonase 
Cellular death ¯ Inhibiton of apoptosis 
Cellular proliferation ¯ Inhibition of SMC proliferation 
¯: reduced or inhibited; ­: enhanced 
Table from Jianglin Fan and Teruo Watanabe: inflammatory reactions in the pathogenesis of 
atherosclerosis, review. J Atheroscler Thromb, 2003; 10: 63-71. 
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5. Proteins involved in HDL metabolism 
 
5.1. Apolipoproteins  
Apolipoproteins are constituents of various lipoproteins. The major apolipoproteins include 
apoA-I, apoA-II, apoA-IV, apoB, apoC-I, apoC-II, apoC-III and apoE. Specific apolipoproteins 
function in the regulation of lipoprotein metabolism through their involvement in the transport 
and redistribution of lipids among various cells and tissues, through their role as cofactors for 
enzymes of lipid metabolism, or through their maintenance of the structure of the lipoprotein 
particles. Defects in apolipoprotein structure or synthesis may affect lipid metabolism 
resulting in progression to coronary artery disease.  
 
5.1.1. ApoA-I 
ApoA-I, a single polypeptide of 243 amino acids is synthesized mainly in the liver and to a 
lower extent in the small intestine. ApoA-I is secreted as a discoidal, nascent HDL particle, 
having little or no core of cholesteryl ester which is then metabolized in plasma to mature 
HDL. It is the major protein found in HDL and plays an important role in HDL cholesterol 
metabolism and regulation of cholesterol transport (54). ApoA-I is the obligatory cofactor of 
the enzyme lecithin-cholesterol acyltransferase (LCAT) and is known to be the most powerful 
LCAT activator which results in enhancement of esterification of free cholesterol and 
cholesteryl ester enrichment of HDL (55;56). Therefore apoA-I is a major participant in the 
regulation of reverse cholesterol transport from peripheral tissues to the liver (57) which 
explain the correlation between plasma apoA-I levels, HDL cholesterol levels and reduced 
risk of atherosclerosis. Further apoA-I may facilitate hepatic cholesterol uptake by serving as 
a ligand for binding of HDL to hepatic receptors (58). ApoA-I production rates can directly 
influence plasma concentrations of HDL-cholesterol (59-61). The relationship between apoA-
I production and HDL cholesterol levels suggests the possibility that increasing expression of 
the apoA-I gene could slow or prevent progression of atherosclerosis which has been shown 
in transgenic mice where overexpression of apoA-I raises HDL cholesterol levels (60) and 
inhibits the development of early atherosclerotic lesions (61). An apoA-I abnormality has 
implicated in lipoprotein disorders such as Tangier disease (62-65). 
 
5.1.2. ApoC-I 
ApoC-I is a 6.6 kDa protein with 57 amino acids in a single polypeptide chain that belongs to 
the apoC family of small apolipoproteins that share a similar molecular mass, a similar 
distribution among lipoprotein classes (constituents of chylomicrons, VLDL, HDL) and 
coincident purification (66). It has been reported that in the fasting state, apoCs are mainly 
associated with HDL, whereas in the fed state, they preferentially redistribute to the surface 
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of chylomicrons and VLDL particles (67). Being predominantly expressed in the liver apoC-I 
is under control of an array of elements throughout the whole gene cluster on chromosome 
19 that also regulates apoC-II, apoC-IV and apoE expression (68;69). The physiological 
function of apoC-I is not clear yet. Modulation of binding properties to the LDL receptor or 
LDL receptor related protein of beta-VLDL through displacement of apoE from the lipoprotein 
particle or conformational changes of apoE in presence of apoC-I has been reported (70-73). 
Further the binding of lipoproteins to the VLDL receptor was completely inhibited by apoC-I 
(74). It has also been shown that apoC-I acitvates the enzyme lecithin cholesterol 
acyltransferase (LCAT) (55;56;75). LCAT is known to catalyze the esterification of free 
cholesterol in plasma and is further able to esterify lysophosphatidylcholine (LPC) to 
phosphatidylcholine (PC) (76). This lysolecithin acyltransferase activity was also activated by 
apoC-I (77). Further apoC-I can inhibit lipoprotein lipase an enzyme which is involved in 
lipoprotein processing (78) and phospholipase A2 (79) which amplify atherogenic processes 
by liberating potent pro-inflammatory lipid mediators and by generating pro-atherogenic LDL 
(80). CETP, which mediates the transfer of cholesterol ester from HDL to apoB-containing 
lipoprotein particles, is inhibited by apoC-I (81;82) which indicates a role of apoC-I in HDL 
metabolism. Because of the fact that apoC-I has inhibitory respectively stimulatory effects on 
a variety of receptors and enzymes involved in the major metabolic pathways of lipoprotein 
metabolism it can be concluded that apoC-I play a complex role in diseases associated with 
hyperlipidemias.  
Human apoC-I transgenic mice overexpressing apoC-I, exhibited hyperlipidemia with 
elevated levels of cholesterol and TGs owing to an accumulation of VLDL-size particles in 
the circulation. The elevated lipid levels in the plasma of apoC-I transgenic mice are primarily 
due to an enhanced production or disturbed lipolysis of VLDL (68;74;83). Overexpression of 
human apoC-I in mice inhibits VLDL uptake by the liver, probably due to displacement of 
apoE or a direct interaction with hepatic receptors (74;83). Surprisingly, apoC-I knockout 
mice had normal serum lipid levels on a chow diet (84). Only when fed a high-fat and high-
cholesterol diet did apoC-I deficient mice develop hyprcholesterolemia. In vitro binding 
experiments revealed that apoC-I deficient VLDL was a poor competitor for LDL binding to 
the LDLR, suggesting that total apoC-I deficiency leads to an impaired receptor-mediated 
clearance of remnant lipoproteins (84). Later, these results were confirmed in a more 
detailed characterization of these apoC-I knockout mice, demonstrating than an impaired in 
vivo hepatic uptake of VLDL is the primary metabolic defect in apoC-I deficient mice (85). 
ApoC-I deficiency in humans does not alter serum lipid levels unless a high fat and 
cholesterol diet is fed also leading to elevated VLDL levels that are likely to result from VLDL-
enrichment with apoA-I and apoA-IV (84;85). 
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5.1.3. ApoE 
ApoE is a member of a 48kb gene cluster on chromosome 19 that also harbours the genes 
encoding for apoC-I, apoC-II, apoC-IV and the apoC-I´ pseudogene (66). ApoE, a 34-kDa 
polypeptide composed of 299 amino acids is a major component of several plasma 
lipoproteins, including VLDL, IDL, chylomicron remnants, and certain subclasses of HDL that 
facilitates transport and metabolism of lipids. It is composed of two domains: a 22-kDa NH2-
terminal domain (residues 1-191) and a 10-kDa COOH-terminal domain (residues 216-299) 
(86). The 22kDa NH2 terminal domain contains the primary heparan sulfate proteoglycan 
(HSPG)-binding site (residues 140-10) (87) colocalized with the LDL receptor binding site 
(88-90). ApoE is mainly synthesized in the liver, but also by cells of the central nervous 
system, VSMCs and macrophages including those within the atherosclerotic plaque where 
apoE has a protective effect on atherosclerosis (91). ApoE binds to cell surface HSPG and 
serves as a ligand for the LDL receptor (LDLR), the LDL receptor related protein-1 (LRP-1) 
and other members of the LRP-family. For the internalization of apoE three major pathways 
are illustrated. First, apoE uptake can take place directly by binding and internalization via 
the LDLR. Another possibility of apoE internalization is the HSPG-LRP pathway in which 
apoE particles interact with cell-surface HSPG and are either transferred to the LRP for 
internalization or are taken up directly with the HSPG-LRP complex (92;93) (Fig. 7). The 
HSPG may serve as a reservoir for apoE, allowing the particles to be enriched in apoE, 
which facilitates their interaction with the LRP. Further HSPGs alone can mediate the direct 
uptake by serving as receptors and as alternate pathway (Fig. 7) (94). Interaction of apoE 
with lipid is necessary for its high affinity binding to the LDLR while lipid association of apoE 
is not required for binding to the LRP or HSPG. In contrast to binding to the LDLR, the 
stringency for binding of apoE to the LRP or HSPG appears to be less severe (95). Another 
molecule, lipoprotein lipase (LPL), binds to HSPG and has also been shown to be a ligand 
that can enhance cellular binding and uptake of triglyceride-rich particles with or without 
apoE (96). 
Binding of apoE to HSPG affects neurite extension in neurons (97) and localizes secreted 
apoE to the surface of macrophages (98). The ability of apoE to interact with members of the 
LDLR family and with HSPG can also be significant for cell signalling events (99). Binding of 
apoE to LRP activates cAMP-dependent protein kinase A and inhibits platelet-derived growth 
factor-stimulated migration of SMCs (100). Inhibition of SMC proliferation by apoE is, on the 
other hand, mediated by its binding to HSPG (99). In addition, the interaction of apoE with 
HSPG has been implicated in neuronal growth and repair and, consequently, is involved in 
the progression of late onset familial Alzheimer´s disease (101). 
Studies on nonhepatic cell lines revealed that the LRP and HSPG pathway begin to function 
only after particle concentration increases above levels required to saturate the LDL receptor 
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(94). The absence of apoE in human subjects or in apoE knockout mice also associated with 
premature atherosclerosis (102) and in apoE deficiency states, triglyceride rich particle 
plasma levels are markedly elevated, and these particles almost certainly enter cells largely 
through nonreceptor pathways. These properties of apoE appear to be involved in what has 
been termed the “secretion-recapture” role of apoE (103). 
Another possibility of apoE and also of apoA-I to induce internalization signals is the binding 
to ATP-synthase (Fig. 7). Mitochondrial ATP synthase has two main domains, F1 and F0. 
The b-chain belongs to F1, a peripheral membrane protein complex containing binding sites 
for ATP and ADP, and the catalytic site for ATP synthesis or hydrolysis. F1 is bound on the 
membrane by its interaction with F0, an integral membrane protein complex in mammalian 
mitochondria that contains a transmembrane channel for protons (104). The protons lead to 
an acidic pH in early endosomes which triggers the dissociation of internalized ligand-
receptor complexes and is also required for the activity of degradative enzymes within 
lysosomes and phagosomes. 
The ectopic b-chain of ATP-synthase was identified as an apoA-I receptor with ATP 
hydrolase activity in hepatic HDL endocytosis (105). Receptor stimulation by apoA-I, binding 
to the b-chain of ATP-synthase on the cell surface, triggers the endocytosis of HDL particles 
by a mechanism that depends strictly on the generation of ADP. Thus, membrane-bound 
ATP-synthase has a role in modulating the concentrations of extracellular ADP and is 
regulated by apoA-I. In addition, the a- and b-chains of ATP synthase have been identified 
as a receptor for apoE-enriched HDL (106;107). The presence of ATP synthase at the cell 
surface of lymphocytes (108) and human endothelial cell has been reported (109). The 
membrane bound ATP-synthase triggers a cellular response, in particular endocytosis 
signalling, by generating ADP through ATP hydrolysis with the probable involvement of 
specific downstream receptors.  
Other ligands for apoE are glycosphingolipids (Fig.7), especially ceramide (Cer) because 
apoE binds more avidly to Cer enriched microdomains on sphingomyelinase (SMase) treated 
liposomes as compared to the unmodified sphingomyelin (SM) rich particle surface and 
incorporation of SM into the emulsion surface reduced the binding capacity of apoE 
(110;111). These observations indicate a function of Cer rafts in apoE dependent lipid 
metabolism. Further it could be demonstrated that the generation of Cer in lipoproteins by 
SMase may stimulate HSPG and LRP-mediated uptake by macrophages, which could be 
intensified by apoE, and play a crucial role in foam cell formation (112). 
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Fig. 7: ApoE is a multireceptor ligand that modulates LRP-receptor family mediated turnover of   
           plasma membrane proteins 
 
ApoE also plays an important role in the process of reverse cholesterol transport by 
promoting cholesterol efflux from macrophages which is mediated via a mechanism that is 
not dependent on ABCA1 (113). Extracellular apoE and endogenously synthesized apoE by 
macrophages facilitate cholesterol efflux through distinct mechanisms (114). Exogenous 
apoE-mediated cholesterol efflux requires its interaction with the scavenger receptor SR-BI, 
while in cells that express endogenous apoE, SR-BI does not promote cholesterol efflux 
(115). Other functions of apoE, unrelated to lipid transport are known, including modulation of 
cell growth and differentiation as well as immunoregulation (116). Recently it has been 
reported that apoE binds lipid antigens and delivers them by receptor-mediated uptake into 
endosomal compartments containing CD1 in antigen-presenting cells (APCs) (117). CD1 
molecules survey endocytic compartments and bind lipid antigens that are presented at APC 
surface to lipid antigen-reactive T cells (118;119). Further ApoE mediates the presentation of 
serum-borne lipid antigens and can be secreted by APCs as a mechanism to survey the local 
environment to capture antigens or to transfer microbial lipids from infected cells to bystander 
APCs (117). Thus, the immune system used a component of lipid metabolism to develop 
immunological responses to lipid antigens. 
The secretion of endogenous apoE by macrophages is modulated by ABCA1 and ABCG1 
(120). After receptor-mediated endocytosis of triglyceride rich lipoproteins (TRL) into the 
liver, TRL particles are immediately disintegrated in peripheral endosomal compartments. 
Whereas core lipids and apoB are delivered for degradation into lysosomes, TRL-derived 
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apoE is efficiently recycled back to the plasma membrane. This is followed by apoE re-
secretion and association of apoE with HDL (121). Further it could be demonstrated that 
apoE is linked to HDL3-dependent and independent cholesterol efflux (121). In the presence 
of HDL the re-secretion of apoE and cholesterol leads to the formation of apoE/cholesterol-
enriched HDL particles. After internalization TRL-derived apoE and cholesterol remain 
associated in early endosomal antigen 1 (EEA1)-positive endosomes. Most importantly, 
apoE recycling involves the internalization of HDL3-derived apoA-I and its targeting to 
apoE/cholesterol-containing endosomes, indicating that endosomal HDL3-derived apoA-I can 
mobilize pre-existing apoE/cholesterol complexes. A number of reports (122) hypothesized 
an interaction between apoA-I and apoE and concluded that apoA-I concurrently stimulates 
secretion of endogenous apoE and cholesterol efflux from lipid-loaded macrophages. In 
addition secretion of apoE from macrophages is at least in part associated with cell-derived 
cholesterol (123;124). 
Degradation of apoE which in turn affects apoE secretion can take place via two pathways: 
the proteasomal ER-associated degradation (ERAD) pathway and the re-uptake pathway 
from the cell surface. Before degradation by proteasomes ubiquitination of apoE is 
necessary. It could be demonstrated that ubiquitinated apoE accumulates in macrophages 
and hepatocytes treated with specific proteasomal inhibitors indicating that the protein 
undergoes degradation in proteasomes (125). The re-uptake from the cell surface takes 
place after binding of nascent apoE containing particles to LDL receptors or HSPGs. After 
endocytosis of apoE, delivery to lysosomes and proteolytic degradation follows (126). The re-
uptake pathway is stimulated by sterol deprivation (127), which induces LDL receptor 
expression. Until now a third pathway, the post ER presecretion proteolysis (PERPP)-
pathway have been shown to be involved in apoB degradation (128) but not in apoE 
degradation (129). This pathway acts between the ERAD and the re-uptake patway after exit 
of apolipoproteins from the ER but before export across the PM. The PERPP patway 
involves the post-ER compartment and phosphoinositol 3 kinase (PI3K) signalling and does 
not act via microsomal transfer protein inhibition, active proteosomes, cell surface LDL-
receptors, cell surface HSPGs or functioning lysosomes. It is regulated by insulin and highly 
unsaturated fatty acids (W-3 fatty acids) such as DHA (docosahexanenoic acid (C22:6)) and 
EPA (eicosapentaneoic acid (C20:5)) in fish oil.  
 
5.2. Transfer proteins 
 
5.2.1. Cholesteryl esterase transfer protein (CETP) 
CETP is a hydrophobic 74 kDa member of the lipid transfer/lipopolysaccharide-binding 
protein (LBP) gene family, which also includes phospholipid transfer protein (PLTP), 
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lipopolysaccharide-binding protein (LBP) and bactericidal/permeability-increasing protein 
(BPI). Although these four proteins possess different physiological functions, they share 
marked biochemical and structural similarities. CETP which is not expressed in murines is 
mainly associated with the HDL particle in the circulation and promotes the transfer of CE 
from HDL to apoB-containing particles (i.e. VLDL and LDL) in exchange for triacylglycerols. 
CETP can be seen as a facilitator of cholesterol flux through the reverse cholesterol transport 
system. Through its action CE (derived from HDL) can be taken up by the liver through 
receptor-mediated uptake of apoB containing lipoproteins. CETP regulates the plasma levels 
of HDL and the size of HDL particles. The deficiency of CETP causes various abnormalities 
in the concentration, composition, and function of both HDL and LDL and causes 
hyperalphalipoproteinemia (HALP) (130). CETP gene is induced by sterols via LXRa/RXRa 
and LXRb/RXRa which transactivates the CETP promoter via its DR4 element (131). Human 
cultured monocyte derived macrophages (MDM) synthesize and secrete CETP (132). 
Induction of CETP expression occurs during the differentiation of monocytes into 
macrophages (133). The intracellular accumulation of CE is positively correlated with 
secretion of CETP, suggesting that CETP may function to maintain intracellular cholesterol 
homeostasis during differentiation and in response to an excess of cholesterol accumulation. 
CETP also mediates HDL conversion like PLTP (134). But in contrast to PLTP no release of 
lipid-poor apoA-I was detected in HDL conversion mediated by CETP (135). 
  
5.2.2. Phospholipid transfer protein (PLTP) 
PLTP (previously known as lipid transfer protein II, LTP-II) is like CETP a member of the LBP 
gene family and was originally characterized in human plasma as a factor capable of 
transferring phospholipids between the major lipoprotein classes (136). PLTP is present in 
human atherosclerotic lesions, is expressed by macrophages and induced during foam cell 
formation (137). The regulatory role of PLTP is achieved via its two main functions, 
phospholipid transfer activity and the capability to modulate HDL size and composition in a 
process called HDL conversion (138;139). PLTP promoted preferentially the formation of 
large HDL particles whereas CETP favoured the occurrence of small HDL (140). Further 
PLTP also participates in the exchange of phospholipids between HDL particles and plays a 
critical role in HDL metabolism. Through HDL conversion with a concomitant release of lipid-
poor apoA-I, PLTP is capable of generating preb-HDL which acts as an efficient acceptor in 
the cholesterol efflux process at the plasma membrane of peripheral cells. On the other hand 
PLTP has a major role in maintaining the HDL levels in the circulation due to its ability to 
transport surface remnants after lipolysis of triglyceride-rich lipoproteins. Thus PLTP could 
play an important role in the prevention of atherosclerosis (141). The activity of PLTP is 
closely related to HDL levels. Disruption of PLTP in mice dramatically reduces plasma HDL 
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cholesterol and phospholipid levels  (142). PLTP is regulated by liver X receptors in vivo and 
plays an important role in LXR agonist-mediated increase in HDL cholesterol and size in 
mice (143).  
PLTP also promotes the transfer of a-tocopherol (144), LPS (145) and cholesterol (146). 
 
6. Atherogenic modified lipoproteins 
 
6.1. Enzymatically degraded LDL (E-LDL)    
After infiltration into atherosclerotic lesions, LDL particles are degraded in situ by enzymes 
secreted by a variety of vascular cells, including macrophages. Enzymatic degradation of 
LDL in vitro is achieved by trypsin which degrades apoB, rendering underlying lipids 
accessible to cholesterol esterase for the cleavage of CE. This modified LDL particles are in 
structure, biological properties, and composition similar to lipid particles that accumulate in 
atherosclerotic lesions (147) and possess an atherogenic moiety (148). E-LDL is rapidly 
internalized by macrophages by means of a scavenger receptor (SR)-dependent pathway 
that is mediated partly via CD36 but not macrophage scavenger receptor A (MSR-A). (149). 
Highest E-LDL binding was observed on CD14 high CD16+ (MNP2) monocytes, suggesting 
a selective interaction of E-LDL with distinct subpopulations of monocytes (149). In addition it 
could be demonstrated that FcgRIIA/CD32 has the highest surface expression density on 
MNP2, proposing an involvement of FcgRII/CD32 in E-LDL binding on peripheral blood 
monocyte subpopulations (149).  Studies have demonstrated the binding of E-LDL to C-
reactive protein (CRP) and  complement activation (150). CRP is an acute-phase protein in 
humans which activates the complement system and is probably involved in early 
atherogenesis. On monocytes, specific CRP binding occurs through FcgRI/CD64 with low 
affinity as well as FcgRIIA/CD32 with high affinity (151). Immunohistochemical colocalization 
of E-LDL and activated complement in the extracellular space at the earliest stage of 
atherosclerotic lesion development (152) could be shown. Further selective adhesion and 
transmigration of monocytes is induced by E-LDL through endothelial cell monolayers (153). 
Further E-LDL stimulates MCP-1 production in macrophages (154). Free fatty acids present 
in E-LDL selectively stimulate IL-8 secretion in endothelial cells which is crucial for firm 
adherence and transmigration of circulating monocytes into the intima (155). These data 
show that the extracellular generation of E-LDL by enzymatic degradation is an event 
occurring during the earliest stage of atherosclerosis and that E-LDL induces monocyte 
recruitment into atherosclerotic lesions and is internalized by monocyte-derived 
macrophages, leading to foam cell formation during atherogenesis. 
 
 
Introduction 
 
 21 
6.2. Oxidized LDL (Ox-LDL) 
A prerequisite for macrophage uptake and cellular accumulation of cholesterol is oxidative 
modification of LDL (156). The initiation of the oxidation process is induced by the 
intracellular generation of lipoperoxides which are transferred to LDL through the 
development of O2 derived free radicals. These species later initiate a series of chemical 
reactions that are generally referred to as lipid peroxidation. Ox-LDL, generated in vitro by 
treatment with copper as a catalyst and extensive dialysis, is taken up avidly by 
macrophages and can cause foamcell formation. Oxidation of LDL leads to a number of 
changes in the composition of the particle, which vary depending on the type and 
concentration of oxidant used and the time of exposure (157;158). The rates at which 
specific components undergo oxidation vary greatly. In general, the unsaturated fatty acyl 
chains of phospholipids, CE, and triglycerides are oxidized most readily, while cholesterol 
and saturated fatty acids react more slowly. In addition, a significant proportion of the 
unsaturated acyl chains of CE and phospholipids is oxidized to hydroperoxides, 
isoprostanes, and more advanced oxidation products (159). A small proportion of cholesterol 
is converted to oxysterols, initially 7-hydroperoxycholesterol. ApoB, the sole protein of LDL, 
is subject to both direct oxidative modification and reaction with products of lipid oxidation. 
Depending on the degree of oxidation, in ‘minimally’, lightly or mildly Ox-LDL, apoB is 
modified only to a minor extent and is still able to bind to the LDL receptor and is taken up via 
clathrin coated pits while in heavily Ox-LDL, apoB prevent LDL from binding to LDL 
receptors, and instead Ox-LDL is recognised by receptors such as scavenger receptor A 
(SR-A) and CD36 (160;161).  
Recent studies have indicated that the subsequent metabolism of Ox-LDL differs 
substantially from non-oxidized lipoproteins (162;163). In particular, Ox-LDL is poorly able to 
induce cytoplasmic CE accumulation. This appears to be the result of the chemical 
alterations during oxidation to components of LDL. For mildly oxidized LDL mediated 
accumulation, it is known that initially lysosomal CE hydrolysis generates free cholesterol 
accumulation in lysosomes (164). This cholesterol, however, is restricted from exiting the 
lysosome. This would suggest that certain modifications of lipoproteins, or excess free 
cholesterol itself, can inhibit trafficking of cholesterol out of the lysosome. 
Mildly oxidized LDL also has a number of biological activities that are potentially 
proatherogenic. These include effects on macrophage viability, migration, and proliferation, 
and on cholesterol export, signalling, protein expression, and secretion. While modest levels 
of OxLDL stimulate macrophage survival and proliferation, there is agreement that high 
doses cause death. The toxic components of Ox-LDL are not well defined, but may include 
oxysterols (165). Ox-LDL contains lysophosphatidylcholine (LPC) which is a potent 
chemoattractant for macrophages (13) because it upregulates the expression of vascular cell 
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adhesion molecule such as ICAM-1 which is present within the endothelium and increases 
monocyte adhesion. 
Ox-LDL itself is directly chemotactic for monocytes and T cells (but not for B cells or 
neutrophils, neither of which are found in lesions) (20;166). Among other biological effects, 
Ox-LDL (and its various oxidized lipid components) is cytotoxic for endothelial cells (167), 
mitogenic for macrophages and smooth muscle cells and stimulate the release of MCP-1 and 
of monocyte colony-stimulating factor (MCSF) from endothelial cells. Further, Ox-LDL can 
stimulate the production of many inflammatory mediators (e.g. endothelin-1) from other 
vascular cells, in turn resulting in diverse inflammatory responses in the arterial wall. 
All atherogenic lipoproteins, once deposited in the intima, may exert direct or indirect 
proinflammatory effects. Table 2 summarizes the potential roles of Ox-LDL in atherogenesis, 
with special reference to its properties as an inflammatory mediator.  
In summary atherogenic lipoproteins exert diverse effects by inducing chronic inflammatory 
reactions during lesion formation. They can augment the production of cytokines by vascular 
cells, and through the autocrine and paracrine mechanisms, the inflammatory reaction may 
lead to a vicious cycle resulting in lesion progression.  
 
Table 2: Possible proatherogenic effects of oxidized LDL 
Effects Possible mechanisms 
Adhesion of monocytes to endothelial cells ­  Increased expression of adhesion molecules 
on endothelial cells 
Monocyte and T lymphocyte chemotaxis ­ Induction of MCP-1 production and direct 
chemoattractant effect 
Scavenger receptor A and CD36 ­ Activation of AP-1 and its transcription 
factors 
Foam cell formation ­ Enhanced uptake of Ox-LDL mediated by 
scavenger receptors 
Induction of proinflammatory genes Activation of NFkB, and AP-1, and increased 
cAMP 
Increased cellular death Activation of apoptosis and formation of 
cholesterol crystals 
Thrombosis ­ Induction of tissue factor, increased platelet 
aggregation 
Impaired vascular functions  Dysfunction of ET-1 and NO 
Plaque rupture ­ Increased MMPs production 
­: enhanced 
Table from Jianglin Fan and Teruo Watanabe: inflammatory reactions in the pathogenesis of 
atherosclerosis, review. J Atheroscler Thromb, 2003; 10: 63-71 and see also Atherosclerosis an 
inflammatory disease, Schmitz G., Torzewski M, Inflammatory and Infectious Basis of Atherosclerosis, 
2001, Birkhäuser Verlag, Basel/Switzerland. 
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7. Uptake of modified lipoproteins by macrophages 
 
7.1. Scavenger receptors (SRs) 
SRs are heterogeneous types of receptors which are expressed on macrophages and 
macrophage derived foam cells in atherosclerotic lesions, and are important for these cells to 
remove lipoproteins deposited in the lesions. 
SRs are defined as receptors binding to chemically modified lipoproteins such as acetylated 
LDL (AcLDL), Ox-LDL and often many other types of ligands. They have heterogeneous 
molecular structures, and consist of various types. These receptors are divided into classes 
A, B, C, D, E, F, and G and different types of receptors are members of each class (23).  
 
7.1.1. SRs: classA 
Class A receptors include type I, type II, and type III macrophage scavenger receptor (MSR), 
and MARCO (macrophage receptor with collagenous structure). These receptors are 
generally called macrophage scavenger receptor class A (MSR-A). They possess a 
collagenous domain required for ligand recognition and are expressed on macrophages. 
(168;169). MSR-A I,II are expressed on the cell membrane of macrophages. Their binding 
properties are currently considered identical. 
The C-terminal type-specific domain in MSR-A I is called the scavenger receptor “cysteine-
rich” domain (SRCR) which is not predictive of SR activity; the selective upregulation of this 
receptor accomplishes the uptake of modified LDL during differentiation of monocytes into 
macrophages, and its expression is important for foam cell formation (170). MSR-A II is also 
important for the uptake of modified LDL by macrophages (171). MSR-A III is localized in 
cytoplasmic vesicles and is not expressed on the cell surface. Thus, this receptor is unable to 
bind to any extracellular ligands (172). In the trans-Golgi system, MSR-A I,II are packed into 
secretory vesicles, and the vesicles are transported into the cell periphery of macrophages, 
thus recycling MSR-A I,II to the cell membrane for reutilization (173).  
A number of different biological roles for the SR-A are suggested. These include the 
endocytosis of modified lipoproteins and its association with vascular disease, the adhesion 
of macrophages to the substratum and other populations of cells, the binding and ingestion 
of microbes, the detoxification of pathogen-specific components and the phagocytosis of 
apoptotic or unwanted host cells (174).  
However, the development of atherosclerosis was not completely inhibited by MSR-A I, II 
deficiency, suggesting that SRs other than MSR-A I,II, such as MARCO, CD36, and 
macrosialin/CD68, are implicated in the uptake of Ox-LDL by macrophages and in the 
transformation of the macrophages into foam cells during atherogenesis.  
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MARCO is a 210-kDa membrane glycoprotein consisting of molecular trimeric structures 
similar to those of MSR-A I,II, and III. It has an extremely long collagen like domain and a 
short α-helical coiled coil domain (175). Because of these molecular structures, the MARCO 
receptor is unable to dissociate from ligands within endosomes, and MARCO-ligand 
complexes are directly transported into lysosomes without receptor-ligand dissociation.  
The SR cystein rich CD163 is a macrophage-restricted endocytic receptor for haemoglobin-
haptoglobin complexes. 
 
7.1.2. SRs: class B 
CD36 and SR-BI (scavenger receptor type BI) belong to class B of SRs. CD36 is a double 
spanning SR with a very different structure from SR-A. CD36 is an 88-kDa glycoprotein 
expressed on monocytes/macrophages, platelets, and endothelial cells, and in adipose 
tissue; it binds to various ligands such as fatty acids, anionic phospholipids, collagen, 
thrombospondin, and Ox-LDL (36). CD36 was shown to function as an Ox-LDL receptor in 
macrophages (160) and a fatty acid transporter in adipocytes (176). In atherosclerotic lesions 
of human aorta, the expression of CD36 predominates in macrophage-derived foam cells 
compared to non-loaded macrophages and is distinct from the expression of MSR-A I,II 
suggesting a different role of these two receptor types (177). CD36 also plays a role in 
macrophage fatty acid metabolism, adhesion, and phagocytosis of apoptotic neutrophils (36). 
SR-BI is a 509-amino-acid-long member of the CD36 superfamily of proteins with two 
transmembrane domains like CD36 but a quite different function. SRB-I and CD36 are fatty 
acylated proteins that cluster in caveola-like cholesterol-rich lipid domains in cultured cells 
(36). SR-BI is regarded as an HDL receptor, and mediates the selective uptake of HDL 
cholesterol by hepatocytes and steroidogenic cells (52). SR-BI can also function as a LDL 
receptor (binding and selective uptake). Although HDL does not bind as tightly as LDL, it 
binds preferentially when both ligands are present. CD36 can also bind HDL and LDL, but it 
cannot efficiently mediate CE uptake (178). The tissue distribution of SR-BI is that expected 
for an HDL receptor. It is highly expressed in liver and steroidogenic tissues, precisely those 
tissues that exhibit the highest levels of selective uptake of HDL-CE. In macrophages in 
atherosclerotic plaques, SR-BI is also present (178). The expression of SR-BI is coordinately 
regulated with cholesterol metabolism. Its expression in steroidogenic cells is regulated via 
the cAMP/protein kinase A signal transduction pathway that includes transcription factors 
such as CCAAT/enhancer-binding proteins (C/EBPs) and steroidogenic factor-1 (SF-1). The 
transcriptional regulation of SR-BI appears to be due to SR-BI promoter binding sites for a 
number of transcription factors including C/EBP, SF-1, and sterol regulatory element binding 
protein-1 (SREBP-1) (179). 
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SR-BI facilitates the cellular selective uptake of cholesterol (primarily in the form of CE) from 
the hydrophobic cores of lipoproteins, but not the apolipoprotein at the lipoprotein´s surface. 
It does not involve the sequential internalization of the intact lipoprotein particle and its 
subsequent degradation which is the case in the uptake of LDL via the LDLR (Fig. 2). (168). 
The detailed molecular mechanism underlying SR-BI-mediated selective lipid uptake has not 
yet been elucidated. In addition SR-BI can also mediate the bidirectional flux of unesterified 
cholesterol and phospholipids between HDL and cells.  
Hepatic SR-BI mediates “reverse cholesterol transport” which implicates the transfer of 
cholesterol from plasma HDL to the bile for excretion. In atherosclerotic lesions of apoE-
deficient mice, SR-BI is expressed in macrophages, and the expression is increased by 
peroxisome proliferator-activated receptors (PPARs), suggesting a contribution of SR-BI to 
the uptake of OxLDL by macrophages in loco (180). 
Thus, SR-BI plays a key role in controlling the structure and amount of cholesterol in plasma 
HDL, steroidogenic and hepatic uptake of HDL cholesterol, and the use of HDL cholesterol 
for biliary cholesterol secretion.  
 
7.1.3. SRs: classes D through G 
CD68/macrosialin, classified as a class D receptor, is a member of the LAMP (lysosomal-
associated membrane protein) family expressed on the endolysosomal compartments and 
partly on the cell surface of macrophages (181). It is demonstrated in macrophages and 
macrophage-derived foam cells in human and murine atherosclerotic lesions and was able to 
bind Ox-LDL in vitro (182;183). Lectin-like Ox-LDL receptor (LOX-1) and SR expressed by 
endothelial cells (SREC) are expressed on vascular endothelial cells and are classified as 
class E and class F, respectively (184;185). LOX-1 is also expressed on macrophages in 
humans and mice (185). It mediates endocytic uptake and subsequent lysosomal 
degradation of Ox-LDL. Binding of Ox-LDL to this receptor induces several cellular events 
such as activation of NFkB (186), upregulation of MCP-1 (187) and reduction in intracellular 
nitric oxide (186). Other ligands for LOX-1 include polyanionic compounds, aged/apoptotic 
cells (188), activated platelets (189) and bacteria (190). In addition, two other distinct novel 
SRs, SR for phosphatidylserine (PS) and Ox-LDL (PSOX, SR-G class) and PS receptor 
(PSR), have been identified (191;192). SR-PSOX recognizes PS and Ox-LDL and is 
predominantly expressed in lipidladen macrophages of human atherosclerotic lesions. This 
receptor does not share any structural homology with other Ox-LDL receptors. PSR is 
expressed not only in macrophages but also in fibroblasts and epithelial cells and is involved 
in the phagocytosis of apoptotic cells (192).  
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7.2. Uptake of lipoproteins by opsonin receptors including Fcg- and complement 
receptors  
Cellular uptake of lipids and lipoproteins by macrophages is either mediated by charge and 
motif receptors (scavenger receptors) directly recognizing non-opsonized ligands or by 
opsonization. Opsonization occurs by either non-specific opsonins (complement components 
or pentraxins including C-reactive protein (CRP), serum amyloid P (SAP), serum amyloid A 
(SAA), β-Amyloid and/or specific opsonins (immunoglobulins) prior to cellular uptake. Fcg-
receptors complement receptors and LRPs mediate uptake of opsonized lipoproteins. 
Amyloid precursor protein (APP) is a type I integral membrane protein. The b-secretase-
processed carboxyl-terminal fragment of APP is further processed to generate b amyloid 
peptide. Isoforms of APP containing the Kunitz proteinase inhibitor domain bind directly to 
LRP (193) and are internalized especially after the APP binds a natural target proteinase, 
such as epidermal growth factor-binding-protein (194). Potential modulation of APP transport 
and processing may involve apoE lipoproteins which may interfere with Kunitz-domain-
mediated binding of APP to the extracellular domain of LRP. Therefore apoE could be 
regarded as an opsonine for APP binding to LRP receptors (195). APP is bridged to LRP-1 
within the cytoplasm by FE65, a bifunctional adaptor protein which interacts with the NPxY 
motifs present in the cytoplasmic tails of LRP and APP (Fig. 8a) (196). This raises the 
possibility that LRP can modulate the intracellular trafficking of APP. Assembly of 
mammalian ena (Mena) on the cytoplasmatic tails of LRP and APP may function in the local 
reorganization of the cytoskeleton. Further tyrosine-phosphorylated mammalian Disabled 
protein 1 (mDab1) can recruit nonreceptor tyrosine kinases, such as src and ab1, to the 
cytoplasmic tails of the receptors to which it binds (e.g.: LDLR, LRP, APP) (Fig. 8a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8: Hypothetical models showing interactions of cytoplasmic neuronal adaptor and scaffold 
proteins with the LDL receptor family and APP (Herz, review, nature neuroscience 2000) 
a. Interaction of Dab1, FE65, LRP and APP b. Hypothetical model of the reelin signalling 
pathway 
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Amyloid-b (Ab) is a 4kDa hydrophobic polypeptide which is produced by proteolytic 
cleavages of the APP by the action of proteases called beta- and gamma secretases. Ab 
deposition, the hallmark of Alzheimer disease (AD) (197) has been identified in brain 
parenchyma, within cerebral blood vessels (198) as well as in atherosclerotic plaques (199). 
Neurons poduce Ab peptides of different sizes. The most prominent being 40 and 42 amino 
acids long (Ab40 and Ab42 respectively). The majority of all Ab isoforms produced is Ab40 but 
about 10% is Ab42 (200). In AD-brains deposits of Ab42 are found more frequently in plaques 
and capillaries than Ab40 (201) which could be due to altered cellular processing of the APP 
with increased production or a reduced removal of cleavage products like Ab42 (202). 
Intracellular cholesterol regulates the generation of insoluble Ab peptides, as increased 
concentrations of free cholesterol in membranes have been shown to stimulate Ab 
production (203). Moreover Stanyer et al demonstrated that LDL and Ox-LDL interact with 
Ab40 and that these complexes were more readily internalized by SMCs than unbound 
peptide (204). Additionally fibrillar Ab42 binds to the class B scavenger receptor CD36 (205-
207), the CD36/a6b1-integrin/CD47 receptor complex (208) and also to LRP which is 
suggested to be involved in Ab42 binding and uptake, acting as an opsonin receptor (209). 
These findings strongly indicate a common link between Ab and lipoproteins in the 
development of cerebrovascular disease as well as AD. However, the exact mechanism how 
capillary Ab-deposits develop and whether macrophages and lipoproteins are involved in this 
process is still unknown. Several cellular processes or pathway in which neuronal apoE 
receptors are involved may affect the pathogenesis of AD. They include interactions with 
APP, modulation of Ab clearance from the extracellular space and transmission of signals to 
neurons. Any of these functions may be modulated by binding of apoE to the extracellular 
domains of the different members of the LDL receptor family. The reelin signalling pathway is 
a downstream target of apoE induced neuronal signalling.  A model is created (195) which 
suggests that binding of Dab1 to the cytoplasmatic tails of the VLDLR and apoE receptor 2 
(ApoER2) is critical for the transmission of reelin signal to migrating neurons (Fig. 8b). An 
extended family of cadherin-related neuronal receptors (CNR) is also thought to participate in 
this process (Fig. 8b). CNRs have been shown to bind the non-receptor tyrosine kinase Fyn 
on their cytoplasmic tail and CNRs may interact with reelin bound to VLDLR or ApoER2 at 
the cell surface, resulting in tyrosine phosphorylation of Dab1. Coupling of p35, p39 and 
Cdk5 to the receptors and Dab1 on the plasma membrane may involve interactions with 
adaptor and scaffold proteins that bind to the cytoplasmic tails of the LDL receptor family 
(Fig.8b). Members of the JIP family of scaffold proteins bind to an alternatively spliced insert 
in the cytoplasmic tail of ApoER2. This may recruit stress-activated and mitogen-activated 
protein (MAP) kinases (for example, MLK3, MKK7 and JNK) and other cellular signalling 
Introduction 
 
 28 
components (for example, rhoGEF) into the complex, resulting in the local reorganization of 
the cytoskeleton and modulation of gene transcription (Fig. 8b). 
CRP, an innate recognition lectin is associated with coronary heart disease (210). Of 
particular importance might be calcium-dependent in vitro binding of CRP to E-LDL 
accompanied by an enhancement of complement activation (211). On monocytes, specific 
CRP binding occurs through FcgRI/CD64 (212) as well as FcgRIIA/CD32 (213). Previously it 
could be shown that cell surface ceramide is a prerequisite for recruitment of cross-linked 
FcgRIIA to rafts, which triggers the receptor tyrosine phosphorylation and signalling (214). 
Further the association of FcgRIIA with rafts leading to signalling events was described for 
platelets (215) and human neutrophils (216). 
SAP is the second pentraxin present in human plasma, which also has been reported to 
locate to atherosclerotic lesions and bind to a variety of ligands such as C4b-binding protein, 
CRP, complement components C1q and C3bi, and human IgG in a calcium-dependent 
manner. SAP specifically interacts with HDL as well as VLDL but not with LDL  (217) and can 
activate the complement system (218). 
SAA, a family of acute-phase reactants, is found on HDL and displaces apolipoprotein AI 
from HDL particles and converts a-migrating mature HDL back to preb1-precursor HDL 
particles (219). Further functions of the SAAs include participation in detoxification, 
depression of immune responses, and interference with platelet functions (220).    
Antibodies, as specific opsonines against different epitopes of lipids and lipoproteins (charge 
modified phospholipids, cholesterol or cryptic protein epitopes), have been demonstrated in 
human plasma. Human IgG1 and IgG3 autoantibodies reactive with Ox-LDL have been 
isolated from human plasma (221).  
 
7.3. Phagocytosis 
Phagocytosis is an actin dependent uptake of relatively large particles (>0.5 mm) into 
vacuoles by the cell. Two types of phagocytosis can be distinguished (Fig. 9):  
 
 
 
 
 
 
 
 
 
Fig. 9: Schematic view of type-I (engulfment) and type-II (sinking in) phagocytosis 
Type-I phagocytosis Type-II phagocytosis
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Type-I phagocytosis (engulfment phagocytosis): This type of phagocytosis is mediated 
by Fcg receptors (FcgRI/CD64, FcgRII/CD32 and FcgRIII/CD16) which bind to IgG-coated 
particles; it goes along with membrane ruffling and pseudopodia extension by a zippering 
mechanism and uses the Rho family GTP-ases Cdc42 and Rac (Fig. 9).  
 
Type-II phagocytosis (sinking in phagocytosis): This type is complement receptor-
mediated (CR3: CD11b/CD18, Mac-1, aMb2) which binds C3bi-opsonized targets and 
particles sink into the cell. This mechanism uses only the GTP-ase RhoA (Fig. 9). 
Previously it has been reported that CR3 mediates type-II and type-I phagocytosis during 
opsonic and nonopsonic phagocytosis, respectively (222). This suggests that CR3 triggers 
different intracellular signals which mediate distinct phagocytic processes. 
 
Interaction between receptors and ligands on the particle results in signal transduction 
events that lead to actin polymerisation, particle engulfment and formation of the 
phagosome. During a maturation process, the phagosome interacts and fuses with early and 
late endosomes as well as with lysosomes transforming it into a phagolysosome where 
digestion takes place. The fusion processes are regulated by small GTP-binding proteins of 
the rab family.  
FcRs recognize the Fc portion of antibodies and deliver signals when they are aggregated at 
the cell surface. FcRs can be functionally divided in two major types: FcRs that can trigger 
cell activation and FcRs that cannot. The aggregation of FcRs having immunoreceptor 
tyrosine-based activation motifs (ITAMs) activates sequentially src family tyrosine kinases 
and syk family tyrosine kinases that connect transduced signals to common activation 
pathways shared with other receptors. FcRs with ITAMs elicit cell activation, endocytosis and 
phagocytosis. There are four multichain FcRs with ITAMs: FcgRI, FcgRIIIA, FceRI and FcaRI. 
FcRs having immunoreceptor tyrosine-based inhibition motifs (ITIMs) do not trigger cell 
activation. FcgRIIB are a family of single-chain low-affinity IgG receptors not containing 
ITAMs. FcgRIIB is a negative coreceptor of all receptors with ITAMs because coaggregation 
of antigen receptors or FcRs having ITAMs with FcRs having ITIMs negatively regulates cell 
activation (223).  
 
8. Peroxisome proliferator-activated receptors (PPARs) 
PPARs, nuclear receptors, are ligand-activated transcription factors that have been 
implicated to play an important role in obesity-related metabolic diseases such as 
hyperlipidemia, insulin resistance, and coronary artery disease. These orphan receptors are 
activated by fatty acids and derivatives and proposed to control lipid homeostasis by 
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regulating the expression of genetic networks involved in lipid metabolism, transport, storage 
and elimination (224).  
PPAR bind, upon heterodimerisation with RXR (retinoid X receptor), to specific peroxisome 
proliferator response elements (PPRE) in the promoter of target genes, thus regulating the 
transcription of these genes. Both the formation of the PPAR/RXR heterodimer and the 
subsequent transcriptional activation of the target gene are ligand-dependent. Ligand binding 
may evoke conformational changes within the DNA-binding domain, thereby altering the 
potential to stimulate transcription of target genes.  
The nuclear receptor subfamily of PPARs consists of isoforms a, g and d with distinct 
expression patterns and biological activities. Although these different members are encoded 
by separate genes, they have a similar protein structure.  
PPARa is expressed in liver, heart, muscle, and kidney where it regulates fatty acid 
catabolism (225) and is the molecular target of the lipid lowering fibrates (e.g. fenofibrate and 
gemfibrozil), whereas PPARg is highly enriched in adipocyte and macrophage and is involved 
in adipocyte differentiation, lipid storage, and glucose homeostasis (226). It mediates the 
activity of the insulin-sensitizing thiazolidinediones (e.g. rosiglitazone and pioglitazone). 
PPARd is expressed ubiquitously with a less defined function. It has been implicated in 
keratinocyte differentiation and wound healing and, more recently in mediating VLDL 
signalling of the macrophage (227-229). 
Furthermore, PPARs are expressed in atherosclerotic lesions and have been shown to affect 
transcription of genes in vascular endothelial cells, smooth muscle cells, monocytes, and 
monocyte-derived macrophages. The down-regulation of several atherogenic genes by 
PPAR activation suggests that stimulation of PPAR expression and/or activation may have 
beneficial effects on the progress of atherosclerotic disease. 
The fact that dietary fatty acids are natural activators of this subfamily implies that 
lipoproteins serve as ligand carriers for PPARs, which in turn modulate lipid homeostasis of 
the body. PPAR activators have effects on both metabolic risk factors and on vascular 
inflammation related to atherosclerosis.  
 
8.1. PPARg and atheroslcerosis 
PPAR-g is present in virtually all vascular- and atheroma-associated cells seen in the vessel 
wall, including VSMCs, endothelial cells, monocytes, macrophages, T lymphocytes, and 
human atherosclerotic lesions (230). Its expression is significantly increased upon monocyte 
to macrophage differentiation and the PPAR-g protein is present at high levels in the 
macrophage-derived foam cells of atherosclerotic lesions (231;232). PPAR-g-regulated target 
genes are relevant to atherosclerosis and PPAR-g agonists limit atherosclerosis in mouse 
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models (230). Furthermore PPARg has been shown to regulate the expression of activation-
dependent genes in macrophages (233). 
 
8.2. PPARg activators and agonists 
PPARg is activated by arachidonic acid metabolites derived from the cyclooxygenase and 
lipoxygenase pathways, e.g. 15-deoxy-D-12, 14-prostaglandin J2 (PG-J2) and 15-
hydroxyeicosatetraenoic acid (15-HETE) (234-236). In addition, fatty acid-derived 
compounds of Ox-LDL, such as 9- and 13-hydroxyoctadecadienoic acid (9- and 13-HODE), 
activate PPARg. Treatment of macrophages with Ox-LDL in vitro induces expression of both 
PPARg and LXRa mRNAs (237). Internalization of Ox-LDL provides the cell with activators of 
PPARg, such as oxidized fatty acids as well as with activators of LXRs such as 27- and 25-
hydroxycholesterol (234;238). PPARg ligands can also be produced locally in atherosclerotic 
lesions through the oxidation of fatty acids by 12/15 lipoxygenase (239). 
Synthetic high affinity PPARg ligands are the antidiabetic glitazones respectively 
thiazolidones (TZDs) (used in treatment of insulin resistance and type 2 diabetes) and the 
pharmacological non steroidal anti-inflammatory drugs (NSAIDs) indomethacin and 
ibuprofen. 
 
8.3. Functions of PPARg activators 
PPARg activators inhibit the expression of MMP-9 of human macrophages (240) and 
VSMCs, thus interfering with VSMC proliferation (241). The production of the inflammatory 
cytokines TNF-a, IL-6 and IL-1b by activated monocytes is inhibited by PPARg (242) and the 
transcription of monocyte chemoattractant protein (MCP)-1 is decreased. The expression of 
inducible nitric oxide synthase (iNOS) and the scavenger receptor A in interferon (IFN)- g-
stimulated mouse macrophages (243) is inhibited by PPARg. Activation of PPARg has been 
shown to enhance CD36 expression of macrophages, which may indicate that PPARg could 
stimulate uptake of oxidized LDL and contribute to foam cell formation (234;237). These 
CD36 effects may be compensated by increased expression of the putative 
cholesterol/phospholipid transporter ABCA1 and apoE in macrophages (244) through the 
activation of LXRa. LXRa forms a heterodimer with the retinoic-X-receptor (RXRa) and is a 
direct transcriptional target of PPARg that promote cholesterol excretion and efflux by 
modulating expression of ABCA1 and apoE (245;246). Inhibition of the expression of the 
intracellular adhesion molecules ICAM-1 and VCAM-1 by troglitazone in human endothelial 
cells (247) and the induction of the scavenger receptor CLA-1/SR-BI by PPARg in human 
macrophages (180) also suggests that PPARg may influence monocyte recruitment and 
cholesterol efflux from foam cells.  
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Earlier results suggested that PPARg is expressed at high levels in circulating human 
monocytes and its activation icreases the expression of macrophage-specific markers, such 
as CD14 and CD11b (237). 
 
9. Retinoic-acid-receptors (RARs) and Retinoid-X-receptors (RXRs) 
RXR are mainly activated by 9-cis retinoic acid, whereas RAR can be bound by 9-cis retinoic 
acid and all-trans retinoic acid (ATRA) (248). Although retinol and β-carotene are only 
marginally metabolized to ATRA and 9-cis RA, these retinoids display a very high biological 
activity. Upon activation, both receptors after heterodimerization are capable of binding to 
retinoic acid responsive elements (RARE) and thereby induce genes important for lipid 
metabolism including apolipoproteins (apoC-I, apoC-II, apoC-IV, apoE), the scavenger 
receptor CD36, steroid-27-hydroxylase CYP17A1, LXRa, and ABCA1 and ABCG1 (249). 
The heterodimeric complexes formed by RARs and RXRs are potent stimuli for apoA-
I/ABCA1 dependent cholesterol efflux (249).  
 
10. Genetic factors affecting macrophage lipid metabolism 
 
10.1. ApoE polymorphism 
In humans three common isoforms of apoE exist which differ from each other by single 
amino acid substitution. The most common isoform is apoE3/3 (cystein 112 and arginin 158) 
with a frequency of 77% in Caucasian population, apoE4/4 (arginin 112 and 158) has a 
frequency of 15% and apoE2/2 (cystein 112 and 158) a frequency of 8%. The apoE4/4 allele 
is known to be a risk factor for coronary atherosclerosis and Alzheimer´s disease (AD). The 
isoforms differ from each other in their binding affinity for the LDL and other apoE receptors 
(116). Thus the apoE polymorphism has a significant impact on plasma lipoprotein levels. 
The E4 allele results in a decrease in plasma HDL levels. Total and LDL cholesterol levels 
are greatest in persons carrying the apoE4 isoform, intermediate in those with the apoE3 
isoform, and lowest in those with the apoE2 isoform (250). Because of the fact that apoE4 
has two arginins (arginin 112 and 158) instead of apoE3 containing only one arginin (cystein 
112 and arginin 158) as an ER retention domain it can be concluded, that apoE4 is trapped 
for a longer time by the ER and therefore its secretion and synthesis is decreased. There are 
higher levels of intracellular and secreted apoE during monocyte differentiation in apoE3/3 
compared with apoE4/4 monocyte derived macrophages (MDM) and also immunological 
differences between the apoE3/3 and apoE4/4 monocytes could be found (25). So in lipid-
free cultured monocytes which express apoE the expression of CD16 (Fcg-receptor IIIa with 
phagocytosis-activity) is increased and the expression of CD40 (surface antigen for co-
stimulation) is decreased in apoE4/4 cells. Thus the question raises if the different apoE3/3 
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and apoE4/4 monocyte differentiation correlate with the changed apoE-expression or with 
the phenotypic differences of the protein. Further it is known that apoE mediates cellular 
cholesterol efflux isoform-dependent which is modulated by cell surface proteoglycans (251). 
The apoE isoforms have a differential cellular cholesterol-modulating effect in macrophages, 
which would be due to the difference in their binding to proteoglycans. Compared with 
apoE3, apoE4 is less efficient in promoting cholesterol efflux in fibroblasts and astrocytes 
(252;253), indicating that apoE isoforms differentially affect the mobilization of cellular 
cholesterol. Heeren et al. demonstrated that HDL-induced recycling, of triglyceride rich 
lipoprotein-derived apoE4 is impaired compared with apoE3, and further associated with a 
decrease in cholesterol efflux and intracellular cholesterol accumulation (254). Thus, 
impaired apoE4 recycling could explain the low apoE protein and cholesterol content of HDL, 
which is associated with the human apoE4 allele (255-257). ApoE also protect cells against 
oxidant-mediated cellular death (258). The antioxidant effect was isoform-specific with the 
apoE2 protein isoforms demonstrating the highest level of antioxidant protection and apoE4, 
the lowest. ApoE modulates the production of RNOs in human MDMs and in RAW cells, a 
clonal mouse macrophage cell line, thus providing another means by which apoE and its 
protein product can modulate oxidative and nitrosative processes (259). ApoE regulates 
production of NO, a critical cytoactive factor released by immune active macrophages. 
Significantly more NO was produced in apoE4 mice compared to apoE3 transgenic mice that 
only express human apoE3 protein. MDM from humans carrying apoE4 gene alleles also 
produce significantly greater NO than those individuals with apoE3. Overall, greater NO 
production in apoE4 carriers where characteristically high levels of oxidative/nitrosative 
stress are found in diseases such as AD provides a mechanism that potentially explains the 
genetic association between apoE4 and human diseases (260-262).  
 
10.2. Genetic HDL-deficiency syndrom, Tangier disease (TD) 
TD is a genetic disorder of cholesterol transport named for the secluded island of Tangier, 
located in front of the coast of Virginia. TD was first identified in a five-year-old inhabitant of 
the island who had characteristic orange tonsils, very low levels of HDL and an enlarged liver 
and spleen. 
Synonyms for Tangier disease are: 
· Alpha High-Density Lipoprotein Deficiency  
· Alphalipoproteinemia  
· Analphalipoproteinemia  
· Familial Alpha-Lipoprotein Deficiency  
· Familial High-Density Lipoprotein Deficiency  
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TD is a rare autosomal codominant condition caused by mutations in both alleles of the ATP-
binding cassette protein 1 (ABCA1) gene on chromosome 9q31 (263). ABCA1 is a key 
gatekeeper influencing intracellular cholesterol transport and it helps cells to get rid of excess 
cholesterol. This cholesterol is then picked up by HDL particles in the blood and carried to 
the liver, which processes the cholesterol to be reused in cells throughout the body. 
Mutations in ABCA1 lead to defective cholesterol efflux from macrophages, with rapid 
catabolism of HDL and increased apoA-I clearance (Fig.:3). This leads to low plasma levels 
of HDL cholesterol <5mg/dl and apoA-I. Cholesterol accumulation in the reticuloendothelial 
system results in enlarged, yellow-orange tonsils and hepatosplenomegaly (263). Intermittent 
peripheral neuropathy can also be seen due to cholesterol accumulation in Schwann cells 
(263). TD is probably associated with some increased risk of premature atherosclerotic 
vascular disease, but this risk does not seem to be proportional to the markedly decreased 
HDL cholesterol and apoA-I levels. Patients with TD have a pathologic accumulation of 
cholesterol in macrophages as well as in cells of the reticuloendothelial system (264). 
Heterozygotes have moderately reduced HDL and apoA-I levels and an increased risk of 
coronary artery disease (CAD), but they show no evidence of cholesterol accumulation (eg. 
tonsillar enlargement or hepatosplenomegaly) (264) and vice versa (Fig. 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10: ABCA1 structure and mutations in HDL deficiency syndromes 
 
 
 
C
A
ABC
B
S
A
N
ABC
B
S
44
23
703
681
718
740
769
747
774-794
822
842
1368
1346
1655
1677
1724
1702
1737
1759
1790
1768
1848
1870
642
660
1
23
4
5
6
7
8
9
1011
12
13
14
15
16
17
18
19
20
21
22
23,24
25
26
27
28
29
30
31
32
33
34
35
36 37
38
39
40
41
42
43
44
45
46 47
48
49 5051 52PEST
domain
Macrophages
Platelets
Macrophages
Platelets
Introduction 
 
 35 
11.  Sphingolipid and phospholipid metabolism 
Atherosclerotic lesions accumulate glycosphingolipids (GSLs) (265) as well as ceramide and 
sphingolipids (SLs) which have emerged as a new class of lipid mediators of the atherogenic 
process. In response to various extracellular stimuli, SL turnover can be stimulated in 
vascular cells and cardiac myocytes. Subsequent generation of SL molecules such as 
ceramide (Cer), sphingosine, and sphingosine-1-phosphate (S1P), is followed by regulation 
of ion fluxes and activation of various signaling pathways leading  to SMC proliferation, 
endothelial cell differentiation or apoptotic cell death, cell contraction, retraction or migration 
(266). Some SLs like S1P participate in the proliferation of vascular wall cells, favoring 
thickening and plaque stabilization (267). Further through an inflammatory response initiated 
by cytokines or Ox-LDL, lipids such as Cer, LacCer, or S1P can upregulate adhesion 
molecule expression and induce adhesion and migration of monocytes, which are crucial 
events in initiation and progression of atherogenesis (266). In addition SLs, eg. Cer or 
sphingosine derivatives, may promote cell death (mostly by apoptosis) in the vascular wall, a 
process implicated in plaque erosion and associated thrombosis. By modulating platelet 
activation and aggregation, glycolipids and sphingosine derivatives may favor thrombosis, as 
Cer could do by affecting tissue factor or plasminogen activator inhibitor (PAI)-1 release. A 
low plasma level of glucosylceramide (GlcCer) has also been proposed as a risk factor for 
venous thrombosis.  
 
 
 
 
 
 
 
 
 
 
Fig.11: Interrelation between sphingolipid and phospholipid metabolism 
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11.1. Sphingomyelin (SM) 
SM has been found to be an abundant constituent in the outer leaflet of the plasma 
membrane lipid bilayer of all tissues, as well as in the polar surface of circulating lipoproteins 
(268). Abnormalities in SM metabolism have been associated with atherosclerosis, cancer 
and genetic disorders (e.g. Niemann-Pick disease). The majority of SM is present in the 
plasma membrane, however a reasonable portion of cellular SM exists also in lysosomes, 
endosomes and the Golgi (269). Due to its unique physicochemical properties, SM is 
enriched in specialized lipid microdomains such as rafts and caveolae. Turnover of SM is a 
critical process and influences the maintenance of membrane integrity and synthesis of new 
membranes (270).  
SM synthesized in the Golgi is transported to the plasma membrane via vesicular transport 
(271). SM synthesis de novo is mediated by SM synthase which transfers the 
phosphorylcholine moiety from phosphatidylcholine (PC) onto Cer forming SM and 
diacylglycerol (DAG) (Fig.11) (272). This enzyme is also able to catalyse the reverse reaction 
and generate PC from SM and DAG (273). Recently, a novel family of membrane proteins 
responsible for SM synthesis has been identified (274). Two members of this family SM 
synthase 1 (SMS1) and SM synthase 2 (SMS2) fulfill the criteria for functional SM synthases. 
SMS1 seems to represent the well-known Golgi-associated SM synthase while SMS2 is 
located to the plasma membrane. The presence of SM synthase in the plasma membrane 
may impair Cer signalling by converting Cer back to SM and generating DAG.  
The degradation of SM leads to the release of Cer and free sphingosine, known signalling 
molecules. However, aside from generation of second messengers, stimulation of SM 
hydrolysis has been shown to induce cholesterol movement from cell surface to intracellular 
membranes (269). This suggests that SM metabolism plays an essential role not only in 
signalling pathways but also in the alteration of membrane physical properties.  
SMases, enzymes catalysing hydrolysis of SM, have been classified into five categories 
based upon their pH optima, cellular localization, and cation dependence and are 
summarized in table 3.  
 
Tab. 3: Different SMases 
Sphingomyelinase (SMase) Localization Unigene Reference 
Ubiquitous acid SMase Lysosome Hs.77813 (Gatt et al. 1966; Kanfer et al. 
1966) 
Neutral Mg-dependent SMase Membrane-bound Hs.55235 
Hs.283616 
(Rao and Spence 1976) 
Mg-independent SMase Myelin sheath, cytosol of  
leukaemic cells 
 (Chakraborty et al. 1997) 
(Okazaki et al. 1994) 
Neutral Mg-stimulated SMase Nuclei of rat ascites cells Hs.55235 
Hs.283616 
 (Tamiya-Koizumi et al 1989) 
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Sphingomyelinase (SMase) Localization Unigene Reference 
Neutral SMase Chromatin and envelope of  
rat liver cell nuclei 
Hs.55235 
Hs.283616 
(Abi and Magni 1997; 
Alessenko and Chatterjee 
1995) 
Alkaline SMase Bile and the digestive tract Hs.114084 (Nyberg et al. 1996) 
Acid secretory Zn- 
dependent SMase 
Serum Hs.77813  (Spence et. al. 1989)  
(Schissel et al. 1996a) 
Acid SMase-like  
phosphodiesterase  
Bladder tumors Hs.277962 
Hs.123659 
(Wright et al. 2002) 
 
Neutral membrane-bound Mg2+-independent neutral-SMase and lysosomal acid -SMase 
have been the best studied for their roles in Cer generation. An increase in neutral-SMase 
activity, a corresponding decrease in SM, and an increase in Cer have been demonstrated in 
response to TNFα, Fas ligand, 1α,25-dihydroxyvitamin D3 γ-interferon, chemotherapeutic 
agents, heat stress, ischemia/reperfusion, and interleukin-1 (275;276). In addition, both 
arachidonic acid and glutathione depletion have been shown to activate this enzyme 
(275;277). 
The acid-SMase gene codes for both lysosomal (cation-independent) and secretory SMase 
(fully or partially dependent on Zn+² for enzymatic activity) (278).  
Lysenin a protein derived from coelomic fluid of the earthworm Eisenia foetida specifically 
recognizes SM (214;279). The specific binding of lysenin to SM makes it possible to use this 
protein as a unique tool to examine the distribution of cell surface and intracellular SM 
(279;280). 
 
11.2. Ceramide (Cer) 
Cer forms the backbone for all sphingolipids. De novo, biosynthesis of Cer, in the 
endoplasmic reticulum (ER), is initiated by the condensation of serine and palmitoyl-CoA 
(Fig.11), a reaction which is catalyzed by serine-palmitoyl CoA transferase (SPT). 
Mammalian SPT is a heterodimer of 35-kDa long-chain base gene 1 (LCB1) LCB1/SPT1 and 
63-kDa long-chain base gene 2 (LCB2) LCB2/SPT2 subunits bound to the ER (281) and 
building the enzyme in a 1:1 ratio (282). SPT is the first and rate-limiting enzyme in the de 
novo pathway (283). The newly formed 3-ketosphinganine is subsequently reduced by 
NADPH-dependent ketosphinganine reductase to dihydrosphingosine. Afterwards 
dihydroceramide is formed by the amide linkage of fatty acyl groups to dihydrosphingosine 
through the action of ceramide synthase. Subsequently Cer is formed from dihydroceramide 
by the introduction of the trans-4,5-double bond. The reaction is catalyzed by 
dihydroceramide desaturase originating from the cytosolic side of the ER. At the state of 
cellular homeostasis, once formed, Cer is not accumulated but translocated to the Golgi 
where it serves as a starting point and metabolic precursor for all other sphingolipids such as 
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sphingomyelin (SM), glycosphingolipids (GSLs) of the lacto-, globo- and ganglioside series, 
and sulfatides. There are at least two pathways by which Cer is transported to the Golgi: an 
ATP- and cytosol-dependent major pathway and an ATP- or cytosol-independent minor 
pathway (284;285). 
Recently, a gene called ceramide transfer protein (CERT) has been identified (286). CERT 
mediates the non-vesicular transport of Cer form the ER to the Golgi apparatus, where Cer is 
further converted to SM. This gene is a splice variant of the Goodpasture antigen-binding 
protein (GPBP-delta26) and codes for a cytoplasmic protein with a lipid-transfer catalysing 
START domain, a phosphoinositide-binding pleckstrin homology (PH) domain and two 
phenylalanines (FF) in an acidic tract (FFAT) motif. The FFAT motif is found on diverse 
human lipid binding proteins (287) and its combination with a PH domain which binds to the 
Golgi apparatus seems to predict the role of CERT. There are other proteins in mammalian 
cells with lipid- and organelle-binding domains that are similar to those in CERT. For 
example, STAR and MLN64 proteins recognize cholesterol (288;289), and 
phosphatidylcholine (PC)-transfer protein is capable of intermembrane transfer of PC in vitro 
(290).  
Cer de novo synthesis is influenced by factors regulating the activity of serine 
palmitoyltransferase (SPT) and it has been documented that SPT mRNA expression and 
SPT activity increase in response to various inflammatory and stress stimuli. Interleukin-1ß 
(291), UVB radiation (292) fatty acids and cholesterol stimulate the activity of SPT resulting 
in the cytotoxic accumulation of palmitate accompanied by the elevation of intracellular Cer 
and induction of apoptosis. Cer is also generated at various subcellular locations by SM 
hydrolysis (293). This process of Cer formation is a receptor-operated pathway (294) which 
remained evolutionary unchanged and is induced by different environmental and 
physiological stimuli. At the plasma membrane, Cer is generated from SM hydrolysis by 
acidic and/or neutral sphingomyelinases (SMases) activated by diverse cytokines, death 
receptor ligands, differentiation factors or drugs (277). Stimulation of cells with 1,25-
dihydroxy-vitamin D3, TNFa and CD40 ligand activates a neutral SMase at the plasma 
membrane of cells, generating at the cytosolic side intracellular Cer and phosphocholine 
(295;296). Cer can also be formed through the action of an acidic SMase (see 10.1.1. 
ceramide and raft formation). Up till now, several SMases have been characterized in 
mammalian tissues and they differ from each other by their location, Mg+2 and Zn+2 
dependence and pH optimum (277) (table 3).  
Cer can follow several metabolic pathways. It can be reutilized for the synthesis of SM via 
SM synthase which transfers the phosphorylcholine moiety from phosphatidylcholine (PC) 
onto Cer forming SM and diacylglycerol (DAG) (272). Or Cer may be phosphorylated to form 
ceramide-1-phosphate. Cer catabolism can also be initiated by glucosylceramidase which 
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forms glucosylceramide (GlcCer) the starting substance of all the other GSLs. Another way of 
Cer degradation starts with a ceramidase catalysing the cleavage of Cer at the amide bond 
resulting in sphingosine and a free fatty acid. Three types of ceramidases have been 
described to date and classified according to pH optima as acid, neutral, or alkaline (297). 
The deficiency of acidic ceramidase, which is located in lysosomes, provides the genetic 
background for Farber’s disease (298). Sphingosine released due to the action of 
ceramidase can be reacylated to Cer or posphorylated by sphingosine kinase (SphK) to 
sphingosine-1-phosphate (S1P) the precursor of phospholipid synthesis. Two SphK isotypes, 
type 1 and type 2 exist. Although highly similar in amino acid sequence and possessing five 
conserved domains, SphK type 1 is smaller than type 2 and expressed mainly in the cytosol, 
while SphK type 2 additionally has several transmembrane regions and a proline-rich SH-3-
binding domain. This suggests different cellular functions and regulation mechanisms of the 
two isotypes (299). S1P is further metabolized by the enzyme S1P-lyase to palmitaldehyde 
and phosphoethanolamine. Afterwards the enzyme phosphate cytidyltransferase 2, 
ethanolamine leads to the formation of CDP-ethanolamine from which the 
aminoglycerophospholipid phosphatidylethanolamine is formed by ethanolamine 
phosphotransferase. Then phosphatdiylcholine is syntesized by adding one methyl residue 
with phosphatidylethanolamine N-methyltransferase. The originated phosphatidylcholine can 
be cleaved into the components choline and phosphatidic acid. 
 
11.2.1. Cer and raft formation 
Lipid rafts are originally defined as sphingolipid- and cholesterol- rich microdomains in the 
plasma membrane which play a role in a number of signalling processes involving specific 
receptors. According to Gulbins and Kolesnick (300) Cer might induce coalescence of sub-
microscopic rafts into large-Cer-membrane macrodomains due to its capacity to self-
associate through hydrogen bonding. These larger structures may serve as platforms for 
protein concentration and oligomerization, transmitting signals across the plasma membrane. 
Cer is generated by the action of acid SMase in response to diverse stress stimuli including 
chemotherapeutic drug treatment, factor withdrawal (e.g. IL3, NGF), radiation, UVA light, 
heat and ischemia. Cer then activates a variety of diverse protein kinase and protein 
phosphatase dependent signalling pathways which in most cases suppress cell growth 
and/or promote programmed cell death. This Cer-dependent organization of signalling 
domains in the membrane may relate to progression and treatment of diseases like cancer, 
degenerative disorders, pathogenic infections or cardiovascular disease. Sudden increases 
of Cer within the membrane have been shown to be involved in the regulation of cell 
apoptosis. Studies on CD95/Fas receptor have demonstrated that stimulation via this 
receptor triggers the translocation of the acid SMase from intracellular stores onto the 
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extracellular leaflet of the cell membrane. This surface acid SMase releases Cer from SM 
that rapidly forms Cer-enriched platforms in the cell membrane, which might serve as 
signalling platforms for the transmission of the apoptotic signal (301). Another example for 
Cer induced signalling is the finding that the generation of cell surface Cer through the action 
of acid SMase is a prerequisite for fusion of cross-linked FcgRII (CD32) and rafts, which 
triggers the receptor tyrosine phosphorylation and signalling (302).  
Recently it has been shown that the formation of Cer-enriched domains in lipid particles 
enhances the binding of apoE and thus inhibits the SMase induced aggregation or fusion of 
the particles (110). Further it could be shown that surface SM reduced apoE mediated 
binding and uptake of lipid particles (111) suggesting a higher affinity of apoE to Cer than to 
SM.  
 
11.2.2. Cer and its homology with lipopolysaccharide (LPS ) 
Cer shares some structural and functional similarities with the lipid A moiety of LPS, a lipid 
from the outer membrane of gramnegative bacteria. The cellular responses to LPS include 
changes in shape, metabolism, and gene expression but also induction of a variety of 
biological effects that are involved in systemic inflammation and sepsis (303). The initiation of 
these effects is due to the activation of monocyte/macrophages, leading to the secretion of 
proinflammatory cytokines such as TNFa, IL-1ß, IL-6 and IL-8. It has been suggested that 
LPS and Cer recognize the same intracellular molecules (304) and LPS was shown to 
mimick some Cer properties. Cer-activated protein kinase (CAPK) appears to be a common 
target and its activation by both agonists leads to the activation of MAP kinase and the 
translocation of activated NF-kB. Recent data emphasize that although LPS and Cer may 
share many signalling components, the signalling pathways are not identical (304). 
In human monocyte derived macrophages exogenous Cer as efficiently as LPS induces the 
coassociation of the LPS receptor CD14 with complement receptor 3 (CD11b/CD18), the 
thrombospondin receptor CD36 and decay accelerating factor CD55 (30;305) (Fig.5). Thus 
clustering of signalling competent receptors may provide an interesting mechanism by which 
different ligands induce distinct cellular processes in systemic inflammation (SIRS or sepsis) 
and cardiovascular disease. 
 
11.3. Sphingosine-1-phosphate (S1P) 
The sphingosine metabolite S1P is produced upon phosphorylation of sphingosine by 
sphingosine kinase 1 and 2 (SPHK) (Fig.11). S1P can be further degraded to 
phosphoethanolamine and palmitaldehyde by S1P-lyase with the exception of platelets which 
lack S1P-lyase. S1P can be also converted back to sphingosine via the action of S1P 
phosphatase increasing the level of sphingosine in the cytosol and cell membranes. The 
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concentration of S1P is quite low, possibly reflecting the low expression of SPHK or the high 
lyase activity. Growth and survival factors, such as platelet derived growth factor (PDGF), 
serum, nerve growth factor (NGF) as well as muscarinic acetylcholine agonists and TNFa 
increase the intracellular concentration of S1P by activating SPHK. S1P is suggested to be 
involved in the regulation of cell shape changes, platelet aggregation, neurite retraction and 
smooth muscle cell chemotaxis (306) and it was implicated as a second messenger in 
cellular proliferation and survival. Through its high affinity G protein-coupled receptors, S1P 
is a physiological mediator regulating heart rate (307) coronary artery blood flow (308), blood 
pressure (309), endothelial integrity in the lung (310) and most recently it has been shown to 
regulate the recirculation of lymphocytes (311).  
The intracellular targets of S1P have not been yet identified and it has been shown that S1P 
binding to its receptors stimulates SPHK to increase its own intracellular level (312). Up till 
now 5 receptors for S1P were identified and named according S1P1 to S1P5 receptors (313). 
All five receptors have been shown to bind S1P with high affinity and activate several 
intracellular processes related to angiogenesis, apoptosis, atherosclerosis, migration and 
proliferation (314;315). The receptors for S1P belong to the edg (endothelial differentiation 
gene) family of the seven transmembrane G protein-coupled receptor superfamily.  
 
11.4. Regulation of cell death/survival by Cer and S1P 
 
 
 
 
 
 
 
 
Fig. 12: The SM/Cer/Sph/S1P rheostat model 
 
Cer has emerged as a lipid messenger of cell functions including differentiation and 
apoptosis. Cer can be generated by diverse kinds of stresses (ultraviolet, irradiation, heat 
shock and hypoxia) or biological factors (TNF-alpha, IFN-gamma and Fas antibody) through 
stimulation of the SM degrading enzyme SMase to execute apoptosis (316) (Fig.12). Cer is 
degraded with ceramidase to sphingosine, which is then phosphorylated by sphingosine 
kinase (SphK) to form S1P (317) (Fig.11/12), a molecule implicated in cell survival and cell 
growth. This suggests that the metabolic conversion of Cer into S1P could switch cells from 
an apoptotic state to a proliferative one. Therefore the balance between cellular 
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concentrations of Cer and S1P has been proposed to determine the physiological fate of the 
cell, which is also known as the “Cer-S1P-rheostat model” (Fig.12).   
Intracellular Cer induces the caspase family and reactive oxygen intermediates (ROI), which 
are signals for inducing apoptosis, whereas S1P is known to extracellularly activate the 
phosphatidylinositol 3-kinase (PI3K) pathway through G-protein-binding EDG family 
receptors (318). Therefore S1P enhances the activation of protein kinase C, leading to the 
inhibition of Cer-induced apoptosis (319), which is activated via inhibition of PI3K activity/Akt 
kinase activity. Further PI3K potentiates inhibition of SMase activity and subsequently inhibits 
the ability to produce intracellular Cer in response to stress (320).  
It can be concluded that Cer and S1P function interdependently and are deeply correlated 
with cell proliferation, cell survival and induction of apoptosis (321). Their interaction in the 
mechanism of maintaining a microdomain structure on the cell membrane is also becoming a 
subject of recent interest (300). 
 
12. Glycosphingolipids  (GSLs) 
 
12.1. Structure and functions of GSLs 
GSLs, amphipathic compounds consisting of sugar and Cer moieties, are ubiquitous 
components of the plasma membrane of all vertebrate cells. GSLs are considered to be 
receptors for bacteria, viruses and their toxins (e.g. Vibrio cholera, HIV), modulators of cell 
growth and differentiation, organizers of cellular attachment to matrices, play roles in cell-cell 
adhesion and receptor mediated signal transduction. Further glycolipids have been identified 
as tumor or differentiation antigens using monoclonal antibodies. More than 400 species of 
GSLs possessing different sugar structures have been reported, although only seven 
monosaccharides have mainly been found in vertebrate GSLs. GSLs show heterogeneity not 
only in their sugar chain but also in their Cer moieties. The biological significance of Cer 
heterogeneity is still not well understood. However, the structure of Cer, especially the fatty 
acid moieties, could influence the localization and functions of GSLs on the plasma 
membrane, possibly by direct interaction with cholesterol, phospholipids, and the 
transmembrane domains of receptor proteins. It is noteworthy that free Cer derived from 
GSLs, could mediate intracellular signal transduction.  
 
12.2. GSLs and raft formation 
The plasma membrane GSLs form clusters, called rafts, with cholesterol and relatively less 
phospholipids than other areas of the plasma membrane. The size of lipid rafts seems to 
range from “vanishingly small” <70 nm (322), to intermediate rafts ~100 nm scale (323), to 
larger-scale macrodomains (~500 nm or larger) (324;325). The partitioning of sphingolipids 
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into rafts allows the lipids themselves to be used as markers for rafts. For example, the GSL 
ganglioside GM1 that binds to the non-toxic b-subunit of cholera toxin is a commonly used 
raft marker. Theta Toxin (perfringolysin O), a thiol-activated cytolysin produced by 
Clostridium perfringens has been shown to bind to cholesterol in membrane microdomains 
that fulfill the biochemical criteria of rafts (326) and has been used as a cytochemical probe 
to evaluate the topology and distribution of cell surface rafts in intact cells (327;328). A recent 
study indicated a high distribution of the saturated, fluorescent phospholipid probe DMPE-
TMR ([1,2-dimyristoyl-sn-glycero-3-phospho-ethanolamine]-tetramethyl-rhodamine) into 
membrane domains of the liquid ordered phase (329). It is very likely that DMPE-TMR 
represent the in vivo correlate of Triton resistant raft-microdomains because of the saturated 
side chain enabling and association with lipid ordered membrane domains such as rafts. The 
fluorophore is able to specifically intercalate with these domains and allows also the 
visualisation of the phagosome compartment. Rafts are extracted in low density fractions, 
insoluble in non-ionic detergents such as Triton X-100 and Lubrol WX and are called 
detergent-insoluble glycolipid-enriched complexes, or detergent insoluble GSL-enriched 
domains (DIGs).  
 
 
 
 
 
 
 
 
 
 
There are receptors for intercellular signal transducers such as glycosylphosphatdiylinositol 
(GPI)-anchored proteins on the exoplasmic face of the rafts and src family kinases on the 
cytosolic face. (Fig.13). Furthermore, endothelial growth factor (EGF) receptor and Ras are 
present in GSL microdomains. Also a specific association of protein kinase C alpha with GSL 
microdomains has been reported (330). Thus they play a role in transmembrane 
signaltransduction. Into this fraction, microinvaginated structures (diameter, around 50 nm) of 
the plasma membrane, caveolae, are also extracted. Caveolae also consist of GSLs, 
cholesterol, GPI-anchored proteins, src family kinases, trimeric G proteins, Ras, and a 
caveolae-specific membrane protein, caveolin, which associate themselves and bind to 
cholesterol and may take the invaginated shape. Caveolae are domains where endocytosis 
can occur. Rafts may be trapped in caveolae and the receptor molecules are clustered more 
Fig. 13: Arrangement of GSLs in the plasma membrane 
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densely. This may improve efficiency of signal transduction. Recently, GSLs were found in 
caveolae, on the exoplasmic membrane, where signal transduction-related proteins are also 
concentrated. GSLs interact with receptor molecules and kinases, and modulate their 
functions. The general function of GSL microdomains in signal transduction may be to 
concentrate receptors and effectors on both sides of the membrane, thus speeding up 
binding during signalling and preventing inappropriate crosstalk between pathways 
(331;332). In table 4 some substances and antibodies are listed for raft detection. 
 
Table 4: Detection of raft lipids (see also Materials and Methods for detailed information) 
Raft Lipid Substance/Antibodies for Detection 
Cholesterol Theta Toxin (perfringolysin O) 
Sphingomyelin Lysenin 
Ceramide Monoclonal antibody (IgM) mouse 
LacCer (CDw17) Monoclonal antibody 
Gb3Cer (CD77) Monoclonal antibody and Shigatoxin 
Dodecasaccharideceramide (CD65s) Monoclonal antibody 
Ganglioside GM1 Cholera Toxin 
 
 
12.3. GSL-biosynthesis 
In the pathway of GSL synthesis, the first step is transfer of glucose or galactose to a Cer 
from the endoplasmatic reticulum (ER) to produce glucosylceramide (GlcCer) or 
galactosylceramide (GalCer), respectively. This transfer reaction is catalyzed by 
glucosyltransferase (GlcT) (333;334) and galactosyltransferase (GalT), respectively (Fig. 12). 
Since over 400 different glycolipids are derived from GlcCer, GlcT-1 is an extremely 
important glycosylation enzyme. The catalytic domain of GlcT is located on the cytosolic side 
of the Golgi membrane, while that of GalT is on the lumen side of the ER. The rule of 
extension of sugar chains for GSLs is common in all mammals, i.e. a monosaccharide is 
sequentially transferred to a GlcCer or GalCer from a nucleotide sugar by one of a series of 
specific glycosyl transferases, all of which are localized on the lumen side of the Golgi 
membrane. In the lumen of the Golgi, GlcCer is galactosylated to lactosylceramide (LacCer) 
(Gal-Glc-Cer). Thus GlcCer produced on the cytosolic side of the Golgi membrane must be 
transferred (flip-flopped) to the lumen side by a putative enzyme. It appears most likely that 
glycolipid transfer protein (GLTP), a nonglycosylated protein with a molecular weight of 
22.000 K, transfers by a carrier mechanism, glycolipids with a beta-glucosyl or beta-
galactosyl residue directly linked to either Cer or diacylglycerol and participates in the 
intracellular traffic of GlcCer from the cytoplasmic side to the luminal side of the Golgi 
apparatus were glycosylation of GSLs occurs (335). Depending on the sugar that attaches to 
the nonreduced end of LacCer  three synthetic pathways leading to the formation of lacto-
series (neolacto-series), globo-series and ganglio-series have been defined (Fig.14). Above 
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all, the ganglio-series glycolipids contain many sialic acids, and are designated gangliosides. 
Most cells synthesize the ganglioside GM3, by the transfer of sialic acid to LacCer, but in 
addition make one other trihexosylceramide. GM3 ganglioside is sialylated to GD3, and GD3 
to GT3 (Fig.14). The three involved sialyl-transferases (SIAT I, SIAT II and SIAT III) 
specifically recognize the acceptor substrate (336;337). GM3, GD3 and GT3 are the starting 
points for the “a-series”, “b-series” and “c-series” gangliosides, respectively. Along each 
series, non-specific N-acetylgalactosaminyl-transferase, galactosyl-transferase and SIAT IV 
introduce in sequence a residue of N-acetylgalactosamine, galactose and sialic acid, 
respectively, giving rise to more complex gangliosides. Further sialosylations can be 
accomplished by SIAT V. From LacCer, a further series of GSL ("O-series") can originate 
from the sequential action of N-acetylgalactosaminyl-transferase, galactosyl-transferase and 
sialyl-transferase IV and V (Fig. 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14: Scheme of the de novo biosynthesis of the oligosaccharide moieties of gangliosides 
 
The activity of galactosyltransferase, which catalyses the synthesis of LacCer, has been 
found increased in familial hypercholesterolemia and atherosclerosis (338;339). The 
increased levels of other GSLs in atherosclerotic lesions have been also reported (340). 
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Further LacCer is associated to plasma lipoproteins and various cell types such as 
endothelial cells and SMCs, monocytes and macrophages (265). LacCer may contribute to 
atherosclerosis as it was found in fatty streaks and intimal plaques (339;340). It stimulates 
also the proliferation of SMCs (341-343) and the expression of CD11b/CD18 on the surface 
of human neutrophils (344). LacCer participates in superoxide generation by induction of 
NADPH oxidase and is involved in removal of macromolecular antigens (345). Ox-LDL also 
stimulates specifically the biosynthesis of LacCer through enhanced activity of 
galactosyltransferase (343) while native LDL exerts an opposite effect (338;346). The neutral 
GSL globotriaosylceramide (Gb3Cer) emerges as an anticoagulant (347) and transducer of 
apoptotic signals (348), eventually abrogating proinflammatory activities of lipid-loaden foam 
cells. The complex sialylated GSL dodecasaccharideceramide (CD65s) may function in 
adherence (349;350) and cellular activation (351). Moreover, the ganglioside GM1 plays an 
immunoregulatory and  structural role in macrophages. 
The biological functions of GSLs as well as the mechanism that regulates GSL metabolism in 
cells seems to still be a true mystery of the Sphinx, which is in fact the origin of the word 
'Sphingolipid.' The recent remarkable progress that has been made in the gene cloning of 
glycosyltransferases and glycosylhydrolase should help provide an answer to this mystery. 
To solve the riddle of glycolipid functions and to gain insight into the role of Cer glucosylation 
in whole animal, a method to eliminate a gene of glycolipid glycosyltransferase in mice has 
been developed and knock out mice have been generated. Since GlcCer is a central lipid as 
a precursor for numerous GSLs including brain gangliosides, the mice would be invaluable 
tools for understanding of the general functions of GSLs (331). 
 
12.3.1. Inhibitors of GSL-biosynthesis 
The experimental approach to deplete cellular GSLs with the specific inhibitors of GSL 
biosynthesis has the potential to identify functions of endogenous GSLs.  
It has been demonstrated by Inokuchi and Radin that an analog of Cer, D-threo-1-phenyl-2-
decanoylamino-3-morpholino-1-propanol (D-PDMP) inhibits the glucosyltransferase, which 
produces GlcCer. D-PDMP not only suppresses GSL biosynthesis, but also accumulates Cer 
and sphingoid bases. Therefore, one should consider carefully both effects of D-PDMP for 
interpretation of the results (352;353).  
Recently, it was found that N-butyldeoxynojirimycin, known as an inhibitor against alpha-
glucosidase I, also inhibits GlcCer synthase. Among various N-alkylimino sugars tested, N-
butyldeoxygalactonojirimycin possesses no visible cytotoxicity and higher specificity for the 
inhibition of GlcCer synthesis. Much progress will be expected on the mechanism of GlcCer 
synthesis inhibition by these N-alkylimino sugars and on its medical application for treatment 
of Gaucher's disease. 
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12.4. Cellular distribution of GSLs  
While their density in plasma membrane is high, two-thirds of the total GSLs are distributed 
in intracellular membrane such as Golgi apparatus, endosomes, lysosomes, nuclear 
membrane, ER and mitochondria. GSLs, along with other membrane components, circulate 
through these organelles. In Golgi apparatus, GSLs are newly synthesized by the addition of 
saccharides one by one and in lysosomes they are degraded by the removal of saccharides 
one by one. GSLs, which are incorporated by endocytosis, are sorted into lysosomes or 
Golgi apparatus from endosomes. Newly synthesized GSLs are sorted into plasma 
membranes through endosomes. A portion of endocytosed GSLs are returned back to the 
plasma membrane (Fig.15). One half of GSLs in plasma membrane were recycled and their 
composition in the plasma membrane remains constant. Most GSLs are transported between 
membranes as small vesicles maintaining a bilayer structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
GSLs not only circulate between the plasma membrane and intracellular organs, but also 
move laterally over the exoplasmic membrane. Such migration could be conducted by the 
cholesterol-rich unit known as a 'raft.' 
On the cytosolic surface of the Golgi, part of Cer is glucosylated to GlcCer. From here, 
GlcCer may follow three pathways, none of which can be excluded at present:  
1) It can translocate across the Golgi membrane, evidence for which has been found in vitro, 
and can be (partially?) converted to higher GSLs GlcCer and the higher GSLs may then 
leave the Golgi on the lumenal side of transport vesicles (293) (Fig.15). 
2) GlcCer may leave the Golgi on the cytosolic surface of secretory vesicles, and 
subsequently undergo tanslocation to the outer leaflet of the plasma membrane by multi drug 
resistant 1 (MDR1) P-glycoprotein. Alternatively, along the retrograde pathway, GlcCer might 
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be translocated across the ER membrane, after which it would have a fate similar to newly 
synthesized GalCer (293). 
3) GlcCer might leave the cytosolic surface of Golgi membrane by desorption from the 
membrane and monomeric exchange with another organelle´s cytosolic surface. Good 
evidence has been presented that higher GSLs follow a vesicular transport pathway from 
their site of assembly in the lumen of the Golgi to the PM. This was demonstrated for the 
early ganglioside GM3, and for the late ganglioside GD 1a (354).  
Ganglioside GM1 and globotriaosylceramide can act as receptors for the bacterial toxins 
cholera toxin (355) and Shiga toxin (356) respectively. These toxins need to reach the ER, 
where they translocate across the membrane to become active in the cytosol. Endocytotic 
transport of the toxin-GSL complex has provided information on vesicular transport pathways 
from SL domains on the plasma mebrane to the ER (357;358). Vesicular traffic of GSLs can 
be expected to display the full complement of properties that characterize vesicular transport 
of proteins, like dependence on energy and cytosolic proteins (coats, SNAREs, 
cytoskeleton). 
 
12.5. Degradation of GSLs 
GSL degradation occurs through the stepwise removal of individual sugar residues, starting 
from the non-reducing terminal unit, by acid exoglucosidases with the formation of Cer, which 
is eventually split into long chain base and fatty acid by ceramidase (336;337). Cer can leave 
the lysosome, reenter the biosynthetic pathway or be further degraded. Since GSLs have 
many of the same outer sugar sequences that are found in N- and O-glycans, many of the 
same glycosidases are used for their degradation. The degradation of plasma derived GSLs 
takes place in the lysosomes as the digesting organelles after internalization through the 
endocytic pathway. All the enzymatic steps of the degradative process require an acidic pH 
inside the organelle which is maintained by a proton pump that brings H+ inside the organelle 
(336). However, specialized hydrolases are needed for cleaving the Glc-Cer and Gal-Cer 
bonds and other linkages near the membrane. Besides these specific enzymes, additional 
noncatalytic sphingolipid activator proteins (SAPs) (some called saposins) help present the 
substrate to the enzyme for cleavage. These proteins are necessary for the degradation of 
GSLs possessing short oligosaccharide chains where they mediate the interaction between 
the water-soluble enzymes and their membrane-bound substrates by forming water-soluble 
complexes, which lift out of the membrane (359). A total number of five SAPs are known, and 
they are encoded by only two genes. One gene codes for prosaposin 524-amino-acid 
precursor (pSAP) (360), which is proteolytically processed to four highly homologous 
proteins (SAP-A, -B, -C and –D). They are glycoproteins with molecular weights of 12-15 
kDA, show highly homologous sequence identities to each other and have similar properties 
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but differ in their function and their mechanism of action. Sap-A and Sap-C both help b-
glucosyl and b-galactosyl ceramidase degradation. Sap-B assists arylsulfatase A, a-
galactosidase, a-sialidase, and β-galactosidase. Sap-D and Sap-B also assist in SM 
degradation by SMase. The second gene encodes GM2 activator protein (GM2AP), which 
acts on the degradation of ganglioside GM1 and GM2 (361). GM2AP forms a complex with 
either GM2 or GA2 and presents them to β-N-acetylhexosaminidase A for cleavage of 
terminal β-GalNAc. Sugars that lie too close to the lipid bilayer apparently have limited 
access to the soluble hexosaminidase. The activator protein binds a molecule of glycolipid, 
forming a soluble complex that can be cleaved by hexosaminidase. The resulting product is 
now inserted back into the membrane, and the activator presents the next GM2 molecule, 
and so on. Genetic loss of this activator protein causes the accumulation of GM2 and GA2, 
resulting in the AB variant of GM2 gangliosidosis. The activator is probably targeted to the 
lysosomes via the Mannose-6-Phosphate pathway.  
All saposins may have more or less nonspecific stimulative effects on activities of lipid 
hydrolases by making more of the lipid substrates available to hydrolases (362). Since SAPs 
form water soluble complex with sphingolipids, as mentioned before, it can be assumed that 
SAPs may also function in lipid transport. Sandhoff and his colleagues showed that saposin 
B can transport gangliosides between liposomes (359). 
The inherited deficiency of both lysosomal hydrolases and SAPs gives rise to sphingolipid 
storage diseases (Fig.16). Complete absence of prosaposin is lethal in humans. 
Glucocerebrosidase, also called β-glucoceramidase, is specific for the degradation of the 
Glc-Cer bond, and its loss causes Gaucher's disease, where GlcCer accumulates (363). A 
specialized β-galactosidase, called β-galactoceramidase, hydrolyzes the bond between Gal 
and Cer, and it can also cleave the terminal Gal from LacCer. Its loss produces Krabbe 
disease. GalCer is often found with a 3-sulfate ester (sulfatide), and thus a specific sulfatase, 
arylsulfatase A, is needed for its removal prior to β-galactosylceramidase action. Loss of this 
sulfatase causes metachromatic leukodystrophy and the accumulation of sulfatide but also 
additional glycolipids, e.g. globotriaosylceramide, accumulate owing to a blockage of 
degradation at several points in the catabolic pathway. Glycolipids terminated with a-
galactosamine residues are degraded by a specific a-galactosidase and its loss causes 
Fabry disease (Fig.16).  
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Fig. 16: GSL metabolism and disease (from Sillence D. J. et. al. 2003 (50)) 
 
 
13. Interrelation between apoE and ceramide metabolism 
 
13.1. Enhanced binding of apoE on ceramide enriched microdomains 
As reported recently, the formation of Cer-enriched domains in lipid particles enhances the 
binding of apoE and thus inhibits the SMase induced aggregation or fusion of the particles 
(110). In contrast to Cer, surface SM reduced apoE mediated binding and uptake of lipid 
particles (111) suggesting a higher affinity for apoE to Cer than to SM. These results indicate 
that the conversion of SM to Cer through the actions of SMases enhances the binding of 
apoE. 
 
13.2. Induction of the monocyte innate immunity receptor cluster  
Cer a component of atherogenic lipoproteins induces as efficiently as LPS the coassociation 
of the LPS receptor CD14 with complement receptor 3 (CD11b/CD18), the thrombospondin 
receptor CD36 and decay accelerating factor CD55 (30;305). Concerning the high binding 
affinity of apoE to Cer this apolipoprotein seems to be also involved in the regulation of this 
monocyte innate immunity receptor cluster. 
 
13.3. Relationship between CRP, ceramide and apoE  
CRP is known as an opsonin for the uptake of atherogenic lipoproteins by monocytes. On 
monocytes, specific CRP binding occurs through FcgRI/CD64 (212) as well as FcgRIIA/CD32 
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(213). Previously it could be shown that cell surface Cer is a prerequisite for recruitment of 
cross-linked FcgRIIA to rafts, which triggers the receptor tyrosine phosphorylation and 
signalling (214). ApoE which binds to Cer could also be involved in the process of FcgRIIA-
raft generation and thereby triggering receptor-mediated endocytosis through a non-clathrin 
dependent mechanism. 
 
13.4. ApoE mediates antigen presentation of ceramide-backbone-lipids 
ApoE is able to bind lipid antigens and delivers them by receptor-mediated uptake into 
endosomal compartments containing CD1 in APCs (118;119). It could be shown that LRP 
and LDL-R are expressed on DCs and they are markedly upregulated during differentiation 
of monocytes to DCs and have a significant function in the uptake of apoE-lipid antigen 
complexes and presentation by CD1 (117). The delivery of lipids to the endosomal system 
can occur through three possible mechanisms (Fig.17). Either secreted or recycled apoE can 
capture lipid antigens (secretion-capture) or infected cells such as macrophages may shed 
lipid antigens associated with apoE that are delivered to bystander (uninfected) DCs 
(bystander acquisition) or serum lipoproteins (VLDL in the case of GGC) serve as a depot for 
lipid antigens and may stimulate a response far from the source of the antigen (Fig.17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17: Apolipoprotein-mediated pathways of lipid antigen presentation (Figure adapted from Van den 
Elzen, nature Vol 437 6 October 2005) 
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To investigate the role of lipoproteins in CD1 antigen presentation an in vitro model of human 
dendritic cells (DCs) was used with the CD1d-presented glycolipid, galactosyl(a1-
2)galactosyl ceramide (GGC) in human serum (117). GGC strictly requires uptake and 
delivery to lysosomes where it is converted to the active antigenic form, a-galactosyl 
ceramide (a-GC) (364). The antigenic activity of GGC was distributed almost entirely in the 
VLDL fraction of human serum which includes apoB and apoE which independently 
participates in receptor-mediated uptake into cells (365). VLDL-mediated T-cell activity was 
effectively blocked by antibodies against apoE. This blockade was specific for VLDL-bound 
GGC which bind in the VLDL fraction of serum, and is acquired by DCs in an apoE-
dependent manner, processed, and then presented to T cells. ApoE depleted serum 
incubated with GGC had a significantly lower capacity to stimulate T cells than normal 
serum, and the presenting capacity was recovered by adding back purified apoE. Therefore 
apoE might be the major factor in human serum mediating the presentation of GGC to CD1d-
reactive T cells (117). ApoE has also a crucial function in the presentation of an exogenous 
lipid antigen in vivo because apoE-deficient mice showed a drastically reduced response to 
intravenously administered GGC although they have similar numbers of a-GC-reactive NK T 
cells as wild-type mice (117).  
Further apoE specifically enhances T-cell responses to a variety of CD1-presented lipid 
antigens for multiple CD1 isoforms which is due to the apoE affinity for a wide diversity of 
lipid classes. T-cell responses to naturally occurring microbial lipid antigens were also 
enhanced in the presence of apoE for the presentation of glucose monomycolate (GMM), 
mycolic acid (CD1b-presented) and manosyl-phosphomycoketide (CD1c-presented) (366).  
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II. Aim of the thesis 
The major aim of this thesis was to analyze the different effects of the two atherogenic 
modified lipoproteins, enzymatically modified LDL (E-LDL) and mildly oxidized LDL (Ox-LDL) 
on cellular cholesterol and phospholipid metabolism, raft microdomain generation and cell 
surface receptor expression during in vitro foam cell formation and HDL3 dependent 
deloading. Experiments were performed with ApoE3/3 and apoE4/4 homozygous human 
monocyte-derived macrophages and macrophages obtained from ABCA1 deficient (Tangier) 
and hyperlipidemia patients. 
Total cell analysis of lipid loaded and deloaded macrophages using lipidomics, genomics and 
proteomics based on mass spectrometry, Affymetrix microarray analysis, Taqman RT-PCR, 
flow cytometry, image microscopy and western blot analysis was applied. Mechanisms 
underlying the regulation of cellular lipid influx, raft formation, lipid efflux and storage as well 
as surface expression of ceramide, glycosphingolipids and receptors of the macrophage 
innate immunity cluster, involved in lipid uptake and processing should be unraveled. In this 
context proteins involved in cholesterol efflux like ABCA1, ApoE, ApoC-I, CETP and PLTP 
were also analyzed. 
The results obtained from macrophages of the apoE3/3 genotype were compared with that of 
macrophages from the apoE4/4 genotype, ABCA1 deficient (Tangier) macrophages and 
macrophages of a patient with excessive hypertriglyceridemia and coronary heart disease in 
order to find out differences in the above mentioned analyzed pathways. 
These investigations should contribute to the understanding of the consequences of the 
different lipoprotein modifications E-LDL and Ox-LDL on foam cell formation which is a 
hallmark in the pathogenesis of atherosclerosis. 
Further macrophages were incubated with RXR and PPARg agonists in order to modulate 
surface expression of receptors involved in lipid uptake and processing and to analyze 
expression of genes involved in macrophage lipid metabolism to elucidate influences of 
these agonists on atherogenesis. 
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III. Materials and Methods 
 
1. Chemicals, Immunoreagents and Disposable Goods 
Table 5: List of antibodies applied for flow cytometry and confocal microscopy 
Antigen clones Provider Label 
CD14 MfP9 Becton-Dickinson, Heidelberg, 
Germany 
APC 
CD45 2D1 Becton-Dickinson, Heidelberg, 
Germany 
PerCP 
Ceramide MID15B4 Alexis, Grünberg, Germany Goat anti 
mouse-FITC 
CDw17 G035 Becton-Dickinson, Heidelberg, 
Germany 
FITC 
CD65s VIM2 Caltag, Burlingham, California, 
USA 
FITC 
CD77 38-13 Coulter/Immunotech, Krefeld, 
Germany 
Goat anti rat-PE 
CD64 22 Coulter/Immunotech, Krefeld, 
Germany 
FITC 
CD32 2E1 Coulter/Immunotech, Krefeld, 
Germany 
PE 
CD16 3G8 Coulter/Immunotech, Krefeld, 
Germany 
FITC 
CD11a 25.3 Coulter/Immunotech, Krefeld, 
Germany 
FITC 
CD11b D12 Becton-Dickinson, Heidelberg, 
Germany 
PE 
CD18 7E4 Coulter/Immunotech, Krefeld, 
Germany 
FITC 
CD36 FAG.152 Coulter/Immunotech, Krefeld, 
Germany 
FITC 
CD91 A2MR-
a2 
Becton-Dickinson, Heidelberg, 
Germany 
FITC 
CD163 GHI/61 Becton-Dickinson, Heidelberg, 
Germany 
PE 
CD47 B6H12 Becton-Dickinson, Heidelberg, 
Germany 
FITC 
CD55 IA10 Becton-Dickinson, Heidelberg, 
Germany 
PE 
apoCI 10-F4 ICN Biomedicals, Eschwege, 
Germany 
Goat anti 
mouse-FITC 
apoE 21-F3-D2 Biotrend, Köln, Germany Goat anti 
mouse-FITC 
CETP ATM192 Dianova, Hamburg, Germany Goat anti 
mouse-FITC 
Adipophilin AP125 Research Diagnostics, 
Flanders, USA 
Goat anti 
mouse-FITC 
Annexin V-Apoptosis 
detection kit 
 Becton-Dickinson, Heidelberg, 
Germany 
FITC 
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Antigen clones Provider Label 
Secondary antibodies    
Goat F(ab)´2 anti mouse Ig  Becton-Dickinson FITC 
Goat F(ab)´2 anti rat IgM  Dianova PE 
Goat polyclonal to mouse 
IgG H&L 
 Abcam, Cambridge, UK Cy5 
Goat polyclonal to anti-
rabbit  
 Calbiochem, Schalbach, 
Germany 
Texas Red 
Toxins    
Cholera toxin subunit B 
(recombinant) (GM1) 
 Molecular Probes Europe BV, 
Leiden, Netherland 
Alexa Fluor 488  
Cholera toxin subunit B 
(recombinant) (GM1) 
 Molecular Probes Europe BV, 
Leiden, Netherland 
Alexa Fluor 555 
Theta-Toxin  
(perfringolysin O) 
 Biotechnology workgroup of the 
Center of Excellence for 
Fluorescent Bioanalysis (KFB), 
Regensburg, Germany 
FITC 
Others    
DMPE-TMR (1,2-
dimyristoyl-sn-glycero-3-
phospho-ethanolamine-
tetramethyl-rhodamine) 
 Avanti Polar Lipids, Inc., 
Alabama, USA 
 
POPC (1-palmitoyl-2-oleoyl-
sn-glycero-3-
phosphocholine) 
 Avanti Polar Lipids, Inc., 
Alabama, USA 
 
Lysenin  gift from Sobota A, Nencki 
Institute of Experimental 
Biology, Department of Cell 
Biology, Warsaw, Poland 
 
anti-His probe (H-15)   Santa Cruz Biotechnology, CA, 
USA) 
 
 
PE = Phycoerythrin, FITC = Fluorescein-isothiocyanate, PerCP = Peridin chlorophyll protein, 
APC = Allophycocyanin 
 
Table 6: List of antibodies applied for western Blot analysis 
Antibody clone provider host gel 
ABCA1 AB.H10 Abcam, Cambridge, UK mouse  
ApoE  Biodesign, Germany goat  
ApoC-I 10-F4 ICN Biomedicals, 
Eschwege, Germany 
mouse  
PLTP  kind gift from 
Jauhiainen M., National 
Public Health Institute, 
Department of 
Molecular Medicine, 
Helsinki, Finland 
mouse  
ATP-synthase 
(b-chain) 
3D5AB1 Acris, Hiddenhausen, 
Germany 
mouse  
CD14  Santa Cruz, CA, USA goat non-reducing 
CD11b  Santa Cruz, CA, USA goat  
CD16 2H7 Serotec, Eching, 
Germany 
mouse non-reducing 
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CD47 BRIC126 Acris, Hiddenhausen, 
Germany 
mouse non-reducing 
CD55  Santa Cruz, CA, USA rabbit  
CD163 EDHu-1 Serotec, Eching, 
Germany 
mouse  
CD64  Santa Cruz, CA, USA goat  
CD32  Santa Cruz, CA, USA goat  
CD11a  Santa Cruz, CA, USA goat  
CD36  Santa Cruz, CA, USA rabbit  
 
Medium, solutions and chemicals 
Macrophage-SFM Medium, low endotoxin  Invitrogen, Karlsruhe, Germany 
M-CSF, human (rec. from E. Coli)   R&D Systems, Minneapolis, Minnesota 
PBS (w/o Ca2+, Mg2+)    Gibco BRL, Berlin, Germany   
BSA (lipid free)     Sigma, Taufkirchen, Germany 
FCS (Fetal calf serum)    Gibco BRL, Berlin, Germany 
Saponin      Sigma, Taufkirchen, Germany 
sodium azide      Sigma, Taufkirchen, Germany 
formaldehyd      Sigma, Taufkirchen, Germany 
CuSO4       Sigma, Taufkirchen, Germany 
DMSO       Sigma, Taufkirchen, Germany 
SDS       Sigma, Taufkirchen, Germany 
Cholesterol esterase     Roche, Basel, Switzerland 
Trypsin      SAA, Basel, Switzerland 
Trizol       Life Technologies, Karlsruhe, Germany 
ALLN (N-acetyl-Leu-Leu-norleucinal)  Calbiochem, Schalbach, Germany 
1,1`-Dioctadecyl-3,3,3´,3´-tetramethylindo-  Sigma, Taufkirchen, Germany 
carbocyanine-perchlorate (Dil)    
9-cis-retinoic-acid     Sigma, Taufkirchen, Germany 
all-trans-retinoic acid      
b-Carotene      Sigma, Taufkirchen, Germany 
Rosiglitazone      Cayman Chemical, MI, USA 
Ciglitazone      Cayman Chemical, MI, USA 
Troglitazone      Cayman Chemical, MI, USA 
Pioglitazone      Cayman Chemical, MI, USA 
human plasma apolipoprotein A-I and apoE Calbiochem, CA, USA 
 
Kits 
BCA, Protein Assay Kit    Pierce, Rockford, IL, USA 
ECL Western Blotting Analysis System  Amersham, Braunschweig, Germany 
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Superscript II kit     Life Technologies, Karlsruhe, Germany 
RNeasy MiniKit     Qiagen, Hilden, Germany 
RNA 6000 Nano Chip    Agilent, Palo Alta, CA, USA 
Reverse Transcription System   Promega, Madison, AL, USA 
Enzo BioArray HighYield RNA    Enzo Life, Farmingdale, NY, USA 
Transcript Labeling Kit 
Cy3, Cy5 Mono reactive dye pack   Amersham, NJ, USA 
PD-10 columns     Amersham, NJ, USA   
  
Microarray 
Human Genome U133 Plus 2.0 Array  Affymetrix, Santa Clara, CA, USA 
 
Cell culture dishes 
Ultra low attachment 6-well plates   Costar Corning, Bodenheim, Germany 
LAB-TEK borosilicate chamber slides  Nalge Nunc Int., Naprville, IL, USA 
Falcon 6- well cell+     Becton Dickinson, NJ, USA 
cell+ 10 cm tissue culture dishes   Sarstedt, Inc. Newton, USA  
   
Instruments 
Heraeus 6000 Incubator    Heraeus, Hanau, Germany 
FACSCalibur flow cytometer    Becton Dickinson, Heidelberg,  
Germany 
2100 Bioanalyzer, Caliper    Agilent, Palo Alto, CA, USA 
ABI Prism 7900 HT Sequence Detection System Perkin Elmer-Applied Biosystems,  
(Taqman) Darmstadt, Germany 
TCS-4D confocal microscope Leica Lasertechnik, Omnichrom 
equipped with a ArKr 75 mV mixed ion laser Heidelberg, Germany Melles Griot, 
electrospray ionization tandem mass spectrometry  
(ESI-MS/MS) 
Thermocycler Gene Amp PCR System 9600 Perkin Elmer, Uberlingen, Germany 
GeneQuant pro RNA/DNA Calculator  Amersham, Braunschweig,Germany 
Gene Chip Fluidics Station 450   Affymetrix, Santa Clara, CA, USA 
Gene Chip Scanner 3000    Affymetrix, Santa Clara, CA, USA 
Affymetrix array scanner    Affymetrix, Santa Clara, CA, USA 
ELISA reader      Tecan, Stuttgart, Germany 
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Analysis Software  
Cellquest software for FACS Analysis  Becton Dickinson, Heidelberg,Germany 
Affymetrix Microarray Suite (version 5.0)  Affymetrix, Santa Clara, CA, USA 
ScanWare software package Universal Imaging, Corp., PA, USA 
Metamorph for microscopy image Analysis   Universal Imaging, Corp., PA, USA 
 
Assays on Demand 
gene-specific assays on demand were supplied by ABI. 
Mastermix: 10 µl 2x TaqMan® Universal PCR Master Mix, 1 µl gene-specific probe-primer-
mix and 4 µl sterile water  
Mastermix for the endogenous control 18sRNA: 10 µl 2x TaqMan® Universal PCR Master 
Mix, 1 µl pre-developed TaqMan® assay reagents (PDAR) endogenous control kit and 4 µl 
sterile water  
 
Table 7: Assays on demand 
Assays on demand Assay ID 
sphingomyelin synthase 1 Hs00153716 
sphingomyelin synthase 2 Hs00380453 
acid sphingomyelinase like phosphodiesterase Hs00205522 
sphingomyelin phosphodiesterase 1 (acid SMase) Hs00609415 
neutral sphingomyelinase (neutral SMase) activation associated factor Hs00182519 
sphingomyelin phosphodiesterase 2 neutral SMase Hs00162006 
CD36 Hs00169627 
glucosidase, beta;acid (includes glucosylceramidase) Hs00400295 
N-acylsphingosine amidohydrolase (acid ceramidase) 1 Hs00188842 
UDP-glucose ceramide glucosyltransferase Hs00326535 
sphingosine kinase 1 Hs00184211 
sphingosine kinase 2 Hs00219999 
serine palmitoyltransferase, long chain base subunit 1 Hs00272311 
serine palmitoyltransferase, long chain base subunit 2 Hs00191585 
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2. Preparation of samples 
 
2.1. Donors 
Leucocyte-enriched apheresates were obtained from healthy, normolipidemic volunteers 
bearing either the apolipoprotein E3/3 or the apolipoprotein E4/4 genotype after informed 
consent. Further patients with Tangier disease and hyperlipidemia were used for 
leukapheresis. 
 
2.2. Elutriation of monocytes 
Suspensions enriched in human peripheral blood leukocytes were isolated by leukapheresis 
in a Spectra cell-separator (Gambro BCT), supplemented with the anticoagulant ADCA and 
diluted with an equal volume of PBS (w/o Ca2+, Mg2+). The diluted apheresate was then 
subjected to counterflow centrifugation (J2-MC centrifuge with JE-6B Rotor, Beckmann) as 
described elsewhere  (367). 
The monocyte content of each fraction obtained during centrifugation was determined using 
flow cytometry based on the different scatter properties of lymphocytes, granulocytes and 
monocytes. Fractions that were devoid of granulocytes with a monocyte content of at least 
90% of leukocytes were pooled, washed with PBS (w/o Ca2+, Mg2+) and resuspended in 
culture medium. The concentration of the suspension was determined with a sysmex 
counter. 
 
2.3. Monocyte cell culture and harvesting 
Elutriated monocytes were cultured either on dishes with Attachment Surfaces (Sarstedt, 
USA) or for analysis by flow cytometry on Ultra Low Attachment 6-well plates (Costar) to 
guarantee viability of the cells with minimal activation. They were seeded at 106 cells/ml in 
macrophage serum-free medium supplemented with monocyte-colony stimulating factor 
(MCSF, 50 ng/ml) (control) and incubated for up to 7 days at 37°C / 5 % CO2 (Heraeus 6000 
Incubator, Heraeus Instruments) to induce phagocytic differentiation as described previously 
(25). On the fourth day E-LDL (enzymatically degraded LDL) (40 mg/ml) respectively Ox-LDL 
(mildly oxidized LDL) (80 mg/ml) was added to the cells for 48 hours until day 6 (Fig.21) to 
generate foam cells resembling lipid-loaden cells within the atherosclerotic lesion. On day 6 
macrophages were deloaded of cholesterol with HDL3. Therefore medium was removed, 
cells were washed with PBS and new medium supplemented with MCSF and HDL3 (100 
mg/ml) was given to the cells for 24h (Fig.21). On the days 1, 4, 6 and 7 cells were harvested 
and experiments were performed. 
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3. Lipoproteins 
 
3.1. Isolation of lipoproteins  
Lipoproteins and lipoprotein-deficient serum were isolated from human plasma or serum by 
sequential preparative ultracentrifugation in KBr gradients according to (211;368) followed by 
extensive dialysis and filter sterilization. All lipoprotein concentrations mentioned are protein 
concentrations determined by Lowry´s method. Lipoprotein fractions were stored at 40C and 
used within two weeks from end of dialysis. 
 
3.2. Enzymatic modification of LDL 
E-LDL was generated under sterile conditions, of LDL isolated from plasma of healthy blood 
donors by dilution to 2 mg/ml protein in PBS (w/o Ca2+, Mg2+) and conduction of trypsin (8 
µg/ml) and cholesterol esterase (60 µg/ml) for 48 h at 37°C.  
 
3.3. Mildly oxidation of LDL 
Mildly oxidized LDL was achieved by dialyzing purified LDL fractions (1 mg protein/ml) 
against 5 µM CuSO4 for 36 h. The oxidation process was stopped by dialysis in PBS/EDTA. 
Further extensive dialysis in PBS was made. Afterwards, the Ox-LDL was sterile filtered and 
protein content was determined by Lowry-method. The mildly oxidation of LDL was controlled 
by electrophoresis. 
Modified lipoproteins were stored at 4°C and used within a week. 
 
3.3. Labelling of lipoproteins with Dil 
5 µl of a 3 mg/ml solution of 1,1`-Dioctadecyl-3,3,3´,3´-tetramethylindo-carbocyanine-
perchlorate (Dil) dissolved in DMSO were mixed with 500 µl lipoprotein deficient serum. 
Subsequent to lipoprotein modification 500 µl of lipoprotein solution (1 mg/ml) were added 
(369). After 12 h incubation at 37°C Dil-labelled lipoprotein solutions were separated from 
unbound chromophore by ultracentrifugation in KBr gradients (d<1,063 g/ml) followed by 
extensive dialysis. 
 
4. Mass spectrometry analysis 
 
4.1. Determination of the lipid composition of lipoproteins 
Lipoproteins were conducted with 50 ml Luric-Plasma, internal standard and 1ml aqua dest..  
Lipids were extracted according to the method of Bligh and Dyer (Chloroform/Methanol 1:2) 
(370). After addition of chloroform and water, the samples were centrifuged (20 min./4000 U 
RT). For the different lipid classes certain parts of the chloroform phase were separated and 
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after removing the solvent, acetylation for cholesterol determination respectively 
solubilisation in a phospholipid solvent was made. For quantification a standard curve with 
five spikes  was created. Extracts were analyzed by electrospray ionization tandem mass 
spectrometry (ESI-MS/MS). 
 
4.2. Determination of the cellular lipid content of macrophages 
Cells were harvested on day 1 and day 4 of monocyte to macrophage differentiation, on day 
6 after 48h E-LDL and Ox-LDL loading and on day 7 after 24h HDL3 deloading. Cells were 
washed twice with PBS, lysed in 0.2 % SDS and lipids were extracted according to the 
method of Bligh and Dyer (370). Extracts were analyzed by electrospray ionization tandem 
mass spectrometry (ESI-MS/MS) as described previously (371;372).  
 
4.3.  Determination of the lipid composition of isolated membrane rafts 
Cells were harvested at the time points according to 5.2.. They were washed twice with PBS 
and scrabbed on ice with TNE-Buffer supplemented with protease-inhibitor and centrifuged 
at 1200 rpm 7min, 4°C. The pellet was resuspended in TNE/protease-inhibitor-Buffer and 
homogenized. From this material membrane-fraction was prepared by centrifugation at 
100000g, 1h, 4°C. The supernatant represents to cytosolic fraction and the pellet the crude 
membrane fraction.  Afterwards Triton- respectively Lubrol-raft preparations were made 
using the OptiPrepTM method with a iodixanol gradient as described under point 10 raft 
preparation. From these raft-preparations lipids were extracted according to the method of 
Bligh and Dyer and extracts were analyzed by ESI-MS/MS. 
 
5. Flow cytometric analysis 
 
5.1. Staining of cell surface antigens 
Cells were detached by rinsing Ultra Low Attachment Surfaces with PBS. After washing with 
PBS (w/o Ca2+, Mg2+) cells were resuspended in PBS (w/o Ca2+, Mg2+), 0,5% BSA at 
5x105/100 µl and incubated for 15 minutes on ice with saturating concentrations of the 
antibodies. Antibodies used for detection were directly fluorochrome-conjugated or indirectly 
labelled by subsequent incubation with fluorochrome-conjugated secondary reagents after 
two washing steps with PBS, 0,5% BSA. 
 
5.2. Staining for intracellular immunofluorescence 
Cytoplasmatic antigens were detected using a modified version of Jung´s staining protocol. 
5x105 monocytes were incubated in 500 ml fixation buffer (PBS (w/o Ca 2+, Mg2+), 4% (w/v) 
formaldehyd) for 15 min on ice. Cells were washed twice with permeabilization buffer (PBS 
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(w/o Ca 2+, Mg2+), 1% (v/v) fetal calf serum, 0.1% (w/v) saponin, 0.1% (w/v) sodium azide) 
and labelled with primary antibodies for 15 min on ice followed by two washing steps with 
PBS (w/o Ca 2+, Mg2+),  0.5% BSA. In case of unconjugated or biotin-conjugated primary 
antibodies labelled cells were washed twice with permeabilization buffer and incubated with 
the respective secondary reagents for 15 min on ice followed by two further washing steps 
with PBS (w/o Ca 2+, Mg2+),  0.5% BSA. 
 
5.3. Analysis of stained cells  
The cellular light-scatter signals and three fluorescence signals of 20 000 cells per sample 
were analyzed in list mode at a channel resolution of 1024 with forward scatter as the trigger 
parameter on a FACSCalibur flow cytometer (excitation: 488 nm (argon) / 635 nm (diode); 
emission filters: 530/30 nm band pass (channel 1) / 585/47 nm band pass (channel 2) / 670 
nm long pass (channel 3): 661/16 nm band pass (channel 4) (Fig.18); data acquisition was 
performed by Cellquest software (Becton Dickinson, Heidelberg, Germany). The 
photomultiplier gains were calibrated with polychromatic fluorescent reference beads 
(Polysciences). Compensation was adjusted with fluorochrome-coated microbeads (Becton 
Dickinson, Heidelberg, Germany). Gating of cultivated monocytes/monocyte-derived 
macrophages (MDM) was based on forward- and side-scatter dot plots as well as CD14 and 
CD45 antibodies. Mean fluorescence values were corrected for background by substraction 
of mean fluorescence of cells without antibody respectively if incubated with secondary 
antibody substraction of mean fluorescence in absence of the primary antibody. 
For analysis of the list files the software CellQuest 2.0 (Becton Dickinson, Heidelberg, 
Germany) on a Macintosh G3 was used. 
The mean and standard deviation of the mean fluorescence intensities of the independent 
experiments were calculated. Statistical significancy was tested by paired student´s t-test. 
For analysis of surface membrane receptors during E-LDL and Ox-LDL loading, FACSCanto 
flow cytometer (BD Biosciences) the successor to FACSCalibur was used. It has two lasers, 
similar to the FACSCalibur (488nm and 633nm), however, the instrument was upgraded to 
detect 6-colors simultaneously (4-colors off the 488nm and 2-colors off the 633nm plus 
forward and side scatter). The FACSCanto has digital electronics and an octagon detection 
system. Data of these experiments were analyzed by FACSDiVa and CellquestPro softwares 
(both BD Biosciences).  
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5.4. Apoptosis-test with AnnexinV-FITC and Propidiumjodid (PI)  
In the early stages of apoptosis, translocation of phosphatidylserine (PS) from the inner part 
of the plasma membrane to the outer layer takes place, by which PS becomes exposed at 
the external surface of the cell (373). AnnexinV is a Ca2+ dependent phospholipid-binding 
protein with high affinity for PS and is therefore suited to detect apoptotic cells. The 
simultaneous DNA stain with PI allows the discrimination of necrotic cells (Annexin V and PI 
positive) from apoptotic cells (Annexin V positive and PI negative).  
Staining procedure: 
After harvesting cells by gently rinsing costar plates with PBS, cells were washed twice with 
PBS and resuspended in AnnexinV Binding Buffer at a concentration of 1x106 cells/ml. 100 ml 
of this solution (1x105 cells) were transferred to a 5 ml tube and 5 ml of AnnexinV-FITC and 5 
ml of PI were added. Cells were gently vortexed and incubated at room temperature for 15 
min in the dark. After adding 400 ml of AnnexinV Binding Buffer, samples were analyzed on a 
flow cytometer using 488 nm excitation and a 515 nm band-pass filter for fluorescein 
detection and a filter >600nm for PI detection. Ustained cells as well as cells stained with 
AnnexinV-FITC alone and cells stained with PI alone were used as controls to set up 
compensation and quadrants. 
 
6. Microscopy 
Cells were cultured in LAB-TEK borosilicate chamber slides, washed with PBS, fixed in 4% 
paraformaldehyde for 15 min, quenched with 50mM NH4Cl/glycin for 15 min and then 
blocked with PBS/0.5% BSA for 15 min at RT.  
For analysis of raft microdomains cells were incubated for 30 min at 4°C with saturated 
concentration of lipid vesicles in PBS, prepared from a mixture of 1-palmitoyl-2-oleyl-sn-
Figure 18: Principle of a FACS 
                  Calibur Flow Cytometer 
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glycero-3-phosphocholine (POPC) and 1,2-dimyristoyl-sn-glycero-3-phospho-ethanolamine-
tetramethyl-rhodamine (DMPE-TMR) at a ratio of 100:1 by sonication for 30 min as described 
by Schütz G. J. et al. (329). Afterwards cells were washed extensively with PBS and 
analyzed by confocal microscopy.  
For differential raft analysis, cells were incubated with anti-ceramide mAB 15B4 (1:20) for 3h 
at 4°C and then labeled with goat anti mouse-Cy5 secondary antibody (1:150) for 1 h at 4°C, 
followed by incubation with theta-toxin-FITC (1:2000) for 20 min at 4°C for cholesterol 
staining or cholera toxin for GM1 ganglioside staining.  
For sphingomyelin staining cells were incubated with lysenin (1:100) for 4h at 4°C. 
Afterwards anti-HIS antibody (1:150) for binding to the HIS of lysenin was added for 2h at 
4°C followed by labelling with anti-rabbit texas-red antibody (1:150) for 30 min at 4°C. 
Confocal images were acquired with an inverted TCS-4D confocal microscope (Leica, 
Heidelberg, Germany) equipped with a ArKr 75 mV mixed-ion laser (Melles Griot, 
Omnichrome, Carlsbad, CA, USA) and observed with an oil immersion objective 100x lens. 
Images were acquired with a 488 nm laser line (excitation) and detected with a 535/40m 
band pass filter (emission). Acquisition was performed with the Scan Ware software package 
of the instrument and analysis was done using the software Metamorph (Universal Imaging, 
Corp., PA, USA). 
Fluorescence images were taken with HCS System Discovery-1 (Universal Imaging, 
Downingtown, PA, USA) which is a conventional high-end flourescence inverse microscope 
with 6-fold ojective-revolver consisting of a multiSpec-imager for emission beam splitting and 
a high end CoolSNAP HQ camera. The system is controlled by a high-end MetMorph 
imaging system for measurements and data handling. 
The C-terminal domain (domain 4) of the -toxin (perfringolysin O) was synthesized by the 
biotechnology workgroup of the Center of Excellence for Fluorescent Bioanalysis (KFB, 
Regensburg, Germany) according to Shimada et al 2002 (374). FITC N-terminus labeling 
was carried out by a standard procedure, yielding in a product with absorbance and emission 
maxima of 490 nm and 520nm, respectively.  
 
7. Preparation of fluorescent labeled ApoE and ApoA-I 
Human plasma apolipoprotein A-I and apolipoprotein E were purchased from Calbiochem, 
CA, USA.  Cy3 and Cy5 Mono-Reactive Dye Pack, as well as PD-10 columns were obtained 
from Amersham Pharmacia Biotech, New Jersey, USA. Protein labelling procedure was 
carried out as described by Mujumdar et al. (375). Briefly, the contents of 1 vial (for labelling 
of 1 mg protein) of Cy3- or Cy5-monofunctional dye was dissolved in 100 mL DMF. The 
amount of dissolved dye was calculated for the used protein concentration. Protein labelling 
reactions were carried out in 0,1 M carbonate buffer (pH 8,8-9,0). After 1 h of incubation at 
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4°C in the dark, the reaction was terminated by adding 20 mL of 10mM lysin solution. 
Unconjugated dye was separated from the labelled protein by gel permeation 
chromatography over Sephadex PD-10 column using PBS (pH 7,4) buffer as eluant. The 
dye/protein ratio for each sample was determined according to manufacturer`s instructions. 
 
7.1. ApoE and ApoA-I binding assay by confocal microscopy 
Cells were washed with PBS and subsequently incubated with 10mg/mL of fluorescent 
labelled apoE (Cy3) and apoA-I (Cy5) at 37°C or 4 °C to 5 min. After incubation, cells were 
washed twice with cold PBS containing 0,5% BSA and then with cold PBS alone.  
Subsequently fixation of cells was performed using 4% paraformaldehyde in PBS for 15 min 
on ice. Afterwards cells were washed three times with cold PBS and analyzed by confocal 
microscopy. By this method at 4°C only binding should occur while at 37°C binding and 
internalization should take place.   
 
7.2. ApoE and ApoA-I time-kinetic binding assay by flow cytometry 
Cells were harvested by smoothly washing the costar plates with a pipete. After washing with 
PBS, cells were resuspended in PBS containing 0,5% BSA at 5 x 106/ml. Cells were 
incubated with 10mg/mL of fluorescent labelled apoE (Cy3) and apoA-I (Cy5) at 37°C or 4 °C 
for 2, 5, 10 min. After incubation cells were washed three times with cold PBS buffer 
containing 0,5% BSA and analyzed by flow cytometry.   
 
8. Affymetrix oligonucleotide array analysis 
Total RNA of day1 monocytes, differentiated, E-LDL and Ox-LDL loaded and HDL3 deloaded 
macrophages was extracted by TRIzol (Life Technologies). The RNA was quantified by 
measuring the spectrophotometric absorbance at 260 nm, the purity was determined by the 
use of the 2100 Bioanalyzer (Agilent technologies). 
Double-stranded cDNA was synthesized by a Superscript II kit (Life Technologies) using T7-
oligo(dT) as primer. Biotin-labeled cRNA was prepared by in vitro transcription reaction using 
an Enzo BioArray HighYield RNA Transcript Labeling Kit (Affymetrix, P/N 900182) based on 
the manufacturer’s protocol. The Biotin-labeled cRNA was purified, fragmented and after 
addition of Control Oligonucleotide B2 (3nM) and 20X Eukaryotic Hybridization Controls 
(bioB, bioC, bioD, cre) hybridized to Affymetrix H-U133A GeneChips (Santa Clara, CA) for 
16hrs at 45°C. The chips were stained with Streptavidin / Phycoerythrin (SAPE), and washed 
in the Fluidics Station 450 with protocol EukGE-WS2 which includes an antibody 
amplification step. The arrays were scanned on the Affymetrix array scanner and the data 
analysis was performed according to instructions and recommendations provided by 
Affymetrix using the Affymetrix statistical data analysis software, Affymetrix Microarray Suite 
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(version 5.0). For each gene, the gene expression of cells treated in different ways was 
compared. The comparison was based on a statistical analysis of probe sets consisting of 16 
oligos recognizing different portions of the target gene. The probe sets were excluded if the 
detection call for both target and reference was absent; or if the change call gave no change 
(NC) in comparison analysis or if the signal log ratio between target and reference was 
between -1 and 1. Signal log ratio is used to describe the change between a target and 
reference array. The change is expressed as log2 ratio. Therefore, signal log ratio of 1 
equals a fold change of 2. 
Genes with significant up- and down-regulation (≥ 2 fold) by loading, deloading or 
differentiation were sorted into 73 categories based on literature search, data base analysis 
and unpublished data sets of our institute. 
 
8.1. Principle of gene combining chromatin immunoprecipitation (Chip) analysis 
The goal of comparative cDNA hybridization is to compare gene transcription in two or more 
different kinds of cells. GeneChip microarrays consist of small DNA fragments (referred to 
here as probes), chemically synthesized at specific locations on a coated quartz surface. The 
precise location where each probe is synthesized is called a feature, and millions of features 
can be contained on one array. 
 
8.1.1. mRNA extraction and reverse transcription 
mRNA for use in a microarray assay must be purified from total cellular contents. To prevent 
the experimental samples from being lost, they are reverse-transcribed back into more stable 
cDNA forms.  
 
8.1.2. Fluorescent labelling of cDNA's 
In order to detect cDNA's bound to the microarray, they must be labelled with reporter 
molecules like fluorescent dyes (fluors) which identifies their presence. A differently-colored 
fluor is used for each sample so that the two samples can be distinguished. The labeled 
cDNA samples are called probes. The choice of red and green colors is reminiscent of the 
emission wavelengths of commonly-used fluors, such as rhodamine and fluorescein or Cy3 
and Cy5. To equalize the total concentrations of the two cDNA probes before applying them 
to the array, the probe solutions are diluted to have the same overall fluorescent intensity. 
 
8.1.3. Hybridization to a DNA microarray 
The two cDNA probes are tested by hybridizing them to a DNA microarray. The array holds 
hundreds or thousands of spots, each of which contains a different DNA sequence. If a probe 
contains a cDNA whose sequence is complementary to the DNA on a given spot, that cDNA 
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will hybridize to the spot, where it will be detectable by its fluorescence. In this way, every 
spot on an array is an independent assay for the presence of a different cDNA. There is 
enough DNA on each spot that both probes can hybridize to it at once without interference.  
 
8.1.4. Scanning the hybridized array 
Once the cDNA probes have been hybridized to the array and any loose probe has been 
washed off, the array must be scanned to determine how much of each probe is bound to 
each spot. The probes are tagged with fluorescent reporter molecules which emit detectable 
light when stimulated by a laser. The emitted light is captured by a detector, either a charge-
coupled device (CCD) or a confocal microscope, which records its intensity. Spots with more 
bound probe will have more reporters and will therefore fluoresce more intensely. Each of the 
two fluorescent reporters (fluors) used has a characteristic excitation wavelength. The 
emitted light has a characteristic emission wavelength which is different from the excitation 
wavelength. If the emission wavelengths are different, light emitted from the two fluors can be 
selectively filtered to measure the amount emitted by each fluor separately. If the excitation 
wavelengths are different, the two fluors can be stimulated and scanned one at a time. If one 
of these conditions is not met, the scanned intensities can be contaminated by crosstalk 
between the two fluorescent channels.  
 
8.1.5. Interpreting the scanned image 
The end product of a comparative hybridization experiment is a scanned array image. The 
measured intensities from the two fluorescent reporters have been false-colored red and 
green and overlaid. Yellow spots have roughly equal amounts of bound cDNA from each cell 
population and so have equal intensity in the red and green channels (red + green = yellow). 
Spots whose mRNA's are present at a higher level in one or the other cell population show 
up as predominantly red or green. The intensities provided by the array image can be 
quantified by measuring the average or integrated intensities of the spots. The ratio of 
fluorescent intensities for a spot is interpreted as the ratio of concentrations for its 
corresponding mRNA in the two cell populations. Even after overcoming detection and 
calibration problems, the measured intensities for each spot only represent the ratio of 
cDNA's in each cell population. 
 
9. TaqMan® polymerase chain reaction (PCR) 
mRNA expression analysis was made from MCSF differentiated, E-LDL and Ox-LDL loaded 
as well as HDL3 deloaded macrophages. Therefore TaqMan® PCR assays were performed 
on the ABI Prism 7900 HT Sequence Detection System (Perkin Elmer-Applied Biosystems, 
Darmstadt, Germany). The gene-specific assays on demand were supplied by ABI. For 
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quantitation of each gene, a mastermix containing 10 µl 2x TaqMan® Universal PCR Master 
Mix, 1 µl gene-specific probe-primer-mix and 4 µl sterile water was prepared and aliquoted in 
a 384-well optical plate. A mastermix for the endogenous control 18sRNA containing 10 µl 2x 
TaqMan® Universal PCR Master Mix, 1 µl pre-developed TaqMan® assay reagents (PDAR) 
endogenous control kit and 4 µl sterile water was treated similarly. Finally triplicates of cDNA 
templates equivalent to 50 ng of RNA were added to a final volume of 20 µl. The thermal 
cycling was performed for 2 min at 50°C and 10 min at 95°C followed by 45 cycles of 15 sec 
at 95°C and 1 min at 60°C. 
Generation of standard curves - For quantification of the results obtained by real-time PCR 
we used the standard curve method. For this purpose a stock of total RNA from 
macrophages was serially diluted. A standard curve with 50, 25, 12.5, 6.25 and 3.125 ng 
total RNA was generated for all. The standard curves were used to determine the relative 
expression of genes and 18sRNA mRNA in each sample. Finally the results were normalized 
to the endogenous control 18sRNA. 
 
9.1. The Taqman-principle  
PCR is a fairly standard procedure now, and its use is extremely wide-ranging. At its most 
basic application, PCR can amplify a small amount of template DNA (or RNA) into large 
quantities in a few hours. This is performed by mixing the DNA with primers on either side of 
the DNA (forward and reverse), Taq polymerase (of the species Thermus aquaticus, a 
thermophile whose polymerase is able to withstand extremely high temperatures), free 
nucleotides (dNTPs for DNA, NTPs for RNA), and buffer. The temperature is then alternated 
between hot and cold to denature and reanneal the DNA, with the polymerase adding new 
complementary strands each time. “Real-time PCR” allows the scientist to actually view the 
increase in the amount of DNA as it is amplified.  
 
                                          
 
Figure 19: The Taqman probe. The red circle represents the quenching dye that disrupts the   
observable signal from the reporter dye (green circle) when it is within a short distance. Image 
created by Dan Pierce. 
While the probe (Fig.19) is attached or unattached to the template DNA and before the 
polymerase acts, the quencher (Q) fluorophore (usually a long-wavelength colored dye, 
such as red) reduces the fluorescence from the reporter (R) fluorophore (usually a short-
wavelength colored dye, such as green Green Fluorescent Protein (GFP)). This occurs 
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through Fluorescence Resonance Energy Transfer (FRET), which is the inhibition of one dye 
caused by another without emission of a proton. The reporter dye is found on the 5’ end of 
the probe and the quencher at the 3’ end.  
 
 
 
Figure 20: The TaqMan® probe binds to the target DNA, and the primer binds as well. 
Because the primer is bound, Taq polymerase can now create a complementary strand. 
Image created by Dan Pierce. 
Once the TaqMan® probe has bound to its specific piece of the template DNA after 
denaturation (high temperature) and the reaction cools, the primers anneal to the DNA (Fig. 
20). Taq polymerase then adds nucleotides and removes the Taqman® probe from the 
template DNA. This separates the quencher from the reporter, and allows the reporter to emit 
its energy (Fig.21). This is then quantified using a computer. The more times the denaturing 
and annealing takes place, the more opportunities there are for the Taqman® probe to bind 
and, in turn, the more emitted light is detected.  
 
 
 
 
 
 
 
 
Figure 21: The reporter dye is released from the extending double-stranded DNA created by 
the Taq polymerase. Away from the quenching dye, the light emitted from the reporter dye in 
an excited state can now be observed. Image created by Dan Pierce. 
The light emitted from the dye in the excited state is received by a computer and shown on a 
graph display, such as this, showing PCR cycles on the X-axis and a logarithmic indication of 
intensity on the Y-axis (Fig.22).  
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10. Detergent lysis and flotation gradient 
The basis for lipid raft isolation is their resistance to non-ionic detergents like Lubrol or Triton 
X-100. Using an iodixanol gradient the intact lipid rafts float to the top of the gradient while all 
the other detergent-solubilized membranes remain at the bottom. 
Cells were harvested at the differentiated, E-LDL and Ox-LDL loaded and HDL3 deloaded 
states, crude membrane fraction was isolated and Lubrol-WX rafts were prepared. In detail, 
cells were washed twice with PBS, scrabbed on ice with buffer A (TNE, 50 mM Tris, 150 mM 
NaCl, 5 mM EDTA, supplemented with protease-inhibitor set III, Calbiochem) and spun down 
at 1200 rpm 7 min, 4°C. The pellet was resuspended in buffer A and homogenized. From this 
material a crude membrane-fraction was prepared by centrifugation at 100000 g, 1 h, 4°C. 
The supernatant represents the cytosolic fraction and the pellet the crude membrane fraction 
(MF). MF was lysed in 300 µL buffer A containing 1% Lubrol-WX (Serva) on ice for 30 min. 
The detergent lysate was adjusted to 40% Iodixanol (OptiprepTM, Axis-Shield) and therefrom 
600 µL were given under a density gradient of 0, 20, 25, 30, and 35% Iodixanol (each 600 
ml). After centrifugation in Beckman SW55Ti-rotor (160000 g, 4 h at 4°C) six 600 µL fractions 
were collected from the top of the gradient. Fraction 2 and 3 were considered as the raft-
fractions and the fractions 4-6 as the non-raft fractions. For immunoblotting same volumes of 
each gradient-fraction were precipitated with chloroform/methanol. 
 
 
 
 
 
 
 
 
 
 
Figure 23: Isolation of lipid rafts by flotation from a postnuclear supernatant (PNS) in a discontinuous  
                  iodixanol gradient. IM =Isolation Medium. 
 
Figure 22: A graph print out of actual 
data found using the TaqMan® probe. 
Courtesy  
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From these raft fractions mass-spectrometry as well as immunoblotting was performed. For 
quantification of the blots with the lumi-imager the sum of the fractions 2 and 3 divided by the 
sum of the fractions 1-6*100 was considered as the raft–portion of the whole expression of 
the detected protein. 
 
11. Western blot analysis 
Cells were harvested at the differentiated, E-LDL and Ox-LDL loaded state, washed with 
PBS, frozen (-20°C). Cell debris was separated by centrifugation at 10.000 x g for 10min at 
4°C. Proteins were separated by SDS-PAGE and transferred to PVDF (polyvinylindene 
fluoride) membranes. Incubations with antibodies were performed in 5% nonfat dry milk in 
PBS, 0.1% Tween. Detection of the proteins was carried out with the ECL Western blot 
detection system and following quantification with the lumi-imager. 
 
12.ELISA 
96 well plates were coated over night at 4-7°C with 200ml/well anti-apoC-I polyclonal 
respectively anti-apoE monoclonal antibody diluted 1:2000 with 10mM PBS. On the next day 
after washing with 400 µl/well PBS-0.1% Tween 20 (PBST0.1) plates were blocked with 200 
µl/well PBS-1% Tween 20 (PBST1) for 45 min -1 h at 36-37°C and were washed again. 
Afterwards incubation with the supernatants of the cells in different concentrations follows 
diluted with PBST0.1 and with PBST0.1 alone as a blank (45 min-1 h at 36-37°C). Then 
plates were washed with PBST0.1 and subsequently incubated with the detection antibody 
anti-apoC-I (monoclonal) respectively anti-apoE (polyclonal) (45 min-1h, 36-37°C). The last 
step after washing with PBST0.1 was incubation with HRP-streptavidin-conjugat 1:5000 
diluted in PBST0.1 (45 min-1h, 36-37°C) followed by addition of ABTS-colour reagent in 
ABTS-Buffer (30-45 min,36-37°C). Measuring of extinction was performed at 405 nm. 
 
13. Cholesterol and choline phospholipid efflux 
RAW264.7 cells were obtained from ATCC (Manassas, USA), cultured in RPMI 1640 
medium (Sigma, St. Louis, USA) supplemented with 10% fetal calf serum (Gibco BRL), 100 
U penicillin per ml, 100 µg of streptomycin per ml, and incubated in 10% CO2 in air at 37°C. 
The cells were stimulated with 5 µM 9-cis RA, 5 µM ATRA, 5 µM b-carotene liposomes, or 
DMSO and PC liposomes as controls for 24 hours. 
RAW264.7 mouse macrophages were maintained in RPMI containing 10% FCS in 12-well 
plates containing 400.000 cells per well. Cholesterol and choline phospholipids were labeled 
by incubation with 1.5 µCi/ml 14C-cholesterol and 10 µCi/ml 3 H-choline chlorides for 2 days. 
As indicated for a part of the cells agonists were added for the last 24 h of the label phase. 
Cells were then rinsed with PBS and incubated for 24 h in DMEM containing 2 mg/ml BSA 
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with or without 10 µg/ml apoA-I and the indicated agonists. Efflux of 14C-cholesterol and 3H-
choline phospholipids from cells was measured by the appearance of label in the medium. 
Lipids in the cells and the medium were extracted according to the method of Bligh and Dyer 
(370) and 3H- and 14C-radioactivity was measured by liquid scintillation counting. Lipid efflux 
was determined as percent fraction of the cpm (count per minute) in media over the total cpm 
(cpm in media + cpm in cells). Specific lipid efflux was calculated as lipid efflux in the 
presence of apoA-I ± the indicated agonist minus the efflux in the absence of apoA-I but the 
presence of the respective agonist. 
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IV. Results 
 
1. The monocyte experimental system 
 
1.1. Macrophage incubation protocol  
Elutriated monocytes were cultured at 106 cells/ml in macrophage serum-free medium 
supplemented with monocyte-colony stimulating factor (M-CSF, 50 ng/ml) (control) and 
incubated for up to 7 days at 37°C/5 % CO2 to induce phagocytic differentiation as described 
previously (25). On the fourth day E-LDL (enzymatically degraded LDL) (40 mg/ml) 
respectively Ox-LDL (mildly oxidized LDL) (80 mg/ml) prepared from the same donor LDL 
was added to the cells for 48 hours until day 6 (Fig.24) to generate foam cells resembling 
lipid-loaden cells within the atherosclerotic lesion. On day 6 macrophages were deloaded of 
cholesterol with HDL3. Therefore medium was removed, cells were washed with PBS and 
new medium supplemented with MCSF and HDL3 (100 mg/ml) was added to the cells for 24h 
(Fig.24). On the days 1, 4, 6 and 7 cells were harvested and experiments were performed. 
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Figure 24: Incubation-scheme of   
                 human monocyte  
                 derived macrophages 
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1.2. Compositional analysis of modified lipoproteins 
The lipid composition of LDL, E-LDL and Ox-LDL preparations of five different donors was 
analyzed by ESI-tandem mass spectrometry. The content of cholesteryl esters (CE) and free 
cholesterol (FC) was similar in LDL and Ox-LDL (Fig.25A). E-LDL however due to the 
treatment with cholesteryl ester hydrolase (acid lipase) contained a significantly higher 
amount of FC at the expense of CE as compared to LDL and Ox-LDL (Fig.25A). In Ox-LDL 
the CE fraction contained oxidized fatty acid moieties (data not shown). Considering the 
major phospholipid components, LDL showed the highest and Ox-LDL the lowest amount of 
phosphatidylcholine (PC) reflecting phospholipid oxidation and activation of phospholipase 
A2 (PLA2) (Fig.25B).  
Acid lipase activity during the generation of E-LDL may also degrade small amounts of PC 
(Fig.25B). The amount of lysophosphatidylcholine (LPC) increased from LDL over E-LDL to 
Ox-LDL (Fig.25B). In Ox-LDL, this is likely due to the activation of platelet activating factor 
(PAF) acetylhydrolase a member of the PLA2 superfamily (37;158;376-379). The content of 
sphingomyelin (SPM) (Fig.25B) and ceramide (Fig.25C) was similar in LDL, E-LDL and Ox-
LDL. 
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Figure 25:  Lipid composition of LDL, E-LDL and Ox-LDL 
Analysis of the lipid composition of LDL and the enzymatically  
and oxidatively modified lipoproteins E-LDL and Ox-LDL by mass 
spectrometry.  
cholesteryl ester (CE), free cholesterol (FC), phosphatidylcholine 
(PC), lysophosphatidylcholine (LPC), sphingomyelin (SPM),  
ceramide (CER) 
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1.3. Viability tests for the cellular experiments 
Cells were incubated according to the incubation protocol with MCSF, loaded with E-LDL (40 
mg/ml) respectively Ox-LDL (80 mg/ml) on day 4 for 48h and deloaded with HDL3 (100 mg/ml) 
on day 6 for 24h. At the days 6 and 7 cells were harvested and apoptosis test was performed 
with AnnexinV-FITC and propidiumjodid (PI) by flow cytometry (Fig.26A). Three individual 
experiments were performed and means and standard deviations of the percent of AnnexinV 
and PI positive cells were calculated. It could be observed that the percent of necrotic cells 
(PI and AnnexinV positive cells) was about 8 percent during MCSF, Ox-LDL, E-LDL and 
HDL3 treatment. Only with HDL3 deloading after E-LDL loading the amount of necrotic cells 
was 12%, which indicates also no critical concentration. Therefore it could be shown that the 
proposed incubation scheme assured viability of the cells for further experiments.  
Moreover cells were incubated with different concentrations of Ox-LDL (20, 40, 50, 60 and 80 
mg/ml) and subsequently tested for apoptosis with the same method (Fig.26B). The 
percentage of necrotic cells (PI and AnnexinV positive cells) of MCSF differentiated 
monocyte derived macrophages (MDM) and also of cells treated with different concentrations 
of Ox-LDL was in all cases negligible about 8%. Therefore an Ox-LDL concentration of 80 
mg/ml can be taken to get lipid loaded cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26A: Propidiumjodid (PI) and Annexin V 
positive cells in percent of total amount of cells 
measured by flow cytometry during MCSF 
differentiation, Ox-LDL and E-LDL loading and 
HDL3 deloading of macrophages. 
Figure 26B: Propidiumjodid (PI) and Annexin V 
positive cells in percent of total amount of cells 
measured by flow cytometry of macrophages 
incubated with MCSF and different concentrations 
of Ox-LDL 
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1.4. Discrimination of four different monocyte subpopulations by flow cytometry 
It is possible to discriminate four different populations of peripheral blood monocytes with 
respect to their expression pattern of CD14 and CD16 by flow cytometry (Fig.27). 
Approximately 60% of monocytes belong to the subset 1 (MNP1) that is characterized by 
bright expression of CD14 and no or dim expression of CD16. The second (MNP2) and third 
(MNP3) subset have high capacity for phagocytosis and have bright expression of CD16 and 
bright (MNP2) or dim (MNP3) expression of CD14, respectively. The fourth subset (MNP4) is 
known to be a precursor subpopulation for antigen-presenting (dendritic) cells as they 
present only dim expression of CD14 and CD16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Four monocyte subsets can be distinguished on their expression patterns of CD14 and 
CD16. The dot plot illustrates the identification of peripheral blood monocyte subpopulations as 
discriminated by flow cytometry: MNP1 (CD14 high; CD16dim), MNP2 (CD14 high; CD16 high),  
MNP3 (CD14 dim; CD16 high) and MNP4 (CD14 dim; CD16 dim). 
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2. Analysis of MCSF differentiated, E-LDL and Ox-LDL loaded and HDL3 deloaded  
    human monocyte derived macrophages of the ApoE3/3 genotype 
 
2.1. Changes in cellular lipid content determined by mass spectrometry 
ESI-tandem mass spectrometry was used to measure cellular content of total, esterified and 
unesterified cholesterol, sphingomyelin, ceramide and sphingosine in four independent 
experiments and the results are shown in Fig.28. Total, esterified and unesterified cholesterol 
did not change during MCSF-induced differentiation (Fig.28A-C). However, monocyte 
derived macrophages loaded with E-LDL (40mg/ml) showed a 4-fold higher content of total 
cholesterol and a 99-fold increase of esterified cholesterol while Ox-LDL loaded cells 
(80mg/ml) showed only a 2.3-fold increase of total cholesterol and an 18-fold enhancement of 
esterified cholesterol (Fig.28A,B). Unesterified cholesterol increased with E-LDL and Ox-LDL 
loading to the same extent (Fig.28C). Cellular sphingomyelin content increased during 
monocyte to macrophage differentiation up to 1.7-fold and no further change could be 
observed during E-LDL and Ox-LDL loading (Fig.28D). The ceramide content during MCSF-
induced differentiation showed no significant change (Fig.28E). Ox-LDL incubation however, 
led to a significant 3.6-fold increase in cellular ceramide content while E-LDL showed only a 
1.4-fold increase (Fig.28E). As shown before, this effect was not due to higher ceramide 
content in Ox-LDL itself (Fig.25C). These data allow the conclusion that E-LDL loading 
predominantly increases cellular cholesterol content while Ox-LDL loading preferentially 
increases cellular ceramide content. Sphingosine content of the cells revealed a 1.6-fold 
upregulation during MCSF-dependent differentiation, an additional 1.2-/1.3-fold increase 
occurred with E-LDL and Ox-LDL respectively (Fig.28F). HDL3-dependent deloading 
reversed the increase of cholesterol mass of both lipid loading agents (Fig.28A-C). Deloading 
of E-LDL loaded cells with HDL3 diminished total cholesterol content up to 40% (Fig.28A), 
mostly (up to 140%) at the expense of esterified cholesterol (Fig.28B) while unesterified 
cholesterol decreased only by 2% (Fig.28C). HDL3 deloading of Ox-LDL loaded cells led to a 
20% decrease of total cholesterol (Fig.28A), a 10% decrease of esterified (Fig.28B) and a 
neglegible decrease of unesterifed cholesterol (Fig.28C). Sphingomyelin content however 
increased during HDL3 deloading for both LDL-modifications up to 24% (Fig.28D) and cellular 
ceramide increased slightly during E-LDL deloading up to 13% (Fig.28E) while it decreased 
during Ox-LDL deloading up to 50%. Along with the decrease in ceramide, sphingosine 
increased with HDL3 deloading of Ox-LDL loaded cells up to 130%. In E-LDL loaded cells 
however, HDL3 did not affect sphingosine levels (Fig.28F).  
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Figure 28: Cellular content of total, esterified and unesterified cholesterol, sphingomyelin, 
ceramide and sphingosine  
Mass spectrometry was used to determine the cellular lipid content of human monocyte derived 
macrophages at the status of differentiation with MCSF (day 0 and day 4), during E-LDL and Ox-LDL 
loading after 48 hours and during HDL3 deloading after 24 hours. The intracellular content of total 
cholesterol (A), esterified cholesterol (B), unesterified cholesterol (C), sphingomyelin (D), ceramide (E) 
and sphingosine (F) is shown. 
 
2.2. RT-PCR analysis of enzymes involved in ceramide generation and degradation 
To elucidate the reason for the Cer elevation during Ox-LDL loading, TaqMan realtime RT-
PCR was performed for the enzymes involved in Cer generation and degradation of MCSF 
differentiated, E-LDL and Ox-LDL loaded and HDL3 deloaded human monocyte-derived 
macrophages. During MCSF-dependent monocyte/macrophage differentiation, mRNA 
expressions of serine palmitoyltransferases 1+2 (SPTLC1+2), which are involved in Cer 
synthesis as well as the transcriptional levels of sphingomyelin synthases, 1 and 2 which 
convert Cer into sphingomyelin were downregulated (Fig.29A,B,C,D). Analysis of the 
sphingomyelinases, which convert sphingomyelin to Cer, revealed an upregulation of mRNA 
expression of acid sphingomyelinase (SMPD1) (2.8fold) and acid sphingomyelinase like 
phosphodiesterase (ASML3B) (3.5fold) (Fig.29E,F) whereas the mRNA expression of neutral 
sphingomyelinase (SMPD2) and neutral sphingomyelinase activation associated factor 
(NSMAF) was downregulated -1,5 fold during differentiation (Fig.29G,H). mRNA expression 
of glucosidase, beta; acid (GBA) which includes glucosylceramidase involved in the 
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degradation of glucosylceramide into Cer  showed no change during differentiation (Fig.29I). 
UDP-glucose ceramide glucosyltransferase (UGCG) the enzyme which converts Cer to 
glucosylceramide and N-acylsphingosine amidohydrolase 1 (ASAH1) (acid ceramidase)  
degrading Cer to sphingosine showed an upregulation of mRNA expression (2 and 3.9 fold) 
during differentiation (Fig.29J,K).  
During E-LDL loading SPTLC1 and SPTLC2 were 1.7 and 1.5 fold and during Ox-LDL 
loading 2.1 and 1.3 fold upregulated (Fig.29A,B). Sphingomyelin synthase 1 was 1.1 fold and 
sphingomyelin synthase 2 was 1.6 fold upregulated during both lipid loading agents 
(Fig.29C,D). SMPD1 and ASML3B mRNA expression was -1.7 and -1.8 fold downregulated 
during E-LDL loading. Ox-LDL loading however revealed a 3.1 fold upregulation of SMPD1 
and a -2.3 fold downregulation of ASML3B compared to MCSF. mRNA expression of SMPD2 
and NSMAF showed a stronger upregulation during Ox-LDL loading (5.2 and 2.2 fold) than 
during E-LDL loading (2.7 and 1.3 fold) (Fig.29G,H). The stronger upregulation of the 
sphingomyelinases SMPD1, SMPD2 and the activation factor NSMAF during Ox-LDL loading 
compared with E-LDL loading can be considered as causal for the Ox-LDL induced Cer 
elevation. 
mRNA expression of GBA, was stronger upregulated during Ox-LDL than during E-LDL 
loading (3.7 vs 1.8 fold) (Fig.29I) while UGCG mRNA expression showed a higher 
upregulation during E-LDL loading (3.2 vs 2.2 fold) (Fig.29J). ASAH1 mRNA expression was  
-1.5 fold downregulated with E-LDL and Ox-LDL loading (Fig.29K). 
E-LDL deloading with HDL3 revealed almost no change of the mRNA expression of SPTLC1 
and 2 (Fig.29A,B). With Ox-LDL deloading SPTLC1 decreased up to 1 fold (Fig.29A) while 
SPTLC2 levels remained unchanged (Fig.29B). Both sphingomyelinases, 1 and 2 were 
upregulated with HDL3 after E-LDL deloading up to 2 fold (Fig.29C,D) With Ox-LDL 
deloading sphingomyelin synthase 1 increased 1.7 fold while sphingomyelin synthase 2 
decreased 1.2 fold (Fig.29C,D). SMPD1, ASML3B as well as SMPD2 and NSMAF 
expression decreased with HDL3 deloading compared to lipid loading, however from a higher 
level in Ox-LDL loaded cells (Fig.29E,F,G,H). HDL3 deloading led also to a downregulation of 
GBA (Fig.29I), UGCG (Fig.29J) and ASHA1 (Fig.29K). These results show that all tested 
sphingomyelinases were strongly downregulated with HDL3 deloading which reflects an 
inversion of the lipid loading effects of E- and Ox-LDL and a reduction of the enzymatic 
functions in converting sphingomyelin to ceramide to provide sphingomyelin for cholesterol 
efflux.  
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Figure 29. Taqman analysis of enzymes involved in ceramide synthesis and degradation  
Using real time Taqman RT-PCR standardized to 18s rRNA as a reference, gene expression was 
monitored of 4 day differentiated macrophages, 48 hours E- and Ox-LDL loaded macrophages (day 4 
to day 6) and  24 hours HDL3 (day 6 to day 7) deloaded macrophages. Serine palmitoyltransferase 1 
(SPTLC1) (A), serine palmitoyltransferase 2 (SPTLC2) (B), sphingomyelin synthase 1 (MOB) (C), 
sphingomyelin synthase 2 (D), acid sphingomyelinase (SMPD1) (E),  acid sphingomyelinase like 
phosphodiesterase (ASML3B) (F), neutral sphingomyelinase (SMPD2) (G), neutral sphingomyelinase 
(N-SMase) activation associated factor (NSMAF) (H), glucosylceramidase (glucosidase beta acid) 
(GBA) (I), UDP-glucose ceramide glucosyltransferase (UGCG) (J), acid ceramidase (ASAH1)  
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2.3. Cell surface expression of sphingo- and glycosphingolipids  
In order to analyze whether the increase of total cellular ceramide content during lipid loading 
of monocyte derived macrophages is paralleled by an increased surface expression of 
ceramide and ceramide derived glycosphingolipids, flow cytometric analysis with antibodies 
specific for ceramide, lactosylceramide (CDw17), globotriaosylceramide (CD77), dodeca-
saccharideceramide (CD65s) and fluorescent labeled cholera toxin for GM1 ganglioside 
staining was performed and the results are shown in Fig.30. Means and standard deviations 
of mean fluorescence intensities of 6 independent experiments were calculated. Statistical 
significance was tested by a student´s t-test for paired samples. The asterisk indicates a 
significant difference with p<0.05 between MCSF differentiated and lipid loaded 
macrophages. Surface expression of ceramide (Fig.30A), globotriaosylceramide (Fig.30C) 
and GM1 ganglioside (Fig.30D) increased during MCSF-dependent differentiation while 
lactosylceramide (Fig.30B) and dodecasaccharideceramide (Fig.30E) decreased during the 
differentiation phase from day 1 to day 4, and following differentiation showed only a slight 
increase. Ox-LDL loading however, led to a significantly increased surface expression of 
ceramide, lactosylceramide, globotriaosylceramide, dodecasaccharideceramide and GM1 
ganglioside while E-LDL loading only slightly increased their expression (Fig.30A-D). These 
data indicate that Ox-LDL in comparison to E-LDL not only increased total cellular ceramide 
content but also induced a higher cell surface expression of ceramide and ceramide-
backbone glycosphingolipids. Neither ceramide, lactosylceramide nor globotriaosylceramide 
responded to HDL3 in Ox-LDL loaded cells (Fig.30A-C) while dodecasaccharideceramide 
and GM1 ganglioside further increased (Fig.30D,E). E-LDL loaded cells responded to HDL3 
with a cell surface decrease in ceramide and lactosylceramide (Fig.30A,B) while 
globotriaosylceramide, dodecasaccharideceramide and GM1 ganglioside increased during 
HDL3 exposure (Fig.30C-E).  
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Figure 30: Surface expression of membrane ceramide, glycosphingolipids and GM1 
ganglioside  
The cell surface expression of membrane ceramide, glycosphingolipids and the GM1ganglioside was 
analyzed by flow cytometry. 
Cellular surface expression of ceramide (Cer) (A), lactosylceramide (LacCer, CDw17) (B), 
globotriaosylceramide (Gb3Cer, CD77) (C), dodecasaccharideceramide (CD65s) (D) and GM1 
ganglioside (E) is shown. 
 
 
2.4. Binding and uptake of apoE and apoA-I 
Flow cytometric analysis of 4°C binding and 37°C binding and uptake of fluorescent labelled 
apoE and apoA-I demonstrated at 4°C higher apoE binding on surface Cer enriched Ox-LDL 
loaded cells as compared to E-LDL loaded cells (Fig.31A). In contrast to apoE, apoA-I 
showed similar binding capacity at 4°C to E-LDL and Ox-LDL loaded cells (Fig.31B). At 
37°C, a higher binding and uptake of both, apoE and apoA-I was found to Cer enriched Ox-
LDL loaded cells (Fig.31C,D) while apoA-I compared to apoE (Fig.31C) showed a smaller 
difference in the uptake and binding capacity between E-LDL and Ox-LDL loaded cells 
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(Fig.31D). These data strongly indicate that apoE not only has a high affinity to artificial 
liposomes enriched in Cer (110) but also to cell surface Cer enriched monocytes loaded with 
Ox-LDL. 
It was also analyzed 37°C binding and uptake of fluorescent labelled apoE (Cy3-apoE) and 
apoA-I (Cy5-apoA-I) and their colocalization with Cer on Ox-LDL loaded macrophages by 
confocal microscopy and the results are shown in Fig.31 E-J. It could be demonstrated a 
higher binding and uptake of apoE on Cer enriched Ox-LDL loaded cells (Fig.31E) 
associated with an impaired colocalization of apoE and Cer compared to apoA-I (Fig.31H,I). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Binding and uptake of apoE and apoA-I determined by flow cytometry and confocal 
microscopy  
At 4°C binding of fluorescent labeled apoE (Cy3-apoE) (A) and apoA-I (Cy5-apoA-I) (B) and at 37°C 
binding and uptake of apoE (C) and apoA-I (D) was analyzed by flow cytometry during 5 min of M-CSF 
differentiation as well as E-LDL and Ox-LDL loaded macrophages. 
Ceramide expression and binding of fluorescent labeled apoE and apoA-I as well as colocalization 
between ceramide and apoE, apoA-I respectively (Merge) was analyzed in Ox-LDL loaded cells by 
confocal microscopy at 37°C. 
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2.5. Analysis of raft formation  
2.5.1. Staining of raft-microdomains with DMPE-TMR 
MCSF differentiated (6 days), E-LDL loaded (day 4-6) and HDL3 deloaded (day 6-7) 
macrophages were stained with lipid vesicles prepared from a mixture of 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC) and 1,2-dimyristoyl-sn-glycero-3-phospho-
ethanolamine-tetramethyl-rhodamine (DMPE-TMR) in order to find out differences in raft-
microdomain formations during macrophage differentiation, E-LDL loading and HDL3 
deloading. DMPE is a phospholipid with a saturated side chain and therefore it specifically 
intercalates with highly lipid ordered membrane domains like rafts as described by Schütz 
G.J. et al. (329). In MCSF differentiated macrophages, a relatively homogenous distribution 
with weak fluorescence of DMPE-TMR on the cell membrane could be observed, which may 
represent small single lipid microdomains (Fig.32A). In contrast to this, macrophages loaded 
with E-LDL showed an inhomogenous distribution of DMPE-TMR staining and the formation 
of large raft-domains bearing intensive fluorescence on the cell surface (Fig.32B). This 
indicates that cholesterol loading promotes the confluence of relatively small rafts into larger 
domains. With HDL3 deloading this phenomenon was reversed indicating a disruption of 
these large microdomains during HDL3 deloading (Fig.32C).   
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Figure 32: Analysis of raft formation with DMPE-
TMR staining of MCSF differentiated (A), E-LDL 
loaded (B) and HDL3 deloaded macrophages (C)  
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2.5.2. Staining of sphingomyelin- and Cer rafts and cholesterol-rich membrane   
          microdomains  
In addition to flow cytometry analysis of Cer surface expression and to the different 
formations of rafts found with DMPE staining during lipid loading and deloading, confocal 
microscopy was used as an additional method to analyze the distribution and raft formation 
of sphingomyelin (SM), cholesterol and Cer of MCSF differentiated, E-LDL and Ox-LDL 
loaded, as well as HDL3 deloaded macrophages. Lysenin, labelled with anti-His antibody 
followed by incubation with anti-rabbit-Texas-Red antibody was used for SM staining, theta 
toxin-FITC for cholesterol staining and fluorescent labelled Cer antibody was used to analyze 
Cer rafts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: E-LDL promotes cholesterol/sphingomyelin rich membrane microdomains while Ox-
LDL induces cholesterol/ceramide rafts  
The surface expression of sphingomyelin (SM), cholesterol and ceramide (Cer) was analyzed by 
confocal microscopy with M-CSF, E-LDL and Ox-LDL loaded and HDL3 deloaded macrophages (MF). 
Fluorescent theta toxin (FITC labeled, green staining, cholesterol column), lysenin (Texas-red-anti-
rabbit; red staining, sphingomyelin column), and ceramide (Cy5-anti-mouse; red patches, ceramide 
column) were used to analyze the expression of SM, cholesterol and Cer rich microdomains. Overlap 
of cholesterol and SM respectively Cer was shown in the merge column. M-CSF treated MF (A), E-
LDL loaded MF (B), Ox-LDL loaded MF (C), E-LDL deloaded MF (D), and Ox-LDL deloaded MF (E).  
 
SM staining (red staining, sphingomyelin column) showed an induction during E-LDL loading 
(Fig.33B) compared to MCSF (Fig.33A) and Ox-LDL loading (Fig.33C). The formation of SM 
rich membrane microdomains during E-LDL loading is obvious from the staining pattern 
(Fig.33B). As compared to MCSF-differentiated cells (Fig.33A), theta toxin expression (green 
staining, cholesterol column) is similarly induced with E-LDL and Ox-LDL loading (Fig.33B,C) 
indicative for the formation of cholesterol enriched microdomains with both lipid loading 
MCSF
(MF diff)
A.
E-LDL
HDL3
(deload)
D.
Ox-LDL
(load)
C.
E-LDL
(load)
B.
Ox-LDL
HDL3
(deload)
E.
Cholesterol Sphingomyelin Merge Cholesterol Ceramide Merge
bar length 10 µm
  Results 
  
 86 
agents. The Cer expression (red staining, ceramide column) was lowest in MCSF treated 
macrophages as a control (Fig.33A) and E-LDL loaded macrophages (Fig.33B), while 
macrophages loaded with Ox-LDL showed a higher expression of Cer rich microdomains 
(Fig.33C). This is in accordance with the flow cytometric data which showed also the highest 
Cer surface expression during Ox-LDL loading (Fig.33A). Cer rich microdomains partially 
colocalize with the theta toxin labeled cholesterol rich microdomains (yellow overlay, Merge 
column).  
With HDL3 deloading a decrease of SM, cholesterol and Cer expression could be observed in 
E-LDL loaded cells (Fig.33D) and to a lower extent in Ox-LDL loaded cells (Fig.33E) 
indicating a differential deprivation of SM, cholesterol and Cer at the cell surface during HDL3 
deloading. 
 
2.5.3. Mass spectrometry analysis of isolated lubrol-detergent resistant membranes 
Tandem mass spectrometric analysis of isolated lubrol-detergent resistant membranes of 
MCSF differentiated, E-LDL and Ox-LDL loaded as well as HDL3 deloaded macrophages, 
confirmed the induction of cholesterol/sphingomyelin rich membrane microdomains with E-
LDL loading and cholesterol/ceramide rich rafts with Ox-LDL loading (table 8) as it was 
observed by confocal microscopy (Fig.33A-E). SM content was induced during E-LDL 
loading to a higher extent than during Ox-LDL loading (32 vs. 2 nmol/mg protein) compared 
with MCSF. During deloading, SM content increased more extensively after E-LDL than after 
Ox-LDL preloading (57 vs. 23 nmol/mg protein). Free cholesterol content (FC) increased with 
E-LDL and Ox-LDL loading (136 vs. 111 nmol/mg protein) in comparison to MCSF and 
decreased more extensively during Ox-LDL deloading (34 vs. 86 nmol/mg protein). The 
increased amount of Cer (4,0 vs. 0,6 nmol/mg protein) and glucosylceramide (GluCer) (1,6 
vs. 0,3 nmol/mg protein) was higher during Ox-LDL than during E-LDL loading in comparison 
to MCSF.  
 
 
 
 
 
 
 
Table 8: Lipid content of lubrol rafts (nmol/mg membrane protein) 
Analysis of free cholesterol (FC), sphingomyelin (SM), ceramide (Cer) and glucosylceramide (GluCer) 
content of isolated detergent resistant membranes (lubrol rafts) determined by ESI mass spectrometry. 
 
 
2.9+/-0.42.0+/-0.3231+/-37272+/-111Ox-LDL (deload)
3.4+/-1.15.5+/-1.4208+/-28358+/-168Ox-LDL (load)
3.3+/-1.12.3+/-1.0295+/-77349+/-66E-LDL (deload)
2.1+/-0.82.1+/-0.6238+/-11383+/-142E-LDL (load)
1.8+/-0.41.5+/-0.4206+/-0247+/-136MCSF (MF diff)
GluCerCerSMFC
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2.6. Gene expression analysis  
In order to elucidate potential mechanisms behind the differential effects of E-LDL and Ox-
LDL, the gene expression profile of 4 day MCSF differentiated, E-LDL and Ox-LDL loaded, 
as well as HDL3 deloaded human monocyte derived macrophages was analyzed by 
Affymetrix U133A Gene ChipsTM. The number and percentage of genes regulated under 
these conditions is shown in table 9. As indicated in table 9, E-LDL specifically 
downregulates (497 vs 105) while Ox-LDL upregulates (178 vs 20) more genes during lipid 
loading. With HDL3 deloading of E-LDL loaded cells, a 3-4 fold higher number of genes was 
found upregulated than during deloading of Ox-LDL loaded cells (625 vs 166). The number 
of genes which were specifically downregulated during deloading is 54 in the case of E-LDL 
and 38 in the case of Ox-LDL deloading. The number of genes that were commonly induced 
during E-LDL and Ox-LDL loading was 29 vs 31. The commonly downregulated genes during 
E-LDL and Ox-LDL loading indicated a much higher number of regulated genes than during 
deloading (129 vs 1). This results indicate greatest dynamics in the gene regulation during 
HDL3 deloading of E-LDL loaded cells which showed the highest number of upregulated 
genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9: Number and percentage of genes regulated in the E-LDL and Ox-LDL loaded, HDL3   
              deloaded and differentiated status 
 
In the next step the related in vitro results of the differential effects of E-LDL and Ox-LDL 
loading and deloading were related to in silico data of published detergent resistant 
membrane proteins that were identified by proteomic analysis and published by Li et al., 
Proteomics 2003 (380) and 2004 (381); Bae et al., Proteomics 2004 (382); Foster et al., 
PNAS 2003 (383) and Blonder et al., Electrophoresis 2004 (384). A gene list derived from 
this detergent resistant membrane proteins was matched with our gene array data analyzed 
by Affymetrix U133A Gene ChipsTM of 4 day M-CSF differentiated, E-LDL and Ox-LDL 
Category
E-LDL Ox-LDL E-LDL Ox-LDL
Load Specific Up 20 178 0,5% 4,2%
Load Specific Down 497 105 11,7% 2,5%
Deload Specific Up 625 166 14,7% 3,9%
Deload Specific Down 54 38 1,3% 0,9%
Category
Load Deload Load Deload
Common Up 29 31 0,7% 0,7%
Common Down 129 1 3,0% 0,0%
Inversly regulated 16 113 0,4% 2,7%
Genes regulated during differentiation
Total significantly reglated genes
Number of genes Percentage
1443 34,0%
4240
Number of genes Percentage
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loaded, and HDL3 deloaded human monocyte derived macrophages and genes were 
considered as significant with an up-(red color) or down- (blue color) regulation of ≥2.0 fold. 
This search list was extended with all significantly regulated membrane receptors and 
proteins present on the U133A Chip in order to further elucidate the differential plasma 
membrane receptor composition according to their specific, common or inverse regulation 
during E-LDL and Ox-LDL loading and deloading. In addition, proteins relevant for 
glycosphingolipid metabolism, lipid transfer proteins, apolipoproteins, ABC transport proteins 
and proteins involved in vesicular trafficking were attached and shown in table 10.  
In the group of detergent resistant membrane proteins, three V-type ATPases (ATP6V1C1, 
ATP6V1D and ATP6V1G1) were found downregulated during E-LDL deloading and 
upregulated during Ox-LDL deloading which may reflect a compensatory increase in 
protonation due to the known impaired degradation of Ox-LDL (161). In contrast the 
ATPsynthase subunits (ATP5I, ATP5L, ATP5A1 and ATP50) were found upregulated during 
E-LDL deloading and showed no response upon Ox-LDL deloading. This regulation may 
relate to the recent observation that ApoA-I binds to the beta chain of ATP synthase at the 
plasma membrane and thereby triggers type II phagocytosis and generation of ADP (105) in 
clathrin independent vesicular processing which is relevant for E-LDL but not minimally Ox- 
LDL processing (161). These endocytotic processes also involve solute carriers and ion 
channels. The adenine nucleotide translocators SLC25A5, SLC25A6 as well as the citrate 
and oxyglutarate carriers SLC25A1 and SLC25A11, the voltage dependent anion channels 
VDAC3 and the sodium- and chloride-activated ATP-sensitive potassium channel SLICK 
showed the same regulation pattern as the ATPsynthase subunits with an upregulation 
during E-LDL deloading and no significant regulation during Ox-LDL deloading.  
Most of the major histocompatibility complex related proteins like HLA-A, HLA-B, HLA-C, 
HLA-E, HLA-DMB, HLA-DPA1 and HLA-DPB1 showed an upregulation during E-LDL 
deloading but no regulation during Ox-LDL deloading. Others like HLA-DQA1 and HLA-DRA 
revealed no significant regulation during E-LDL loading but a downregulation during Ox-LDL 
loading. During E-LDL deloading no significant regulation while during Ox-LDL deloading an 
upregulation could be observed. These MHC class proteins were described by M. Desjardins  
and CV Harding (385;386) as a part of the phagosome compartment and involved in 
phagocytosis and clathrin independent MHC processing.  
This compartment involves also part of the proteasome/ubiquinone protein processing 
system which was found not regulated during E-LDL loading and upregulated during Ox-LDL 
loading while deloading with HDL3 led to an upregulation during E-LDL deloading and no 
regulation during Ox-LDL deloading. The ribosomal proteins showed a similar regulation 
pattern during deloading with an upregulation during E-LDL deloading and no regulation 
during Ox-LDL deloading. This indicates that E-LDL and Ox-LDL loading and deloading exert 
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differential effects on the degradation and translation machinery with a higher translational 
acitivation during E-LDL deloading. 
In the group of membrane receptors relevant for innate immunity, the gene expression of 
CD32/Fcg-receptor 2A was not significantly regulated during E-LDL loading but was 
downregulated during Ox-LDL loading. Decay acceleration factor CD55 was only 
upregulated with Ox-LDL loading. In relation to this raft associated membrane receptors, it 
was focused on the innate immunity receptor cluster described by Pfeiffer et al. (30) and 
other published ABCA1 pathway related proteins. This receptor cluster was induced by 
binding of ceramide and is involved in raft formation and signaling. The GPI-anchored LPS 
receptor CD14 was downregulated during lipid loading and upregulated during E-LDL 
deloading. The integrin associated pentaspan protein CD47 and the integrin CD11b were not 
significantly regulated during E-LDL deloading and upregulated during Ox-LDL deloading. 
The Fcg-receptors CD64 and CD32 were not significantly regulated during E-LDL loading 
and downregulated during Ox-LDL loading while the Fcg-receptor IIIa/CD16 was 
downregulated with both lipid loading agents. During HDL3 deloading CD64 was upregulated 
with Ox-LDL deloading. The scavenger receptor CD36 was upregulated during E-LDL 
loading while the scavenger receptor cysteine rich/CD163 was downregulated during Ox-LDL 
loading. During E-LDL deloading CD163 and LRP1 were upregulated and CD163 was also 
upregulated during Ox-LDL deloading. Results of flow cytometric analysis of this innate 
immunity receptor cluster were shown in Fig.34.  
ABCA1 and ABCG1 are proteins involved in lipid efflux of macrophages (387). ABCA1 was 
upregulated during E-LDL and Ox-LDL loading while ABCG1 was only significantly regulated 
during Ox-LDL loading. Both were not significantly regulated during HDL3 deloading in the 
gene array data. ABCA1 related proteins like CDC42 which is involved in vesicular trafficking 
was not significantly regulated during E-LDL deloading and upregulated during Ox-LDL 
deloading reflecting a higher dynamic of vesicular trafficking during HDL3 deloading of Ox-
LDL loaded cells probably by abolishing the trapping of Ox-LDL in the lysosomal pathway. 
The proteins Sec6like 1 and the exocyst complex component 7 which is involved in the 
exocytotic vesicular pathway are upregulated during E-LDL deloading and downregulated 
respectively not significantly regulated during Ox-LDL deloading. This could indicate a higher 
dynamic of the exocytosis pathway during vesicular trafficking in E-LDL deloaded compared 
with Ox-LDL deloaded macrophages. The apolipoproteins C-I, C-II and C-IV were all 
upregulated during E-LDL deloading and not significantly regulated during Ox-LDL deloading 
indicating a higher lipid efflux and transport dynamic during E-LDL deloading. In addition 
apoC-II was downregulated during E-LDL loading while apoC-I and apoC-IV were 
upregulated during Ox-LDL loading.  
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2.6.1. Pathway specific analysis of microarray expression data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10: Raft proteins, membrane receptors/proteins, proteins for GSL degradation and   
              ABCA1 and related proteins on U133 A 
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Raft proteins deduced from Li et al., Proteomics 2004, Bae et al., Proteomics 2004, 
Foster et al., PNAS 2003, Li et al., Proteomics 2003, Blonder et al., Electrophoresis 
2004
ATPasen/synthasen
Hs.86905 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C, isoform 1 ATP6V1C1 8q22.3 ++ 500 ++ 1,5 ++ -2,8 ++ 1,4 ++ 4
Hs.272630 ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D (Vacuolar ATP synthase catalytic subunit d)ATP6V1D 14q23-q24.2 ++ 463 ++ 1,3 ++ -2,1 ++ 1 ++ 2,5
Hs.90336 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G isoform 1 ATP6V1G1 9q32 ++ 1082 ++ 1,3 ++ -3,2 ++ -1,3 ++ 2,6
Hs.85539 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit e ATP5I 4p16.3 ++ 683 ++ 1 ++ 3,5 ++ 1,7 ++ -1,5
Hs.107476 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit g *S ATP5L 11q23.3 ++ 2553 ++ -1,5 ++ 2,6 ++ 1,2 ++ 1,1
Hs.298280 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscleATP5A1 18q12-q21 ++ 2223 ++ 1,1 ++ 2,3 ++ 1,6 ++ 1,2
Hs.409140 ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit (oligomycin sensitivity conferring protein)ATP5O 21q22.11 ++ 1444 ++ -1,1 ++ 2,3 ++ 1,5 ++ 1,1
Solute Carrier/Ion channels
Hs.79172 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5 SLC25A5 xq24-q26 ++ 2961 ++ -1,2 ++ 2 ++ 1,4 ++ 1,1
Hs.350927 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6 SLC25A6 xp22.32 and yp ++ 1768 ++ -2,1 ++ 3,5 ++ 1,4 ++ -1,2
Hs.111024 solute carrier family 25 (mitochondrial carrier; citrate transporter), member 1 SLC25A1 22q11.21 ++ 190 ++ -2,5 ++ 1,9 ++ -1,9 ++ 1,6
Hs.184877 solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), member 11 SLC25A11 17p13.3 ++ 520 ++ -1,5 ++ 3 ++ 1,4 ++ -1,1
Hs.439253 voltage-dependent anion channel 3 VDAC3 8p11.2 ++ 1396 ++ 1,1 ++ 2,3 ++ 1,6 ++ -1,1
Hs.444376 Sodium- and chloride-activated ATP-sensitive potassium channel SLICK 1q31.3 ++ 19 + -3 ++ 4 + -1,3 + 1,1
Membrane Receptors/Proteins
Hs.352642 Fc fragment of IgG, low affinity IIa, receptor for (CD32) FCGR2A 1q23 ++ 285 ++ -1,5 ++ 1,5 ++ -2,1 ++ 1,4
Hs.408864 decay accelerating factor for complement (CD55, Cromer blood group system) DAF 1q32 + 78 ++ 1,5 ++ -1,6 ++ 2,3 ++ -1,3
HLA class I,II family
Hs.181244 major histocompatibility complex, class I, A /// major histocompatibility complex, class I, C HLA-A 6p21.3 ++ 6916 ++ -1,3 ++ 2 ++ 1,1 ++ 1
Hs.77961 major histocompatibility complex, class I, B HLA-B 6p21.3 ++ 7668 ++ -1,1 ++ 2 ++ 1,2 ++ -1,1
Hs.274485 major histocompatibility complex, class I, C /// major histocompatibility complex, class I, B HLA-C 6p21.3 ++ 8347 ++ -1,4 ++ 2,1 ++ 1,1 ++ -1,1
Hs.381008 major histocompatibility complex, class I, E HLA-E 6p21.3 ++ 2038 ++ -1,4 ++ 2,1 ++ 1 ++ 1
Hs.1162 major histocompatibility complex, class II, DM beta HLA-DMB 6p21.3 ++ 250 ++ -1,2 ++ 1,9 ++ -1,1 ++ 1,7
Hs.914 major histocompatibility complex, class II, DP alpha 1 HLA-DPA1 6p21.3 ++ 1010 ++ -1,1 ++ 2,1 ++ -1,3 ++ 1,3
Hs.368409 major histocompatibility complex, class II, DP beta 1 HLA-DPB1 6p21.3 ++ 540 ++ -1,9 ++ 3 ++ -1,9 ++ 1,2
Hs.387679 major histocompatibility complex, class II, DQ alpha 1 HLA-DQA1 6p21.3 + 67 ++ -1,7 ++ 1,3 ++ -3,7 ++ 2,6
Hs.409805 major histocompatibility complex, class II, DR alpha HLA-DRA 6p21.3 ++ 1322 ++ -1,4 ++ 1,1 ++ -2,3 ++ 2,8
Membrane Receptors/Proteins
GPI anchors/Pentaspans
Hs.519624 CD14 antigen CD14 5q31.1 ++ 1174 ++ -3,5 ++ 3,5 ++ -2,8 ++ 1,1
Hs.408864 decay accelerating factor for complement (CD55) DAF 1q32 + 78 ++ 1,5 ++ -1,6 ++ 2,3 ++ -1,3
Hs.446414 CD47 antigen (Rh-related antigen, integrin-associated signal transducer) CD47 3q13.1-q13.2 ++ 1010 ++ -1,1 ++ -1,1 ++ -1,1 ++ 1,9
Integrins/Complement Receptors
Hs.172631 integrin, alpha M (complement receptor 3, alpha) CD11b ITGAM 16p11.2 ++ 2204 ++ -1,1 ++ 1,9 ++ -1,6 ++ 2,3
Fcg-Receptors
Hs.534325 Fc fragment of IgG, high affinity Ia, receptor for (CD64) FCGR1A 1q21.2-q21.3 ++ 208 ++ -1,3 ++ 1 ++ -3,7 ++ 4
Hs.126384 Fc fragment of IgG, low affinity IIa, receptor for (CD32) FCGR2B 1q23 ++ 285 ++ -1,5 ++ 1,5 ++ -2,1 ++ 1,4
Hs.372679 Fc fragment of IgG, low affinity IIIa, receptor for (CD16) FCGR3B/3A 1q23 ++ 131 ++ -2,5 ++ 2 ++ -3 ++ 1,9
Scavenger Receptors
Hs.443120 CD36 antigen (collagen type I receptor, thrombospondin receptor) CD36 7q11.2 ++ 2864 ++ 2,3 ++ -1,4 ++ 1,6 ++ 1,6
Hs.74076 CD163 antigen (scavenger receptor cysteine rich) CD163 12p13.3 ++ 1354 ++ -1,7 ++ 2,1 ++ -2,8 ++ 2,1
Hs.162757 Low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) LRP1 12q13-q14 ++ 177 ++ -1,5 ++ 2,6 ++ -1,2 ++ 1,3
Proteins involved in Glycosphingolipid Processing
Hs.406455 prosaposin PSAP 10q21-q22 ++ 4280 ++ 1,1 ++ 1,9 ++ 1,5 ++ -1,2
Hs.387156 GM2 ganglioside activator GM2A 5q31.3-q33.1 ++ 1065 ++ 1,1 ++ 1,9 ++ 1,5 ++ 1,1
Hs.381256 glycolipid transfer protein GLTP 12q24.12 + 90 + 4 + -3 + 2 ++ 2,6
ABCA1and related Proteins
Hs.147259 ATP-binding cassette, sub-family A (ABC1), member 1 ABCA1 9q31.1 ++ 130 ++ 2 ++ -1,4 ++ 2 ++ -1,2
Hs.355832 cell division cycle 42 (GTP binding protein, 25kDa) CDC42 1p36.1 + 436 + 1,7 ++ -1,1 ++ 1 ++ 2,5
Hs.134514 ATP-binding cassette, sub-family A (ABC1), member 7 ABCA7 19p13.3 ++ 67 ++ -2,5 ++ 3,5 + -1,5 + -1,1
Hs.369055 ATP-binding cassette, sub-family G (WHITE), member 1 ABCG1 21q22.3 ++ 95 ++ 1,5 + -1,2 ++ 2,5 ++ -1,4
Lipid Transfer Proteins and Apolipoproteins
Hs.439312 phospholipid transfer protein PLTP 20q12-q13.1 - 4 ++ -1,4 ++ 1,1 ++ -3 ++ 1,5
Hs.268571 apolipoprotein C-I APOC1 19q13.2 + 47 ++ 1,1 ++ 2,5 ++ 1,6 ++ -1,1
Hs.75615 apolipoprotein C-II APOC2 19q13.2 + 109 + -3,2 ++ 3,5 + -4 + 1,3
Hs.491896 apolipoprotein C-IV APOC4 19q13.2 ++ 268 ++ -1,3 ++ 2,3 ++ 1,7 ++ -1,1
Hs.110675 apolipoprotein E APOE 19q13.2 ++ 200 ++ -1,1 ++ 1,7 ++ 1,3 ++ 1,4
Vesicular trafficking
Hs.448580 SEC6-like 1 (S. cerevisiae) SEC6L1 5p15.33 + 99 + -1,7 ++ 4,3 ++ 1,7 ++ -2,3
Hs.325530 exocyst complex component 7 EXOC7 17q25.1 ++ 221 ++ -1,3 ++ 2,1 ++ 1,4 ++ -1,1
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2.7. Analysis of gene expression, protein and surface expression of membrane  
          receptors during E-LDL and Ox-LDL loading and HDL3 deloading  
In order to further elucidate the possible functions of the differential raft microdomain 
formations through E-LDL and Ox-LDL, the expression of membrane receptors and their 
downstream signaling elements were analyzed by Affymetrix chips (table 10). According to 
Pfeiffer et al., binding of Cer, that is present at the surface of atherogenic lipoproteins or 
apoptotic cells, induces a receptor cluster including the LPS receptor CD14, complement 
receptor 3 constituents CD11b/CD18, the Fcg-receptors CD64, CD32 and CD16, scavenger 
receptor B CD36, integrin associated protein CD47 and decay acceleration factor CD55. 
Formation of this cluster leads to ligand dependent activation of downstream signaling 
pathways related to the receptor composition. In order to find out differential regulation of 
membrane receptors during E-LDL and Ox-LDL loading and HDL3 deloading we focused on 
this known receptor cluster and also on the lipoprotein receptor CD91/LRP1 and the 
scavenger receptor cystein rich CD163.  
In addition to Microarray analysis, surface and protein expression analysis of these receptors 
was performed by flow cytometry and Western Blot respectively. E-LDL and Ox-LDL loaded 
and HDL3 deloaded human monocyte derived macrophages were analyzed. 
 
E-LDL and Ox-LDL loading 
In the Fcg-receptor family (Fig.34A) surface and protein expression of CD64/FcgRI showed 
almost no change during E-LDL loading while CD32/FcgRIIA was increased. CD16/FcgRIII 
surface expression during E-LDL loading was decreased, which is in accordance with gene 
array data indicating a -2,5 fold decrease of CD16/FcgRIII during E-LDL loading, but it is in 
contrast to the protein expression which showed an increase of CD16/FcgRIII. Ox-LDL 
loading led to a decrease of the surface expression of all three FcgRs (Fig.34A). This 
corresponds with the chip data which showed a 3.7 fold decrease of CD64, a 2,1 fold 
decrease of CD32 and a 3 fold decrease of CD16 during Ox-LDL loading. With western blot 
analysis a decrease of CD64, CD32 and CD16 could not be clearly confirmed.  
The surface expression of scavenger receptor B (SR-B), CD36 showed an increase during 
E-LDL and a stronger increase during Ox-LDL loading while CD91/LRP1 and CD163/SR 
were inversely regulated with an increase during E-LDL and a decrease during Ox-LDL 
loading (Fig.34B). The gene array data confirmed these results with a 2.3 fold upregulation of 
CD36 during E-LDL and 1.6 fold upregulation during Ox-LDL loading. In the case of CD163 a 
decrease of -2,8 fold during Ox-LDL loading was observed. The protein expression of CD36 
showed also an upregulation with lipid loading which is stronger in the case of Ox-LDL. The 
protein expression of CD163 is also consistent with the data obtained by flow cytometry and 
gene analysis.  
  Results 
  
 92 
Cell surface expression of the integrins respectively complement receptor 3 (CD11a, 
CD11b) and CD18 was increased during E-LDL but decreased during Ox-LDL loading 
(Fig.34C). This indicates that E-LDL in contrast to Ox-LDL activates complement. In the case 
of CD11a and CD11b an increase during E-LDL but not during Ox-LDL loading could be 
confirmed with western blot analysis. The integrin associated protein, pentaspan CD47 
surface expression was increased during E-LDL loading but decreased during Ox-LDL 
loading while the decay acceleration factor CD55 was increased during E-LDL and Ox-LDL 
loading which could be confirmed by Western Blot (Fig.34D). The surface expression of LPS 
receptor CD14 was decreased during E-LDL and Ox-LDL loading (Fig.34D). This could also 
be shown with western blot analysis and in the gene array data this could be confirmed with 
a decrease of -3.5 fold during E-LDL and -2.8 fold during Ox-LDL loading. 
 
HDL3 deloading 
HDL3 deloading showed a decrease of surface and protein expressions of FcgRs CD64, 
CD32 and CD16 compared to MCSF (Fig.34A).  
SR-B, CD36 surface and protein expression was increased with HDL3 deloading compared to 
MCSF (Fig.34B). CD91 and CD163 were decreased during lipid deloading which could be 
confirmed by western blot analysis in the case of CD163. While gene array analysis showed 
an increase of CD163 during HDL3 deloading (Fig.34B). CD11a was decreased during E-LDL 
and Ox-LDL deloading while CD11b was increased during E-LDL and decreased during Ox-
LDL deloading (Fig.34C). CD18 was increased during E-LDL and Ox-LDL deloading 
(Fig.34C).  
CD47 and CD55 surface expression was increased with E-LDL deloading and decreased 
with Ox-LDL deloading (Fig.34D). The LPS receptor CD14 was increased during E-LDL and 
Ox-LDL deloading (Fig.34D). The increase of CD14 during lipid deloading could be 
confirmed by western blot and gene array analysis which showed an increase of 3.5 fold 
during E-LDL and 1.1 fold during Ox-LDL deloading.  
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Figure 34:  Flow cytometric and western blot analysis of membrane receptors 
The surface expression of membrane receptors was analyzed by flow cytometry and the protein 
expression by western blot during E-LDL and Ox-LDL loading (48 h, day 4 to day 6) and HDL3 
deloading (24 h, day 6 to day 7) of macrophages. The mean fluorescence intensities of the receptor 
surface expressions were calculated in % of the mean fluorescence intensities of MCSF differentiated 
macrophages as a control. CD64/FcgRI, CD32/FcgRII, CD16/FcgRIII (A), CD36/SRBII, CD91/LRP1, 
CD163/Srcysteine rich (B), CD11a, CD11b, CD18 (C), CD47, CD55, CD14 (D) 
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2.8. Raft association of FcgRIIA /CD32  
In a next step it should be analyzed if the different lipid loading agents E-LDL and Ox-LDL or 
HDL3 deloading had influences on the raft association of FcgRIIA/CD32. This is in 
accordance with Shakor who published that cell surface Cer generation precedes and 
controls CD32 clustering in rafts (302). In our case Ox-LDL leads to a higher expression level 
of Cer which could influence CD32 raft association. Therefore lubrol-raft fractions 
respectively non raft fractions were isolated from membrane preparations of cells from the 
different incubation states and the protein expression of FcgRIIA/CD32 was analyzed in 
these fractions. Cells loaded with E-LDL showed a higher raft association of FcgRIIA/CD32 
compared to MCSF differentiated macrophages and a lower raft association than Ox-LDL 
loaded cells (Fig.35). This raft association was partially reversed by HDL3 deloading of the 
cells (Fig.35). 
This result is reflecting a different receptor clustering associated with diverse raft formations 
during E-LDL and Ox-LDL loading and could lead to unequal signaling pathways activated by 
the different lipoproteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.9. Analysis of proteins involved in cholesterol metabolism 
 
2.9.1. Gene expression analysis 
The analysis of genes involved in cholesterol metabolism by Microarray analysis during E-
LDL and Ox-LDL loading and also during HDL3 deloading of macrophages revealed 
regulatory principles of the cholesterol metabolism during foam cell formation with the two 
different lipid loading agents E-LDL and Ox-LDL and cholesterol efflux with HDL3 (table 10). 
lubrol-raft non-raft
MCSF
E-LDL
E-LDL/HDL3
Ox-LDL
Ox-LDL/HDL3
Figure 35: Raft association of FcgRIIA/CD32 
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The LDL-receptor (LDLR), responsible for the binding and subsequent cellular uptake of 
apoB/E-containing lipoproteins plays a crucial role in cellular cholesterol homeostasis. The 
LDL-receptor is internalized via “clathrin coated pits” and following internalization of the LDL 
particles takes place. Cholesterol which is released into the cytoplasm suppresses cell 
surface expression of LDL receptors. This regulation corresponds with our chip data, which 
showed a -8.6 fold downregulation of the LDL receptor during E-LDL loading and a -4 fold 
downrgulation during Ox-LDL loading. During E-LDL deloading an upregulation of 3.2 fold 
and during Ox-LDL deloading an upregulation of 1.4 fold could be observed. The ABCA1 
transporter responsible for cholesterol efflux was 2-fold upregulated during lipid loading 
indicating an enhanced amount of ABCA1 resulting in more effective cholesterol efflux due to 
an increase of cellular cholesterol.  
 
2.9.2. Analysis of ABCA1 
 
2.9.2.1. mRNA expression of ABCA1 
The mRNA expression of ABCA1 determined with Taqman RT-PCR showed only a slight 
increase during E-LDL loading while upon Ox-LDL loading the mRNA expression was 
significantly induced. With HDL3 deloading a reduction of ABCA1 mRNA  expression took 
place (Fig.36). The gene array data reflect these findings partly with a 2 fold increase of 
ABCA1 gene expression during E-LDL and Ox-LDL loading and a decrease (-1.4 and -1.2 
fold) during HDL3 deloading (table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.9.2.2. Protein expression of ABCA1 
Protein expression analysis of ABCA1 by Western Blot was performed to verify the 
Affymetrix gene array data with an additional method. Macrophages loaded with E-LDL and 
Ox-LDL showed in accordance with the gene array data an induction of ABCA1 total protein 
Figure 36: mRNA expression of ABCA1 0
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expression compared to MCSF differentiated cells while the increase during Ox-LDL loading 
was stronger than the increase during E-LDL loading (Fig.37). This is in accordance to the 
mRNA expression of ABCA1 (Fig.36). The induction of ABCA1 protein expression was 
partially reversed during E-LDL deloading with HDL3 and there was a stronger reduction of 
ABCA1 protein expression during Ox-LDL deloading with HDL3 (Fig.37). 
 
 
 
 
 
 
Figure 37: Protein expression of ABCA1 
 
 
2.9.2.3. Analysis of membrane raft association of ABCA1 
In a next step it should be analyzed whether the different lipid loading agents E-LDL and Ox-
LDL or HDL3 deloading have influences on the raft association of ABCA1. Therefore raft 
fractions respectively non raft fractions were isolated from membrane preparations of cells 
from the different incubation states and the protein expressions of ABCA1 in these fractions 
were analyzed. 
During MCSF differentiation no raft association of ABCA1 could be detected while during E-
LDL and Ox-LDL loading a slight raft association could be observed (Fig.38). Also during E-
LDL and Ox-LDL deloading with HDL3 a slight raft association was detectable. However the 
strongest raft association could be observed during Ox-LDL deloading (Fig.38). 
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Figure 38: Raft association of ABCA1  
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2.9.3. Analysis of apoE 
 
2.9.3.1. Protein expression of apoE 
Total protein expression of apoE was analyzed with western-blot. Protein expression of apoE 
was only slightly induced during E-LDL and Ox-LDL loading compared to MCSF 
differentiated macrophages (Fig.39). Deloading with HDL3 after E-LDL loading led to a 
stronger upregulation of apoE protein expression than after Ox-LDL loading compared to 
lipid loading (Fig.39). 
 
 
 
 
Figure 39: Protein expression of apoE 
 
2.9.3.2. Extracellular (surface) and intracellular expression of apoE 
Extracellular (surface) and intracellular expression of apoE was measured by flow cytometry 
of MCSF differentiated, E-LDL and Ox-LDL loaded and HDL3 deloaded macrophages. In the 
differentiation phase with MCSF from day 1 to day 4 apoE surface expression was 
increased. From day 4 to day 6 no change and from day 6 to day 7 a further increase of 
apoE surface expression could be detected (Fig.40A). During lipid loading apoE surface 
expression increased with a stronger induction during E-LDL than during Ox-LDL loading 
(Fig.40A). This is in accordance with the protein expression of apoE (Fig.40). During HDL3 
deloading apoE surface expression was decreased compared to lipid loading (Fig.40A). 
Intracellular expression of apoE was increased during differentiation with MCSF from day 1 
to day 6 and was decreased from day 6 to day 7. During E-LDL loading a slight increase and 
during Ox-LDL loading a decrease of apoE intracellular expression could be observed 
compared to MCSF differentiation (Fig.40B). HDL3 deloading decreased intracellular apoE 
expression compared to lipid loading (Fig.40B).   
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Figure 40A: ApoE surface expression 
                    analyzed by flow cytometry  
 
Figure 40B: ApoE intracellular expression  
                    analyzed by flow cytometry  
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2.9.4. Analysis of apoC-I 
 
2.9.4.1. Protein expression of apoC-I 
Protein expression of apoC-I was analyzed with western-blot. Protein expression of apoC-I 
was slightly reduced during E-LDL while it was induced during Ox-LDL loading compared to 
MCSF differentiated macrophages (Fig.41). E-LDL and especially Ox-LDL deloading with 
HDL3 led to a stronger upregulation of apoC-I protein expression compared to lipid loading 
which is probably due to apoC-I as a constituent of HDL3 (Fig.41). 
 
 
 
 
2.9.4.2. Extracellular (surface) and intracellular expression of apoC-I 
Extracellular (surface) and intracellular expression of apoC-I was measured by flow 
cytometry of MCSF differentiated, E-LDL and Ox-LDL loaded and HDL3 deloaded 
macrophages. ApoC-I surface and intracellular expression was increased during 
differentiation with MCSF from day 1 to day 4, was slightly decreased from day 4 to day 6 
and was increased from day 6 to day 7 (Fig.42A). ApoC-I intracellular expression was much 
higher compared to extracellular expression, which is obvious from the higher mean 
fluorescence intensity. During E-LDL loading apoC-I surface expression was only slightly 
increased while during Ox-LDL loading it was strongly increased compared to MCSF 
(Fig.42A). E-LDL deloading with HDL3 increased and Ox-LDL deloading slightly decreased 
apoC-I surface expression compared to lipid loading (Fig.42A).  
Intracellular expression of apoC-I increased during lipid loading to a higher extent with Ox-
LDL than with E-LDL loading compared to MCSF differentiated macrophages (Fig.42B). 
During Ox-LDL deloading with HDL3 a slight decrease of apoC-I intracellular expression was 
observed while there was no change during E-LDL deloading compared to lipid loaded cells 
(Fig.42B).  
 
 
 
 
 
 
 
 
 Figure 42B: ApoC-I intracellular expression  
                    analyzed by flow cytometry  
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Figure 42A: ApoC-I surface expression  
                    analyzed by flow cytometry  
 
Figure 41: Protein expression of apoC-I 
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2.9.5. Analysis of CETP 
 
2.9.5.1. Extracellular (surface) and intracellular expression of cholesteryl ester transfer  
             protein (CETP) 
Extracellular (surface) and intracellular expression of CETP was measured by flow cytometry 
of MCSF differentiated, E-LDL and Ox-LDL loaded and HDL3 deloaded macrophages. During 
differentiation with MCSF from day 1 to day 7 CETP surface expression was increased 
(Fig.43A). During lipid loading CETP surface expression was increased with E-LDL loading 
while it was decreased with Ox-LDL loading compared to MCSF (Fig.43A). During E-LDL 
deloading with HDL3 CETP surface expression was slightly increased while during Ox-LDL 
deloading it was slightly decreased compared to lipid loading (Fig.43A).  
Intracellular expression of CETP increased during differentiation with MCSF from day 1 to 
day 6 while no further change was observed from day 6 to day 7 (Fig.43B). During lipid 
loading intracellular expression of CETP was decreased compared to MCSF with a stronger 
decrease during Ox-LDL than during E-LDL loading (Fig.43B). HDL3 deloading of E-LDL 
loaded cells increased while deloading of Ox-LDL loaded cells slightly decreased intracellular 
CETP expression compared to lipid loading (Fig.43B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.9.6. Analysis of PLTP 
 
2.9.6.1. Protein expression of PLTP 
Total protein expression of PLTP was analyzed with western-blot. Protein expression of 
PLTP was increased during E-LDL and Ox-LDL loading compared to MCSF differentiated 
macrophages (Fig.44). E-LDL deloading with HDL3 led to an increase of PLTP protein 
expression while Ox-LDL deloading led to a decrease of PLTP protein expression compared 
Figure 43A: CETP surface expression  
                    analyzed by flow cytometry  
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Figure 43B: CETP surface expression  
                     analyzed by flow cytometry  
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to lipid loading (Fig.44). Western Blot shows the two forms of PLTP with the molecular 
masses of 67kDa and 77kDa as described by Huuskonen et al. (388). 
 
 
 
 
Figure 44: Protein expression of PLTP 
 
2.9.7. Analysis of ATP-synthase (b-chain) 
 
2.9.7.1. Protein expression of ATP-synthase (b-chain) 
Total protein expression of ATP-synthase (b-chain) was analyzed with western-blot. Lipid 
loading with E-LDL and Ox-LDL revealed no change of ATP-synthase protein expression 
compared to MCSF (Fig.45). HDL3 deloading after E-LDL loading led to a slight increase of 
ATP-synthase protein expression compared to lipid loading (Fig.45). 
 
 
 
 
Figure 45: Protein expression of ATP-synthase (b-chain) 
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3. Incubation of ApoE3/3 macrophages with LDL, E-LDL and Ox-LDL alone and as  
    opsonized complexes with Amyloidb42  
 
3.1. Cell surface expression of sphingo- and glycosphingolipids 
In these experiments it should be analyzed if incubation of macrophages with Amyloid b42 
complexes (16mg/ml) of LDL, E-LDL and Ox-LDL (opsonized lipoproteins) compared to 
incubation of lipoproteins without Amyloid b42 have different effects on the surface expression 
of Cer and the GSLs LacCer (CDw17), Gb3Cer (CD77), dodecasaccharideceramide (CD65s) 
and GM1 ganglioside. Therefore 4 day differentiated macrophages were treated with 40mg/ml 
LDL, E-LDL and Ox-LDL, respectively with the LDL/ßA42, E-LDL/ßA42 and Ox-LDL/ßA42 
complexes for 16h. The incubation protocol was established by our institute previously. Four 
different experiments were performed and means and standard deviations of the mean 
fluorescence intensities were calculated. Significance was tested by student’s t-test and the 
asterisk indicates significance with p<0.05. 
LDL loading of macrophages compared to MCSF differentiation slightly increased LacCer 
and CD65s surface expression (Fig.46B,D) while Cer, Gb3Cer and GM1 surface expression 
was not affected by LDL loading (Fig.46A,C,E). Loading with the LDL/bA42 complex 
increased LacCer, Gb3Cer and GM1 surface expression (Fig.46B,C,E) and decreased Cer 
and CD65s surface expression (Fig.46A,D) compared to LDL loading without bA42. But none 
of these results reached statistical significance.  
During E-LDL loading LacCer, Gb3Cer and CD65s surface expression was clearly increased 
compared to MCSF (Fig.46B,C,D) whereas surface expression of Cer and GM1 was only 
slightly increased (Fig.46A, E). Loading the macrophages with the E-LDL/bA42 complex a 
significant increase of Cer, LacCer, Gb3Cer and GM1surface expression could be observed 
compared with the non-opsonized E-LDL alone (Fig.46A,B,D,E). In contrast to this CD65s 
surface expression showed a slight decrease during loading with the E-LDL/bA42 complex 
compared with E-LDL (Fig.46D).  
During Ox-LDL loading only slight changes could be observed compared to MCSF due to the 
small concentration of Ox-LDL (40mg/ml) used in these experiments. A small decrease of Cer 
(Fig.46A) and a small increase of GM1 surface expression (Fig.46E) could be detected while 
there was no change of LacCer, Gb3Cer and CD65s surface expression (Fig.46B,C,D). 
Loading with the Ox-LDL/bA42 complex revealed a small increase of Cer, LacCer and GM1 
surface expression (Fig.46A,B,E) while CD65s and Gb3Cer surface expression was 
decreased (Fig.46C,D). But none of these results reached statistical significance. 
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Figure 46: Determination of the surface expression of ceramide (A), lactosylceramide (CDw17) (B), 
dodecasaccharideceramide (CD65s), globotriaosylceramide (Gb3Cer, CD77) (D) and GM1 ganglioside 
(C) by flow cytometry of macrophages incubated for 16h with LDL, E-LDL and Ox-LDL alone (black 
columns), with the lipoprotein-Amyloid b42 complex (white columns) or with MCSF as a control 
(columns with stripes).  
 
 
 
 
 
 
 
 
 
 
 
 
MCSF lipoprotein lipoprotein + β-Amyloid (1-42)
A. ceramide (Cer)
LDL Ox-LDLE-LDL
0
10
20
30
40
50
60
70
80
m
ea
n 
flu
or
es
ce
nc
e
0
100
200
300
400
500
m
ea
n 
flu
or
es
ce
nc
e
0
20
40
60
80
100
120
m
ea
n 
flu
or
es
ce
nc
e
B. lactosylceramide (LacCer, CDw17)
0
2
4
6
8
10
12
14
16
m
ea
n 
flu
or
es
ce
nc
e
0
50
100
150
200
250
m
ea
n 
flu
or
es
ce
nc
e
0
5
10
15
m
ea
n 
flu
or
es
ce
nc
e
*
*
m
ea
n 
flu
or
es
ce
nc
e
m
ea
n 
flu
or
es
ce
nc
e
m
ea
n 
flu
or
es
ce
nc
e
m
ea
n 
flu
or
es
ce
nc
e
m
ea
n 
flu
or
es
ce
nc
e
m
ea
n 
flu
or
es
ce
nc
e
C. dodecasaccharideceramide (CD65s)
0
5
10
15
20
25
30
35
m
ea
n 
flu
or
es
ce
nc
e
0
5
10
15
20
25
m
ea
n 
flu
or
es
ce
nc
e 
0
5
10
15
20
25
m
ea
n 
flu
or
es
ce
nc
e
m
ea
n 
flu
or
es
ce
nc
e
m
ea
n 
flu
or
es
ce
nc
e 
m
ea
n 
flu
or
es
ce
nc
e
D. globotriaosylceramide (Gb3Cer, CD77)
0
100
200
300
400
m
ea
n 
flu
or
es
ce
nc
e
0
200
400
600
m
ea
n 
flu
or
es
ce
nc
e
0
100
200
300
m
ea
n 
flu
or
es
ce
nc
e
*
m
ea
n 
flu
or
es
ce
nc
e
m
ea
n 
flu
or
es
ce
nc
e
m
ea
n 
flu
or
es
ce
nc
e
E. GM1 ganglioside
0
50
100
150
200
m
ea
n 
flu
or
es
ce
nc
e
0
100
200
300
m
ea
n 
flu
or
es
ce
nc
e
0
100
200
300
m
ea
n 
flu
or
es
ce
nc
e
m
ea
n 
flu
or
es
ce
nc
e
m
ea
n 
flu
or
es
ce
nc
e
m
ea
n 
flu
or
es
ce
nc
e
  Results 
  
 103 
3.2. Binding of Dil-LDL, Dil-E-LDL and Dil-LDL/Ab42, Dil-E-LDL/Ab42 complexes to  
       monocyte subpopulations 
The highest binding of Dil–LDL, Dil-E-LDL and their complexes with Amyloid b42 could be 
observed on the CD14 high CD16 high monocyte subset (MNP2) (Fig.47A,B). Moreover 
Ab42-complexed LDL and E-LDL bound more efficiently to all subpopulations than the non-
opsonized lipoproteins. Further E-LDL and the Ab42 complexed E-LDL bind to a higher extent 
to all subpopulations than LDL and the LDL complex with Ab42. 
 
 
 
 
 
 
 
 
 
 
 
 
4. Incubation of apoE3/3 macrophages during differentiation, E-LDL loading and HDL3    
    deloading with the proteasomal inhibitor ALLN 
In order to find out differences of the proteasomal degradation of apoE and CETP between 
the two genotypes apoE3/3 and apoE4/4, macrophages of the two genotypes should be 
treated with proteasomal inhibitors. Subsequently surface and intracellular expression of 
apoE and CETP should be analyzed by flow cytometry. Because of the interesting findings of 
different raft formations during E-LDL and Ox-LDL loading, there was only time to perform 
these experiments with apoE3/3 but not apoE4/4 macrophages. 
Elutriated apoE3/3 monocytes were incubated after 1 day resting in serum free medium with 
50mM of the proteasomal inhibitor ALLN respectively the solvent DMSO and MCSF as a 
control. On the fourth day of MCSF differentiation and ALLN treatment, macrophages were 
loaded with E-LDL (40mg/ml) and on day 6, E-LDL loaded cells were deloaded with HDL3 
(100mg/ml). Extracellular (surface) and intracellular expression of apoE and CETP was 
measured by flow cytometry during MCSF differentiation on days 4, 6 and 7 as well as after 
E-LDL loading on day 6 and after HDL3 deloading on day 7. Three different experiments 
were performed and the means of mean fluorescence intensities of incubation with ALLN and 
the solvent DMSO were calculated in % change of MCSF, E-LDL, HDL3 respectively as a 
control and results were shown for apoE in Fig.48 and for CETP in Fig.49.  
Figure 47B: Binding of Dil-E-LDL (black columns) 
and Dil-E-LDL/Ab42 (white columns) to monocyte 
subpopulations as determined by flow cytometry. 
Figure 47A: Binding of Dil-LDL (black columns)  
and Dil-LDL/Ab42 (white columns) to monocyte 
subpopulations as determined by flow cytometry. 
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4.1. Extracellular (surface) and intracellular expression of apoE 
During all states of incubation ALLN treated cells had a higher surface expression of apoE 
compared to DMSO as a control. On days 4, 6 and 7 of MCSF differentiation surface 
expression of apoE was induced during incubation of ALLN compared to DMSO. During E-
LDL loading and HDL3 deloading apoE surface expression of cells treated with ALLN was 
reduced compared to MCSF differentiation. The difference between ALLN treatment and 
DMSO was greater during HDL3 deloading than during E-LDL loading (Fig.48A).  
ApoE intracellular expression of ALLN treated cells on day 4 of differentiation was stronger 
reduced than the expression of DMSO treated cells compared to MCSF. On day 6 of MCSF 
differentiation and on day 6 of E-LDL loading apoE intracellular expression was increased 
with ALLN treatment compared to DMSO treated cells (Fig.48B). On day 7 of differentiation 
almost no difference could be observed between ALLN and DMSO treated macrophages 
while during HDL3 deloading apoE intracellular expression was stronger increased with ALLN 
treatment than with DMSO (Fig.48B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48: Extracellular (surface) expression 
(A) and intracellular expression (B) of apoE 
in % change of control (MCSF, E-LDL, HDL3) 
measured by flow cytometry during 
incubation with the proteasomal inhibitor 
ALLN respectively DMSO as a solvent. 
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4.2. Extracellular (surface) and intracellular expression of CETP 
Surface and intracellular expression of CETP of macrophages treated with the proteasomal 
inhibitor ALLN and DMSO as a solvent was similar to the expression profile obtained with 
apoE. Surface expression of CETP was during all incubation states (day 4, 6 and 7 
differentiation, day 6 E-LDL loading and d7 HDL3 deloading) increased in ALLN compared to 
DMSO treated macrophages. On day 7 of differentiation the strongest increase could be 
observed (Fig.49A). 
Intracellular expression of CETP on the fourth day of differentiation was stronger decreased 
in DMSO treated cells than in cells incubated with ALLN compared to MCSF. On day 6 and 
day 7 of MCSF differentiated and on day 6 of E-LDL loaded cells CETP intracellular 
expression was increased with ALLN treatment compared to DMSO treated cells which 
showed a decrease. During HDL3 deloading cells incubated with DMSO showed a stronger 
decrease than ALLN treated cells compared to MCSF (Fig.49B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49: Extracellular (surface) expression 
(A) and intracellular expression (B) of CETP 
in % change of control (MCSF, E-LDL, HDL3) 
measured by flow cytometry during 
incubation with the proteasomal inhibitor 
ALLN respectively DMSO as a solvent. 
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5. Analysis of MCSF differentiated, E-LDL and Ox-LDL loaded and HDL3 deloaded 
human monocyte derived macrophages of the ApoE3/3 vs. the ApoE4/4 genotype 
 
5.1. Analysis of the cellular lipid content with mass spectrometry 
ESI-mass spectrometry was used to analyze cellular content of total, esterified and 
unesterified cholesterol (Fig.50); sphingomyelin (SM), ceramide (Cer) and sphingosine 
(Fig.51); phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylcholine (PC) 
and lysophosphatidylcholine (LPC) (Fig.52). MCSF differentiated, E-LDL and Ox-LDL loaded 
and HDL3 deloaded macrophages of the apoE3/3 and the apoE4/4 genotype were analyzed. 
Four independent experiments of each genotype were performed and the results were 
compared between the apoE3 and the apoE4 genotype.  
 
5.1.1. Analysis of total, esterified and unesterified cholesterol  
The description is focused only on the differences between apoE3/3 and apoE4/4 
macrophages because the results of apopE3/3 macrophages were described in detail earlier 
(s. 3.1.). The amount of total and unesterified cholesterol during Ox-LDL loading and 
deloading was lower in apoE4/4 compared with apoE3/3 macrophages (Fig.50A,B,E,F). 
During E-LDL loading and deloading the content of unesterified cholesterol was decreased in 
apoE4/4 macrophages (Fig.50A,B,E,F). The content of esterified cholesterol was the same in 
apoE3/3 and apoE4/4 macrophages during all incubation states (Fig.50C,D).  
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Figure 50: Cellular content of total cholesterol (A,B), esterified cholesterol (C,D) and unesterifed 
cholesterol (E,F) of apoE3/3 (left column) vs. apoE4/4 (right column) homozygous macrophages 
analyzed by mass spectrometry 
 
 
 
5.1.2. Analysis of sphingomyelin (SM), ceramide (Cer) and sphingosine (Sph)  
The description is focused only on the differences between apoE3/3 and apoE4/4 
macrophages because the results of apoE3/3 macrophages were described in detail earlier 
(s. 3.1.). In apoE3/3 macrophages, SM content on day 1 was lower while on day 4 it was 
higher compared to apoE4/4 macrophages. During Ox-LDL loading SM content was stronger 
reduced in apoE4/4 than in apoE3/3 macrophages compared with MCSF differentiation 
(Fig.51A,B). During Ox-LDL deloading with HDL3 an increase of SM content could be 
observed to a higher level in the apoE3 than in the apoE4 genotype (Fig.51A,B). During E-
LDL loading and deloading no differences of SM content could be detected between the two 
genotypes (Fig.51A,B). Cer content during Ox-LDL loading and deloading was lower in the 
apoE4 genotype compared to the apoE3 genotype. No differences could be detected during 
the other incubation states (Fig.51C,D). The amount of Sph was increased during Ox-LDL 
deloading with HDL3 to a higher level in apoE3/3 than in apoE4/4 macrophages (Fig.51E,F). 
The other incubation states showed no differences of Sph content between the apoE3 and 
the apoE4 genotype (Fig.51E,F). The described differences in the cellular SM, Cer and Sph 
content between apoE3/3 and apoE4/4 macrophages failed to be statistically significant. The 
difference in the Cer content between E-LDL and Ox-LDL loading in both genotypes was 
statistically significant with p<0.05 determined by a student´s t-test. The significance is 
indicated by an asterisk. 
The lower amount of SM during Ox-LDL loading in apoE4/4 macrophages compared to 
apoE3/3 macrophages could lead to a lower Cer content which could result in a decreased 
synthesis of glucosylceramide and GSLs. This in turn could result in a decreased surface 
expression of Cer and GSLs during Ox-LDL loading.  
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Figure 51: Cellular content of sphingomyelin (SM) (A,B), ceramide (Cer) (C,D) and sphingosine (E,F) 
of apoE3/3 (left column) vs. apoE4/4 (right column) homozygous macrophages analyzed by mass 
spectrometry 
 
5.1.3. Analysis of phosphatidylethanolamine (PE), phosphatidylserine (PS),  
          phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) 
ApoE4/4 macrophages had a higher PE content on day 1 compared with apoE3/3 
macrophages (Fig.52A,B). PE content was increased during MCSF differentiation, decreased 
during E-LDL and Ox-LDL loading compared to MCSF and increased during HDL3 deloading 
compared to lipid loading in both genotypes to the same extent (Fig.52A,B). PS content was 
increased during MCSF differentiation in apoE3/3 macrophages while it was decreased in 
apoE4/4 macrophages from a higher level on day 1 (Fig.52C,D). E-LDL loading increased 
PS content in apoE3/3 macrophages to a higher extent than in apoE4/4 macrophages. Ox-
LDL loading decreased PS content in apoE4/4 macrophages to a higher extent than in 
apoE3/3 macrophages (Fig.52C,D). E-LDL deloading increased PS content in the apoE3 and 
to a higher extent in the apoE4 genotype compared to E-LDL loading. Ox-LDL deloading 
increased PS content to the same level in both genotypes compared to Ox-LDL loading 
(Fig.52C,D). PC content increased during MCSF differentiation in apoE3/3 while it didn’t 
change in apoE4/4 macrophages which had a higher PC content than apoE3/3 macrophages 
(Fig.52E,F). Lipid loading increased PC content compared to MCSF. In the apoE3 genotype 
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PC content was higher during Ox-LDL loading while in the apoE4 genotype PC content was 
higher during E-LDL loading (Fig.52E,F). HDL3 deloading increased PC content of both 
genotypes compared to lipid loading (Fig.52E,F). Altogether in apoE4/4 macrophages the PC 
content was higher during all stages of incubation compared to apoE3/3 macrophages 
(Fig.52E,F). LPC content increased during MCSF differentiation in both genotypes 
(Fig.52G,H). Ox-LDL loading led to an increase of LPC content in apoE3/3 while it didn´t 
change LPC content in apoE4/4 macrophages compared to MCSF (Fig.52G,H). E-LDL 
loading decreased LPC content in both genotypes compared to MCSF (Fig.52G,H). Ox-LDL 
deloading decreased while E-LDL deloading increased LPC content in both genotypes to a 
higher level in apoE3/3 than in apoE4/4 macrophages compared to lipid loading (Fig.52G,H) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52: Cellular content of phosphatidylethanolamine (Ptdeth) (A,B), phosphatidylserine (PS) 
(C,D), phosphatidylcholine (PC) (E,F) and lysophosphatidylcholine (LPC) (G,H) of apoE3/3 (left 
column) vs. apoE4/4 (right column) homozygous macrophages analyzed by mass spectrometry 
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The described differences in the cellular PS, PC and LPC content measured by mass 
spectrometry between the apoE3/3 and apoE4/4 macrophages failed to be statistically 
significant tested by a student´s t-est for independent samples with p<0.05. 
 
5.2. Cell surface expression of sphingo- and glycosphingolipids  
In order to analyze wether there are differences in the surface expression of Cer, the GSLs 
lactosylceramide (LacCer, CDw17), globotriaosylceramide (Gb3Cer, CD77), 
dodecasaccharideceramide (CD65s) and GM1 ganglioside between the apoE3/3 and 
apoE4/4 genotype, macrophages of the two different genotypes were loaded with E-LDL and 
Ox-LDL and deloaded with HDL3 according to the previous experiments and surface 
expression was analyzed by flow cytometry. Four different experiments were performed and 
means and standard deviations of the mean fluorescence intensities were calculated. 
Differences between apoE3/3 and apoE4/4 macrophages that are significant at p<0.05 in a 
student’s t-test for independent samples are indicated by an asterisk. 
During differentiation of apoE3/3 and apoE4/4 macrophages with MCSF, Cer, Gb3Cer, and 
GM1 ganglioside surface expression was increased from day 1 to day 7 (Fig.53A,C,E) while 
LacCer and CD65s surface expression was decreased from day 1 to day 4 and didn’t change 
from day 4 to day 7 (Fig.53B,D). During E-LDL loading Cer, LacCer, CD65s and GM1 
ganglioside surface expression was increased nearly to the same extent in both genotypes 
(Fig.53A,B,D,E) compared to MCSF differentiated cells. Gb3Cer surface expression however 
was increased to a lower extent in apoE3/3 than in apoE4/4 macrophages during E-LDL 
loading compared to MCSF (Fig.53E,F). But during Ox-LDL loading cell surface expression 
of Cer, LacCer and CD65s (Fig.53A,B,D) was only significantly induced in apoE3/3 but not in 
apoE4/4 macrophages compared to MCSF differentiated cells. Also Gb3Cer and GM1 
surface expression was higher induced in apoE3/3 than in apoE4/4 macrophages during Ox-
LDL loading but the differences were not statistically significant (Fig.53E,F,I,J).  
During HDL3 deloading of E-LDL loaded cells no change of Cer and LacCer surface 
expression could be observed between the two genotypes (Fig.53A,B,C,D) while surface 
expression of Gb3Cer, CD65s and GM1 ganglioside was increased in apoE3/3 and 
decreased in apoE4/4 macrophages during HDL3 deloading (Fig.53E,F,G,H,I,J). Ox-LDL 
deloading with HDL3 showed no change of LacCer, Gb3Cer and CD65s surface expression 
between the two genotypes (Fig.53C,D,E,F,G,H). Cer surface expression was increased 
(Fig.53A,B) and GM1 ganglioside surface expression was decreased (Fig.53I,J) in apoE4/4 
macrophages compared with apoE3/3 macrophages during Ox-LDL deloading with HDL3. 
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Figure 53: Surface expression of membrane ceramide, glycosphingolipids and GM1ganglioside 
of ApoE3/3 vs. ApoE4/4 macrophages 
Cell surface expression of ceramide (A,B), lactosylceramide (C,D), globotriaosylceramide (E,F), 
dodecasaccharideceramide (G,H) and GM1 ganglioside (I,J) of apoE3/3 (left column) vs. apoE4/4 
homozygous macrophages (right column) measured by flow-cytometry  
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5.3. Pathway specific analysis of microarray expression data –  
       sphingolipid metabolism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11: Genes involved in glycosphingolipid and lipid metabolism of apoE3/3 and apoE4/4 
macrophages 
 
Pathway specific analysis of genes involved in Cer and sphingolipid metabolism revealed 
some regulatory differences between the apoE3/3 and the apoE4/4 genotype which could 
explain the decreased Cer and GSL expression on the cell surface of apoE4/4 macrophages 
(Fig.53) and the decreased cellular phospatidylserine (PS) and lysophosphatidylcholine 
(LPC) content as well as the increased cellular phosphatidylcholine (PC) content of apoE4/4 
macrophages (Fig.52C-H) during lipid loading. Gene-expression data obtained from 
microarray analysis of E-LDL and Ox-LDL loaded and HDL3 deloaded macrophages of the 
apoE3/3 and the apoE4/4 genotype were compared.  
UDP-glucose ceramide glucosyltransferase (UGCG) which catalyses the formation of 
glucosylceramide (GlcCer) from Cer didn´t change during E-LDL loading in apoE3/3 
macrophages and was 2.1 fold upregulated in apoE4/4 macrophages. During Ox-LDL 
loading UGCG was -1.9 fold downregulated in apoE3/3 macrophages while in apoE4/4 
macrophages it was 2.0 fold upregulated. This shows that GlcCer, the starting substance of 
the GSLs was probably synthesized to a higher extent in apoE4/4 macrophages during E-
LDL and Ox-LDL loading. Therefore the fact that GSLs cannot be detected at the cell surface 
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Sphingomyelinases
Hs.277962 sphingomyelin phosphodiesterase, acid-like 3A SMPDL3A 6q22.31 ++ 594,0 ++ 1,1 ++ -1,5 ++ 1,7 ++ -1,5 ++ 485,0 ++ 2,0 ++ -2,8 ++ 1,7 ++ -1,3
Hs.77813 sphingomyelin phosphodiesterase 1, acid lysosomal (acid sphingomyelinase)SMPD1 11p15.4-p15.1++ 295,0 ++ -1,6 ++ 2,8 ++ 1,1 ++ 1,1 ++ 209,0 ++ -1,1 ++ -1,1 ++ -1,9 ++ 1,5
Hs.372000 neutral sphingomyelinase (N-SMase) activation associated factor NSMAF 8q12-q13 ++ 631,0 ++ 1 ++ 1,2 ++ 1,6 ++ -1,3 ++ 895,0 ++ -1,1 ++ 1,1 ++ 1,7 ++ -1,2
Hs.324808 N-acylsphingosine amidohydrolase (acid ceramidase) 1 ASAH1 8p22-p21.3 ++ 4612,0 ++ 1,0 ++ 1,5 ++ 1,5 ++ -1,1 ++ 5104,0 ++ 1,0 ++ 1,5 ++ 1,1 ++ 1,1
Hs.282997 glucosidase, beta; acid (includes glucosylceramidase) GBA 1q21 ++ 492,0 ++ -1,1 ++ 1,6 ++ 1,5 ++ 1,3 ++ 593,0 ++ 1,0 ++ 1,6 ++ -2,0 ++ 1,2
Hs.408273 galactosylceramidase (Krabbe disease) GALC 14q31 ++ 562,0 ++ -1,1 ++ 1,7 ++ -1,1 ++ 1,7 ++ 988,0 ++ -1,1 ++ 1,1 ++ -2,0 ++ 1,2
Glucosyltransferase
Hs.432605 UDP-glucose ceramide glucosyltransferase UGCG 9q31 ++ 716,0 ++ 1,1 ++ -4,0 ++ -1,9 ++ 3,0 ++ 704,0 ++ 2,1 ++ -1,4 ++ 2,0 ++ -4,9
Galactosyltransferases
Hs.396798 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 B4GALT1 9p13 ++ 216,0 + -2,3 ++ 3,2 ++ 1,7 + -2,0 + 147,0 + 1,0 + -1,1 ++ -1,3 ++ 1,4
Hs.534404 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 4 B3GALT4 6p21.3 ++ 257,0 ++ -3,0 ++ 2,6 ++ -1,2 ++ -1,6 ++ 259,0 ++ -2,0 ++ -1,1 ++ -2,8 ++ 1,9
Acetylglucosaminyltransferases
Hs.173203 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 B3GNT1 2p15 + 105,0 ++ 2,1 + -3,7 + -1,2 ++ 7,0 ++ 111,0 ++ 3,5 ++ -1,7 ++ 1,7 ++ -1,7
Hs.69009 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 B3GNT3 19p13.1 + 145,0 ++ -2,1 ++ 1,5 + -1,4 + 1,2 ++ 78,0 + 1,2 + -2,6 + -2,0 + 2,1
Hs.8526 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 B3GNT6 11q13.2 ++ 184,0 ++ -2,0 ++ 4,6 ++ 1,1 ++ 1,1 ++ 202,0 ++ 1,1 ++ -1,4 ++ -1,7 ++ 1,5
Sialyltransferases
Hs.2554 sialyltransferase 1 (beta-galactoside alpha-2,6-sialyltransferase) SIAT1 3q27-q28 ++ 402,0 ++ -2,3 ++ 2,1 ++ -1,3 ++ 1,0 ++ 258,0 ++ -1,1 ++ -1,2 ++ -1,6 ++ 1,4
Hs.288215 sialyltransferase 7 ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase) BSIAT7B 17q25.1 - 30,0 + 2,3 + 1,6 + 7,0 + -1,1 + 102,0 + 2,0 + -6,5 ++ 1,9 + -1,7
Hs.415117 sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 synthase)SIAT9 2p11.2 ++ 433,0 ++ -1,2 ++ 1,9 ++ -1,4 ++ 2,0 ++ 273,0 ++ 1,6 ++ 1,1 ++ -1,2 ++ 2,8
Hs.440913 sialyltransferase 10 (alpha-2,3-sialyltransferase VI) SIAT10 3q12.1 ++ 134,0 ++ 1,9 ++ -2,3 ++ -1,4 ++ 3,0 ++ 134,0 ++ 2,0 ++ -1,1 ++ 1,5 ++ 1,3
Glycosphingolipid Degradation
Hs.69089 galactosidase, alpha GLA xq22 ++ 1655,0 ++ -1,3 ++ 1,9 ++ 1,5 ++ 1,1 ++ 2082,0 ++ 1,1 ++ -1,6 ++ -1,1 ++ 1,1
Hs.387156 GM2 ganglioside activator GM2A 5q31.3-q33.1++ 6001,0 ++ 1,1 ++ 1,9 ++ 1,5 ++ 1,1 ++ 6053,0 ++ 1,2 ++ -1,1 ++ -1,4 ++ 1,7
Hs.411157 hexosaminidase A (alpha polypeptide) HEXA 15q23-q24 ++ ++ -1,6 ++ 2,0 ++ 1,4 ++ -1,3 ++ ++ 1,0 ++ -2,0 ++ -1,7 ++ 1,4
Hs.69293 hexosaminidase B (beta polypeptide) HEXB 5q13 ++ 3785,0 ++ 1,1 ++ 1,6 ++ 1,7 ++ 1,1 ++ 4770,0 ++ 1,1 ++ -1,1 ++ -1,2 ++ 1,7
Hs.406455 prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)PSAP 10q21-q22 ++ 8013,0 ++ 1,1 ++ 1,9 ++ 1,5 ++ -1,2 ++ 10790,0 ++ -1,1 ++ -1,1 ++ -1,2 ++ 1,1
Phospholipid Metabolism
Hs.24678 sphingosine-1-phosphate phosphatase 1 SGPP1 14q23.2 ++ 43,0 ++ 1,1 + -2,0 ++ 1,0 ++ 4,3 ++ 43,0 ++ 3,2 ++ -1,4 ++ 2,1 ++ -1,4
Hs.77221 choline kinase alpha CHKA 11q13.2 + 76,0 ++ -1,4 ++ 2,5 ++ 1,6 ++ 1,3 + 53,0 + 1,5 + 1,0 ++ 1,1 ++ 1,3
Hs.68061 sphingosine kinase 1 SPHK1 17q25.2 ++ 277,0 ++ -1,9 ++ 1,9 ++ 1,0 ++ -1,2 + 125,0 + 1,6 + -1,4 ++ 1,7 ++ -1,1
Hs.186613 sphingosine-1-phosphate lyase 1 SGPL1 10q21 ++ 809,0 ++ -1,5 ++ 1,5 ++ -1,1 ++ 1,1 ++ 1001,0 ++ -1,4 ++ -1,1 ++ -3,0 ++ 2,1
Hs.77329 phosphatidylserine synthase 1 PTDSS1 8q22 ++ 1462,0 ++ -1,3 ++ 2,3 ++ 1,5 ++ -1,1 ++ 1267,0 ++ 1,0 ++ 1,1 ++ -1,1 ++ 2,1
Hs.12851 phosphatidylserine synthase 2 PTDSS2 11p15 + 68,0 + -1,1 + 2,3 + 1,9 + -1,9 + 67,0 - -3,2 - -1,3 + -2,0 + 2,1
Hs.15192 phosphatidylethanolamine N-methyltransferase PEMT 17p11.2 + 74,0 + -1,1 + 2,1 ++ 1,5 + 1,2 + 27,0 + 2,5 + -1,1 + 2,3 ++ 1,4
Hs.120439 ethanolamine kinase 1 ETNK1 12p12.1 ++ 156,0 ++ 1,1 ++ 1,2 ++ 1,0 ++ 2,3 ++ 199,0 ++ 1,4 ++ 1,7 ++ 2,3 ++ 1,1
Hs.18858 phospholipase A2, group IVC (cytosolic, calcium-independent) PLA2G4C 19q13.3 ++ 357,0 + -1,7 + 3,0 ++ 2,0 ++ -1,7 + 366,0 + 1,1 + -1,2 + -1,7 + 2,0
Hs.93304 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) PLA2G7 6p21.2-p12 ++ 1977,0 ++ 1,9 ++ -1,1 ++ 2,8 ++ 1,1 ++ 3121,0 ++ 1,1 ++ 1,1 ++ -1,1 ++ 2,0
Hs.127958 1-acylglycerol-3-phosphate O-acyltransferase 4 (lysophosphatidic acid acyltransferase, delta)AGPAT4 6q26 + 113,0 + -1,5 + 2,5 ++ 2,1 + -1,1 + 66,0 + 1,5 + -2,5 + 1,3 ++ 1,4
Hs.77221 choline kinase alpha CHKA 11q13.2 + 76,0 ++ -1,4 ++ 2,5 ++ 1,6 ++ 1,3 + 53,0 + 1,5 + 1,0 ++ 1,1 ++ 1,3
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of apoE4/4 macrophages during Ox-LDL loading seems to be due to a defect in transporting 
the GSLs from the Golgi to the cell surface. 
Enzymes involved in GSL degradation like galactosidase alpha, GM2 ganglioside activator, 
hexosaminidase B and prosaposin were downregulated during Ox-LDL loading in apoE4/4 
macrophages but upregulated in apoE3/3 macrophages. This could be due to a lower level of 
GSLs on the cell surface of apoE4/4 macrophages which should not be further reduced by 
degradation. During E-LDL deloading also an inverse regulation of GSL-degradation-
enzymes could be observed. While the enzymes were increased in apoE3/3 macrophages 
they were decreased in apoE4/4 macrophages. 
Glycolipid transfer protein which transports glucosylceramide was inversely regulated during 
HDL3 deload between apoE3/3 and apoE4/4 macrophages. In apoE3/3 macrophages it was -
3.0 fold downregulated during E-LDL deloading and 2.6 fold upregulated during Ox-LDL 
deloading while in apoE4/4 macrophages it was 2.0 fold upregulated during E-LDL deloading 
and -5.7 fold downregulated during Ox-LDL deloading. 
From the genes involved in phospholipid metabolism, the phosphatidylserine synthases 1 
and 2 (PTDSS1 and 2) which are involved in phosphatidylserine (PS) synthesis from 
phosphatidylcholine (PC) and phospatidylethanolamine (PE) respectively were differentially 
regulated between apoE3/3 and apoE4/4 macrophages. During E-LDL loading PTDSS1 was 
-1.3 fold downregulated in apoE3/3 and 1.0 fold regulated in apoE4/4 macrophages and 
PTDSS2 was -1.1 fold downregulated in apoE3/3 and significantly -3.2 fold downregulated in 
apoE4/4 macrophages. During Ox-LDL loading PTDSS1 was 1.5 fold and PTDSS2 1.9 fold 
upregulated in apoE3/3 macrophages while in apoE4/4 macrophages PTDSS1 was -1.1 fold 
and PTDSS2 -2.0 fold downregulated. It is concluded that the significant downregulations of 
PTDSS1 and 2 during lipid loading in the apoE4/4 but not in the apoE3/3 genotype could 
lead to a lower synthesis of PS and could explain the decreased amount of cellular PS in 
apoE4/4 macrophages during lipid loading as detected with mass spectrometry (Fig.52C,D). 
Phosphatidylethanolamine N-methyltransferase (PEMT) which forms PC from PE was -1.1 
fold downregulated during E-LDL loading in apoE3/3 and 2.5 fold upregulated in apoE4/4 
macrophages. During Ox-LDL loading PEMT was 1.5 fold upregulated in apoE3/3 and 2.3 
fold upregulated in apoE4/4 macrophages. The greater upregulation of PEMT during lipid 
loading in apoE4/4 compared to apoE3/3 macrophages could explain the increased cellular 
amount of PC in apoE4/4 macrophages found with mass spectrometry (Fig.52E,F). 
Phospholipases A2, group IVC and VII and lysophospholipid acyltransferase involved in LPC 
processing were significantly upregulated during Ox-LDL loading in apoE3/3 macrophages 
but not significantly regulated in apoE4/4 macrophages which may explain the decreased 
cellular LPC content in apoE4/4 compared with apoE3/3 macrophages (Fig.52G,H). 
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5.4. Taqman analysis of enzymes involved in Cer generation and degradation  
To verify the gene array data and to get informations about the regulation of further enzymes 
involved in Cer generation and degradation, Taqman realtime PCR was performed. ApoE3/3 
and apoE4/4 macrophages during E-LDL and Ox-LDL loading and HDL3 deloading were 
used and enzymes involved in sphingolipid metabolism were analyzed. In the following 
results fold changes are related to the non differentiated state of the monocytes. 
Serine palmitoyltransferase 1 and 2, which were not present on the chip were decreased 
during differentiation in both genotypes (Fig.54A,B). During lipid loading both serine 
palmitoyltransferases were stronger upregulated in apoE4/4 than in apoE3/3 macrophages. 
In apoE3/3 macrophages serine palmitoyltransferase 1 was 1.7 fold increased during E-LDL 
and 2.1 fold during Ox-LDL loading (Fig.54A) while in apoE4/4 macrophages serine 
palmitoyltransferase 1 was 4.7 fold increased during E-LDL and 3.8 fold increased during 
Ox-LDL loading (Fig.54B). Serine palmitoyltransferase 2 was 1.3 fold upregulated during E-
LDL and 1.5 fold upregulated during Ox-LDL loading in apoE3/3 macrophages (Fig.54C) 
while in apoE4/4 macrophages serine palmitoyltransferase 2 was 2.4 fold upregulated during 
E-LDL and 4.3 fold during Ox-LDL loading (Fig.54D). Sphingomyelin synthase 1 and 2 
(SMS1 and 2) were decreased during differentiation in both genotypes (Fig.54E,F). During 
lipid loading SMS1 and 2 were stronger upregulated in apoE4/4 than in apoE3/3 
macrophages. ApoE3/3 macrophages showed a 1.5 fold upregulation of SMS1 during E-LDL 
and a 1.3 fold upregulation during Ox-LDL loading (Fig.54E) and SMS2 was 1.6 fold 
upregulated during E-LDL and Ox-LDL loading (Fig.54G). Whereas in apoE4/4 macrophages 
SMS1 was 4.6 fold upregulated during E-LDL and 1.6 fold during Ox-LDL loading (Fig.54F) 
and SMS2 increased up to 5.9 fold during E-LDL loading and 3.8 fold during Ox-LDL loading 
(Fig.54H). Acid Sphingomyelinase (acidSMase) showed only a significant regulation in 
apoE3/3 macrophages (Fig.54I). It was induced during differentiation up to 2.8 fold. E-LDL 
loading led to a -1.7 fold decrease while Ox-LDL loading led to a 3.1 fold increase (Fig.54I). 
In apoE4/4 macrophages during differentiation a 1.4 fold increase of acid SMase could be 
observed with no further changes during lipid loading (Fig.54J). The increase during Ox-LDL 
loading in apoE3/3 macrophages of acid SMase which degrade SM to Cer could lead to an 
increased Cer formation in apoE3/3 but not in apoE4/4 macrophages. Neutral SMase was 
regulated similarly in both genotypes (Fig.54K,L). It was decreased during differentiation and 
increased during lipid loading. During E-LDL loading the upregulation was lower than during 
Ox-LDL loading with 2.6 fold in the apoE3 and 3.9 fold in the apoE4 genotype while with Ox-
LDL loading it was 5.2 fold in the apoE3 and 4.7 fold in the apoE4 genotype (Fig.54K,L). 
Neutral SMase activation associated factor (NSMAF) was decreased during differentiation 
in both genotypes (Fig.54M,N). During lipid loading it was stronger induced in apoE4/4 
compared with apoE3/3 macrophages. E-LDL loading of apoE3/3 macrophages showed a 
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1.3 fold upregulation of NSMAF while in apoE4/4 macrophages were 7.2 fold upregulated 
(Fig.54M,N). Ox-LDL loading led to a 2.3 fold upregulation of NSMAF in apoE3/3 and to a 11 
fold upregulation in apoE4/4 macrophages (Fig.54M,N). Acid ceramidase was increased 
during differentiation in apoE3/3 macrophages while it was slightly decreased in apoE4/4 
macrophages (Fig.54O,P). During lipid loading acid ceramidase was 1 fold decreased in the 
apoE3 genotype compared to MCSF while it was 11.8 fold increased in the apoE4 genotype 
during E-LDL loading and 7.9 fold during Ox-LDL loading (Fig.54O,P). The increase of acid 
ceramidase during lipid loading in the apoE4 genotype could enhance ceramide degradation 
leading to a lower level of Cer with decreased generation of GSLs. Glucosylceramidase 
was not regulated during differentiation in both genotypes (Fig.54Q,R). During E-LDL loading 
it was 1.8 fold upregulated in apoE3 and 1.3 fold in apoE4 macrophages. During Ox-LDL 
loading it was 3.6 fold upregulated in apoE3/3 macrophages while in apoE4/4 macrophages 
it was only 1.6 fold upregulated (Fig.54Q,R). This could lead to a stronger increase of GlcCer 
during Ox-LDL loading in apoE4/4 than in apoE3/3 macrophages. This could allow the 
conclusion that there may be a defect in the traffic of Cer and GSLs from the Golgi to the cell 
surface as a reason for the lower Cer and GSL surface expression in the apoE4 genotype. 
UDP-glucose ceramide glucosyltransferase was not regulated during differentiation but 
during E-LDL and Ox-LDL loading the upregulation was higher in apoE4/4 than in apoE3/3 
macrophages (Fig.54S,T). E-LDL loading led in apoE3/3 macrophages to a 2.1 fold 
upregulation while in apoE4/4 macrophages a 13 fold upregulation could be observed. Ox-
LDL loading of apoE3/3 macrophages led to a 3.2 fold upregulation while Ox-LDL loading of 
apoE4/4 macrophages led to 15.2 upregulation of UDP-glucose ceramide 
glucosyltransferase (Fig.54S,T). Upregulation of UDP-glucose ceramide glucosyltransferase 
which transfers Cer to GlcCer could lead to an increased degradation of Cer with an increase 
of GlcCer in apoE4/4 macrophages. These data could also lead to the conclusion that there 
may be a defect in the traffic of Cer and GSLs from the Golgi to the cell surface.  
With HDL3 deloading of E-LDL loaded cells of the apoE3/3 genotype almost no change 
could be observed of serine palmitoyltransferase 1 and 2 mRNA expression (Fig.54A,C). 
While in the apoE4/4 genotype the mRNA expression of serine palmitoyltransferase 1 and 2 
was decreased from 4.7 and 4.3 fold respectively up to 1.3 fold (Fig.54B,D). Deloading of 
Ox-LDL loaded cells led in the case of apoE3/3 macrophages to a decrease from 2.1 to 1 
fold of serine palmitoyltransferase 1 while no change of serine palmitoyltransferase 2 mRNA 
expression could be observed (Fig.54A,C). In the case of apoE4/4 macrophages during Ox-
LDL deloading an increase from 4.7 fold to 5.4 fold of serine palmitoyltransferase 1 (Fig.54B) 
and an increase from 2.4 fold to 7 fold of serine palmioyltransferase 2 (Fig.54D) could be 
detected. SMS1 was upregulated in apoE3/3 macrophages during E-LDL deloading from 1.1 
fold to a 2.1 fold while there was no change of SMS2 mRNA expression (Fig.54E,G). In 
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apoE4/4 macrophages during E-LDL deloading a decrease of mRNA expression of SMS1 
from 4.6 fold to 1.2 fold and in the case of SMS2 from 5.9 fold to 1.7 fold could be observed 
(Fig.54F,H). During Ox-LDL deloading SMS1 was upregulated from 1.1 fold to 1.7 fold and 
SMS2 was decreased from 1.6 fold to 1.2 fold in apoE3/3 macrophages (Fig.54E,G). While in 
the apoE4 genotype an upregulation from 1.6 fold to 3.5 fold of SMS1 and a decrease from 
3.8 fold to 3 fold of SMS2 could be observed during Ox-LDL deloading (Fig.54F,H). The 
mRNA expression of acid SMase was decreased in the apoE3 genotype from 1.7 fold to 1 
fold during E-LDL deloading (Fig.54I) while in the apoE4 genotype acid SMase was slightly 
increased during E-LDL deloading from 1.5 fold to 1.8 fold (Fig.54J). During Ox-LDL 
deloading a decrease of acid SMase from 3.1 fold to 0.4 fold could be observed in apoE3/3 
(Fig.54I) and from 1.5 fold to 0.9 fold in apoE4/4 macrophages (Fig.54J). With HDL3 
deloading the mRNA expression of neutral SMase was decreased in both genotypes. In the 
apoE3 genotype during E-LDL deloading from 2.6 fold to 0.9 fold (Fig.54K) and in the apoE4 
genotype from 3.9 to 1 fold (Fig.54L). During Ox-LDL deloading a decrease from 5.2 fold to 
0.3 fold took place in the apoE3 (Fig.54K) and from 4.7 fold to 1.3 fold in the apoE4 genotype 
(Fig.54L). NSMAF decreased during Ox-LDL deloading with HDL3 from a higher level in 
apoE4/4 macrophages (Fig.54M,N). During E-LDL deloading almost no change could be 
observed in the apoE3 genotype while NSMAF was downregulated in the
apoE4 genotype (Fig.54M,N). Acid ceramidase was decreased during HDL3 deloading from 
a higher level in apoE4/4 than in apoE3/3 macrophages (Fig.54O,P). The upregulation of 
glucosylceramidase in apoE3/3 macrophages was reversed with HDL3 deloading (Fig. 
54Q,R). During E-LDL deloading from 1.8 fold to 1.1 fold and during Ox-LDL deloading from 
3.6 to 0.4 fold (Fig.54Q) while in apoE4/4 macrophages almost no change of 
glucosylceramidase mRNA expression could be detected during E-LDL and Ox-LDL 
deloading (Fig.54R). UDP-glucose ceramide glucosyltransferase was decreased during 
HDL3 deloading. In apoE3/3 macrophages during E-LDL deloading from 3.2 fold to 0.8 fold 
and during Ox-LDL deloading from 2.1 fold to 0.7 fold (Fig.54S). In apoE4 macrophages 
UDP-glucose ceramide glucosyltransferase was decreased from a higher level during HDL3 
deloading. During E-LDL deloading it was decreased from 15.2 fold and during Ox-LDL 
deloading from 13 fold up to 1.1 fold (Fig.54T). 
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Figure 54: Taqman analysis of enzymes involved in sphingolipid metabolism  
Macrophages of apoE3/3 (left column) and apoE4/4 (right column) genotype; serine 
palmitoyltransferase 1 (A,B), serine palmitoyltransferase 2 (C,D), sphingomyelin syntase 1 (E,F), 
sphingomyelin synthase 2 (G,H), acid sphingomyelinase (I,J), neutral sphingomyelinase (K,L), neutral 
sphingomyelinase activation associated factor (M,N), acid ceramidase (O,P), glucosylceramidase 
(Q,R), UDP-glucose ceramide glucosyltransferase (R,T) 
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5.5. Analysis of proteins involved in cholesterol metabolism 
 
5.5.1. Analysis of mRNA expression of apoE and apoC-I  
The mRNA expression of apoE and apoC-I obtained by microarray data analysis was 
increased during differentiation to a higher extent in apoE3/3 than in apoE4/4 macrophages.  
ApoE mRNA expression of apoE3/3 macrophages was at all incubation states, except of E-
LDL loading, higher than apoE mRNA expression of apoE4/4 macrophages (Fig.55A).  
ApoC-I mRNA expression pattern was similar to that of apoE. ApoC-I mRNA expression of 
apoE3/3 macrophages was at all incubation states higher than apoC-I mRNA expression of 
apoE4/4 macrophages. The highest mRNA expression of apoC-I was observed in apoE3/3 
macrophages during E-LDL deloading and Ox-LDL loading (Fig.55B). 
 
 
 
 
 
 
 
 
 
 
5.5.2. Analysis of secreted apoE and apoC-I  
In a next step, the amount of secreted apoE and apoC-I in the culture media was analyzed. 
Therefore culture media of 6 day differentiated and of E-LDL respectively Ox-LDL loaded 
macrophages (day 4 to day 6) of the apoE3/3 and the apoE4/4 genotype were collected and 
the amounts of apoE and apoC-I were determined by ELISA. Because serum-free culture 
medium without apoE and apoC-I was used in these experiments, the measured apoE 
respectively apoC-I concentrations correlate directly with the apoE and apoC-I secretion of 
the cells.  
In both genotypes it could be observed that the amount of secreted apoE was decreased 
during E-LDL and was further decreased during Ox-LDL loading compared with MCSF 
differentiated macrophages (Fig.56A). ApoE3/3 macrophages secreted more apoE than 
apoE4/4 macrophages during all incubation states (Fig.56A).  
ApoC-I was increased in both genotypes to a higher extent during E-LDL than during Ox-LDL 
loading compared with MCSF differentiated macrophages (Fig.56B). The amount of secreted 
apoC-I of the different genotypes was almost the same during MCSF differentiation while it 
was higher in apoE3/3 than in apoE4/4 macrophages during E-LDL and Ox-LDL loading 
(Fig.56B). 
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Figure 55A: mRNA expression of apoE Figure 55B: mRNA expression of apoC-I  
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 5.5.3. Extracellular (surface) and intracellular expression-analysis of proteins involved 
in cholesterol metabolism 
Flow cytometry was used to analyze the extracellular (surface) and intracellular expression of 
apoE, apoC-I and CETP. ApoE3/3 and apoE4/4 macrophages were analyzed during MCSF 
differentiation (day 1-7), E-LDL and Ox-LDL loading (48h, day 4-6) and HDL3 deloading (24h, 
day 6-7). Six different experiments were performed and means and standard deviations of 
the mean fluorescence intensities were calculated.  
 
5.5.3.1. ApoE 
During MCSF differentiation of apoE3/3 macrophages apoE surface expression was 
increased from day 1 to day 4, didn’t change from day 4 to day 6 and was further increased 
from day 6 to day 7 (Fig.57A). In the apoE4 genotype apoE surface expression during MCSF 
differentiation increased from day 1 to day 6 and showed almost no change from day 6 to 
day 7 (Fig.57B). During lipid loading apoE surface expression was increased compared to 
MCSF in both genotypes. In the apoE3 genotype the increase was stronger during E-LDL 
loading than during Ox-LDL loading while in the apoE4 genotype a stronger increase could 
be observed during Ox-LDL than during E-LDL loading (Fig.57A,B). HDL3 deloading of 
apoE3/3 macrophages decreased apoE surface expression compared to lipid loading 
(Fig.57A). ApoE4/4 macrophages showed also a decrease of apoE surface expression 
during Ox-LDL deloading while there was no change during E-LDL deloading compared to 
Ox-LDL and E-LDL loading (Fig.57B). 
The intracellular expression of apoE during MCSF differentiation was increased in both 
genotypes from day 1 to day 6 and was decreased from day 6 to day 7 (Fig.57C,D). During 
Ox-LDL loading apoE intracellular expression decreased compared to MCSF in both 
genotypes to the same extent while during E-LDL loading a slight increase in the apoE3 
genotype and a slight decrease in the apoE4 genotype could be detected (Fig.57C,D). HDL3 
deloading led to a decrease of apoE intracellular expression in apoE3/3 macrophages 
compared to lipid loading while in apoE4/4 macrophages during E-LDL deloading a decrease 
Figure 56A: amount of secreted apoE  
                    determined by ELISA  
Figure 56B: amount of secreted apoC-I 
                    determined by ELISA 
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and during Ox-LDL deloading an increase could be observed compared to E-LDL and Ox-
LDL loading (Fig.57C,D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57: ApoE expression extracellular (Fig.51A,B) and intracellular (Fig.51C,D) of apoE3/3 (left 
column) and apoE4/4 (right column) homozygous macrophages. 
 
5.5.3.2. ApoC-I 
During differentiation apoC-I surface expression was similar regulated in both genotypes with 
almost no change from day 1 to day 6 and an increase from day 6 to day 7 (Fig.58A,B). 
During lipid loading apoC-I surface expression increased compared to MCSF in both 
genotypes to a higher extent during Ox-LDL than during E-LDL loading (Fig.58A,B). E-LDL 
deloading of the apoE3 genotype increased apoC-I surface expression compared to E-LDL 
loading while during Ox-LDL deloading apoC-I surface expression didn’t change compared to 
Ox-LDL loading (Fig.58A). In the apoE4 genotype E-LDL deloading decreased while Ox-LDL 
deloading increased apoC-I surface expression compared to lipid loading (Fig.58B). 
The intracellular expression of apoC-I was higher in apoE4/4 than in apoE3/3 macrophages 
during all incubation states. During differentiation apoC-I was upregulated from day 1 to day 
4 to a higher level in apoE4/4 than in apoE3/3 macrophages and showed almost no further 
change from day 4 to day 7 in both genotypes (Fig.58C,D). During lipid loading an 
upregulation of apoC-I could be observed which was higher during Ox-LDL than during E-
LDL loading in both genotypes (Fig.58C,D).   
During HDL3 deloading almost no change of intracellular apoC-I expression could be 
observed in apoE3/3 macrophages compared to lipid loading (Fig.58C). In apoE4/4 
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macrophages intracellular apoC-I expression was increased during E-LDL deloading and 
didn’t change during Ox-LDL deloading compared to E-LDL and Ox-LDL loading (Fig.58D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58: ApoC-I expression extracellular (Fig.52A,B) and intracellular (Fig.52C,D) of apoE3/3 (left 
column) and apoE4/4 (right column) homozygous macrophages. 
 
5.5.3.3. CETP 
Surface expression of CETP was increased during MCSF differentiation from day 1 to day 6 
in both genotypes while from day 6 to day 7 it was increased in apoE3/3 macrophages and 
didn’t change in apoE4/4 macrophages (Fig.59A,B). During E-LDL loading CETP surface 
expression was increased in the apoE3 genotype while it was slightly decreased in the 
apoE4 genotype compared to MCSF. Ox-LDL loading led to a decrease of CETP in both 
genotypes compared to MCSF (Fig.59A,B). During E-LDL deloading with HDL3 both 
genotypes showed a small increase of CETP surface expression. During Ox-LDL deloading 
apoE3/3 macrophages showed a decrease and apoE4/4 macrophages an increase of CETP 
surface expression compared to lipid loading (Fig.59A,B). 
Intracellular expression of CETP was increased during MCSF differentiation from day 1 to 
day 6 to a higher level in apoE4/4 than in apoE3/3 macrophages (Fig.59C,D). From day 6 to 
day 7 of differentiation apoE3/3 macrophages showed almost no change of CETP 
intracellular expression while in apoE4/4 macrophages a decrease could be observed 
(Fig.59C,D). Lipid loading led in both genotypes to a decrease of intracellular CETP 
expression compared to MCSF with a stronger decrease during Ox-LDL loading than during 
E-LDL loading (Fig.59C,D) compared to MCSF. HDL3 deloading led to almost no changes in 
CETP intracellular expression of the apoE3 genotype while in the apoE4 genotype a 
decrease could be observed compared to lipid loading (Fig.59C,D). 
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Figure 59: CETP expression extracellular (Fig.53A,B) and intracellular (Fig.53C,D) of apoE3/3 (left 
column) and apoE4/4 (right column) homozygous macrophages 
 
 
5.6. Intracellular expression-analysis of adipophilin 
Intracellular expression of adipophilin, a protein associated with intracellular lipid storage 
droplets and further a marker for lipid loading was analyzed on fixed and permeabilized cells 
during MCSF differentiation (day 1-7), E-LDL and Ox-LDL loading (day 4-6) and HDL3 
deloading (day 6-7). 
During MCSF differentiation from day 1 to day 4 adipophilin expression didn’t change while 
from day 4 to day 7 the expression increased in both genotypes. During E-LDL loading an 
increase of adipophilin expression could be observed which was stronger in apoE3/3 than in 
apoE4/4 macrophages. Ox-LDL loading showed almost no change of adipophilin expression 
in the apoE3 genotype and a small increase in the apoE4 genotype. During E-LDL deloading 
with HDL3 adipophilin expression decreased while during Ox-LDL deloading with HDL3 
adipophilin expression increased in both genotypes compared to lipid loading (Fig.60A,B). 
 
 
 
 
 
 
 
 
 
 
Figure 60: Intracellular expression analysis of adipophilin of apoE3/3 (A) and apoE4/4 macrophages 
(B)  
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5.7. Gene expression analysis of receptors involved in lipid uptake and processing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12: Genes involved in regulation of membrane receptors 
 
The LDL receptor was downregulated during E-LDL and Ox-LDL loading and upregulated 
during HDL3 deloading in both genotypes. The low density lipoprotein-related protein (LRP) 
1, 6 and 8 as well as the sortilin-related receptor, L (SORL1) and the very low density 
lipoprotein receptor (VLDLR) were downregulated during E-LDL loading in apoE3/3 
macrophages but upregulated in apoE4/4 macrophages. Also E-LDL deloading with HDL3 led 
to an inverse regulation of these receptors except of LRP8 but including the LDL receptor 
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0 LDL Receptor and Related Proteins
Hs.213289 Low density lipoprotein receptor (familial hypercholesterolemia)LDLR 19p13.3 ++ 491,0 + -8,6 ++ 3,2 ++ -4,0 ++ 1,4 ++ 639,0 ++ -6,1 ++ 2,1 ++ -7,5 ++ 1,5
Hs.162757 Low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)LRP1 12q13-q14 ++ 417,0 ++ -1,5 ++ 2,6 ++ -1,2 ++ 1,3 ++ 382,0 ++ 1,4 ++ -2,0 ++ -1,9 ++ 1,9
Hs.75140 low density lipoprotein receptor-related protein associated protein 1LRPAP1 4p16.3 ++ 1785,0 ++ -1,4 ++ 2,5 ++ 2,0 ++ -1,2 ++ 1520,0 ++ -1,1 ++ -1,5 ++ -2,0 ++ 2,1
Hs.210343 Low density lipoprotein receptor-related protein 6 LRP6 12p11-p13 ++ 92,0 + -3,0 + 2,6 ++ -1,1 + -1,2 + 11,0 + 4,6 + -1,4 + 3,5 + -1,1
Hs.410784 Low density lipoprotein receptor-related protein 8, apolipoprotein e receptorLRP8 1p34 ++ 86,0 + -2,0 ++ 1,7 ++ -1,2 ++ 1,9 + 53,0 + 1,1 ++ 1,7 ++ 1,1 ++ 1,1
Hs.438159 Sortilin-related receptor, L(DLR class) A repeats-containing SORL1 11q23.2-q24.2 ++ 618,0 ++ -6,5 ++ 3,7 ++ -4,0 ++ -1,1 ++ 213,0 ++ 1,2 ++ -1,9 ++ -2,3 ++ 1,5
Hs.445299 Oxidised low density lipoprotein (lectin-like) receptor 1 OLR1 12p13.2-p12.3 ++ 79,0 ++ 1,0 ++ 1,0 ++ -2,1 ++ 1,6 ++ 35,0 ++ 2,1 ++ -1,1 ++ -1,3 ++ 1,2
Hs.370422 very low density lipoprotein receptor VLDLR 9p24 ++ 78,0 ++ -1,6 + 1,4 ++ 1,0 ++ 1,0 ++ 39,0 ++ 1,9 ++ -1,9 ++ 3,0 ++ -1,6
Hs.1239 alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150)ANPEP 15q25-q26 ++ 705,0 ++ -2,3 ++ 2,3 ++ -1,1 ++ 1,0 ++ 672,0 ++ -1,1 ++ -1,4 ++ -7,5 ++ 2,0
0 LPS-/Toll-like Receptors
Hs.519624 CD14 antigen CD14 5q31.1 ++ 6150,0 ++ -3,5 ++ 3,5 ++ -2,8 ++ 1,1 ++ 5168,0 ++ -1,9 ++ -1,7 ++ -7,0 ++ 2,6
Hs.111805 toll-like receptor 1 TLR1 4p14 ++ 132,0 ++ 1,0 ++ 1,1 ++ -1,2 ++ 1,5 ++ 151,0 ++ 1,1 ++ -1,1 ++ 1,1 ++ 1,1
Hs.519033 toll-like receptor 2 TLR2 4q32 ++ 663,0 ++ -1,3 ++ 1,1 ++ -2,0 ++ 1,3 ++ 613,0 ++ -1,5 ++ -1,4 ++ -3,7 ++ 2,6
Hs.174312 toll-like receptor 4 TLR4 9q32-q33 ++ 128,0 ++ -1,1 ++ -1,2 ++ -1,4 ++ 4,0 ++ 92,0 ++ 2,3 ++ -1,6 ++ 1,0 ++ -1,5
Hs.114408 toll-like receptor 5 TLR5 1q41-q42 ++ 383,0 ++ -1,7 ++ 1,7 ++ -1,7 ++ 1,6 ++ 433,0 ++ -1,3 ++ -1,1 ++ -2,0 ++ -1,2
Hs.179152 toll-like receptor 7 TLR7 xp22.3 ++ 236,0 ++ -1,7 ++ 2,3 ++ -3,0 ++ 1,2 ++ 350,0 ++ -1,2 ++ -1,2 + -18,4 ++ 5,3
Hs.272410 toll-like receptor 8 TLR8 xp22 - 7,0 + 4,0 + -3,7 + -1,4 + 6,1 + 59,0 ++ 1,9 + -2,0 + -2,3 - -2,5
0 Fcg-Receptors
Hs.534325 Fc fragment of IgG, high affinity Ia, receptor for (CD64) FCGR1A 1q21.2-q21.3 ++ 972,0 ++ -1,3 ++ 1,0 ++ -3,7 ++ 4,0 ++ 1220,0 ++ 1,1 ++ -1,7 ++ -6,5 ++ 3,7
Hs.352642 Fc fragment of IgG, low affinity IIa, receptor for (CD32) FCGR2A 1q23 ++ 958,0 ++ -1,5 ++ 1,5 ++ -2,1 ++ 1,4 ++ 1266,0 ++ -1,1 ++ -1,1 ++ -9,2 ++ 3,2
Hs.372679 Fc fragment of IgG, low affinity IIIa, receptor for (CD16) FCGR3B /FCGR3A1q23 + 114,0 + -2,5 + 1,1 - -10,6 + 13,9 + 123,0 ++ 2,5 ++ -1,4 + -3,0 - -2,1
0 Scavenger Receptor
Hs.443120 CD36 antigen (collagen type I receptor, thrombospondin receptor)CD36 7q11.2 ++ 1088,0 ++ 2,8 ++ 1,1 ++ 2,5 ++ 1,7 ++ 730,0 ++ 3,0 ++ 1,9 ++ 2,5 ++ 2,3
Hs.349656 scavenger receptor class B, member 2 SCARB2 4q21.1 ++ 231,0 ++ 2,0 ++ -2,8 ++ -2,3 ++ 6,1 ++ 185,0 ++ 2,6 ++ 1,6 ++ 2,0 ++ -2,0
Hs.436887 macrophage scavenger receptor 1 MSR1 8p22 ++ 692,0 ++ 2,6 ++ -1,1 ++ 1,9 ++ 1,6 ++ 877,0 ++ 2,6 ++ 1,6 ++ 2,3 ++ 1,0
Hs.74076 CD163 antigen (scavenger receptor cysteine rich) CD163 12p13.3 ++ 3754,0 ++ -1,7 ++ 2,1 ++ -2,8 ++ 2,1 ++ 5881,0 ++ -2,1 ++ 1,2 ++ -7,0 ++ 4,9
0 Integrins/Complement Receptors
Hs.172631 integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide)ITGAM 16p1 .2 ++ 1427,0 ++ -1,1 ++ 1,9 ++ -1,6 ++ 2,3 ++ 1405,0 ++ 1,2 ++ 1,9 ++ -2,5 ++ 4,3
Hs.408864 decay accelerating factor for complement (CD55, Cromer blood group system)DAF 1q32 ++ 139,0 ++ 1,5 ++ -1,6 ++ 2,3 ++ -1,3 ++ 147,0 ++ 1,5 ++ -2,1 ++ 2,8 ++ -2,3
Hs.446414 CD47 antigen (Rh-related antigen, integrin-associated signal transducer)CD47 3q13.1-q13.2 ++ 1211,0 ++ -1,1 ++ -1,1 ++ -1,1 ++ 1,9 ++ 1685,0 ++ -1,2 ++ 1,2 ++ -1,7 ++ 2,0
0 Signal Regulators of Fc Receptors
Hs.387579 CD9 antigen (p24) CD9 12p13.3 ++ 2653,0 ++ 1,3 ++ 1,1 ++ 1,1 ++ 1,9 ++ 3244,0 ++ 1,5 ++ 1,0 ++ -1,2 ++ 1,6
Hs.287692 CD33 antigen-like 3 CD33L3 18q12.3 ++ 238,0 ++ -1,7 + -2,1 ++ 1,3 ++ 1,3 ++ 196,0 ++ -1,2 ++ 1,6 ++ 3,7 ++ -9,2
Hs.83731 CD33 antigen (gp67) CD33 19q13.3 ++ 134,0 ++ -1,4 ++ 1,7 + 1,5 ++ 1,3 ++ 164,0 + -2,3 + -1,5 + -2,8 ++ 4,0
0 Genes involved in Fc Receptor Signalling
Hs.352554 CDC42 effector protein (Rho GTPase binding) 3 CDC42EP3 2p21 ++ 257,0 ++ 1,2 ++ -1,6 ++ 1,7 ++ 1,6 ++ 292,0 ++ 1,0 ++ -1,1 ++ 2,0 ++ -2,6
Hs.355832 cell division cycle 42 (GTP binding protein, 25kDa) CDC42 1p36.1 ++ 414,0 ++ 1,7 ++ -1,1 ++ 1,0 ++ 2,5 ++ 664,0 ++ 1,5 ++ 1,9 ++ -1,1 ++ -1,7
Hs.372800 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 ARHGEF6 xq26 ++ 375,0 ++ -2,0 ++ 2,6 ++ -1,4 ++ 1,1 ++ 301,0 ++ -1,4 ++ 1,1 ++ -3,7 ++ 3,5
Hs.528296 activated Cdc42-associated kinase 1 ACK1 3q29 ++ 227,0 + -2,6 ++ 2,8 ++ -1,5 + -1,4 ++ 176,0 ++ -1,1 ++ -1,4 + -3,7 ++ 3,2
Hs.185140 phosphoinositide-binding protein PIP3-E PIP3-E 6q25.2 + 33,0 + -1,5 ++ 1,9 + 1,2 + -1,1 + 27,0 + 1,5 + 1,4 + -1,2 + -1,1
Hs.239818 phosphoinositide-3-kinase, catalytic, beta polypeptide PIK3CB 3q22.3 ++ 343,0 ++ -1,1 ++ 2,0 ++ 1,9 ++ -1,5 ++ 364,0 ++ 1,0 ++ -1,1 ++ 1,1 ++ 1,5
Hs.249235 Phosphoinositide-3-kinase, class 2, alpha polypeptide PIK3C2A 11p15.5-p14 ++ 161,0 ++ 1,1 ++ -1,2 ++ 1,1 ++ 2,0 ++ 211,0 ++ 1,2 ++ 1,3 ++ 1,9 ++ -1,2
Hs.306747 phosphoinositide-3-kinase, regulatory subunit 4, p150 PIK3R4 3q21.3 ++ 143,0 ++ -1,2 ++ -1,1 ++ 1,0 ++ 1,7 ++ 147,0 ++ 1,1 ++ 1,1 ++ 1,4 ++ 1,1
Hs.418150 phosphoinositide-3-kinase, class 3 PIK3C3 18q12.3 ++ 199,0 ++ 1,1 ++ 1,4 ++ 1,9 ++ -1,1 ++ 234,0 ++ 1,1 ++ 1,1 ++ 1,2 ++ 1,2
Hs.426967 phosphoinositide-3-kinase, catalytic, delta polypeptide PIK3CD 1p36.2 ++ 948,0 ++ -1,1 ++ 2,1 ++ 1,6 ++ -1,3 ++ 1074,0 ++ -1,3 ++ -1,1 ++ -1,9 ++ 2,0
Hs.85701 phosphoinositide-3-kinase, catalytic, alpha polypeptide PIK3CA 3q26.3 ++ 94,0 ++ -1,1 + -1,7 ++ -1,2 ++ 2,6 ++ 89,0 ++ 1,7 ++ -1,1 ++ 1,1 ++ -1,1
0 Integrins/Complement Receptors
Hs.97199 Complement component 1, q subcomponent, receptor 1 C1QR1 20p11.21 ++ 341,0 ++ -3,5 ++ 2,6 + -2,5 + 1,3 ++ 375,0 ++ -2,5 ++ -1,3 + -6,1 + 1,9
Hs.134012 complement component 1, q subcomponent-like 1 C1QL1 17q21 ++ 147,0 ++ -2,5 ++ 3,0 ++ -1,1 ++ 1,1 ++ 109,0 ++ 1,1 ++ -1,2 ++ -1,1 ++ 1,1
Hs.155935 Complement component 3a receptor 1 C3AR1 12p13.31 ++ 2009,0 ++ 1,1 ++ 1,2 ++ -2,3 ++ 2,3 ++ 3666,0 ++ -1,1 ++ 1,0 ++ -11,3 ++ 8,0
Hs.334019 Complement component (3b/4b) receptor 1, including Knops blood group systemCR1 1q32 ++ 138,0 ++ -1,9 ++ 2,5 ++ -1,2 ++ 1,0 ++ 102,0 ++ -1,1 ++ -1,2 ++ -1,5 ++ 1,2
Hs.389133 Integrin, alpha E (CD103, human mucosal lymphocyte antigen 1)ITGAE 17p13 ++ 738,0 ++ -1,4 ++ 2,1 ++ 1,9 ++ -1,3 ++ 470,0 ++ 1,5 ++ -1,2 ++ 1,6 ++ 1,6
Hs.287797 Integrin, beta 1 (fibronectin receptor, CD29) ITGB1 10p11.2 ++ 1695,0 ++ 1,5 ++ -1,2 ++ 1,5 ++ 1,2 ++ 1678,0 ++ 1,4 ++ 1,3 ++ 1,5 ++ 1,1
Hs.408468 integrin beta 1 binding protein 1 ITGB1BP1 2p25.2 ++ 383,0 ++ 1,6 ++ 1,9 ++ 3,5 ++ -1,2 ++ 343,0 ++ 1,7 ++ -1,2 ++ 1,9 ++ 2,0
Hs.265829 Integrin, alpha 3 (CD49c, alpha 3 subunit of VLA-3 receptor)ITGA3 17q21.33 + 69,0 + 1,1 + 3,2 + 2,1 ++ 1,6 - 13,0 + 9,8 + -1,1 + 8,0 + 1,4
Hs.145140 Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)ITGA4 2q31-q32 ++ 86,0 ++ -2,1 ++ 1,4 + -2,5 ++ 1,6 ++ 46,0 ++ 1,9 ++ -1,3 ++ -1,4 ++ -1,1
Hs.149846 Integrin, beta 5 ITGB5 3q21.2 ++ 537,0 ++ 1,5 ++ 1,9 ++ 1,1 ++ 1,5 ++ 657,0 ++ 1,3 ++ 1,7 ++ -2,5 ++ 4,0
Hs.212296 integrin, alpha 6 ITGA6 2q31.1 ++ 143,0 ++ 1,7 ++ 1,0 ++ 2,1 ++ 1,1 + 30,0 ++ 7,0 ++ -1,3 ++ 1,9 ++ 2,5
Hs.524484 Integrin, alpha 7 ITGA7 12q13 - 16,0 - - - - + 13,0 - - - -
Hs.385521 integrin, alpha X (antigen CD11C (p150), alpha polypeptide) ITGAX 16p11.2 ++ 742,0 ++ -1,6 ++ 3,0 ++ 1,7 ++ -1,6 ++ 300,0 ++ 1,7 + -2,8 ++ -1,4 ++ 4,9
Hs.92033 integrin-linked kinase-associated serine/threonine phosphatase 2CILKAP 2q37.3 ++ 132,0 ++ -1,2 ++ 2,5 ++ 1,4 ++ -1,2 ++ 84,0 ++ 1,0 ++ 1,1 ++ -1,1 ++ 1,4
0 Chemokines
Hs.78913 Chemokine (C-X3-C motif) receptor 1 CX3CR1 3p21.3 ++ 170,0 + -8,6 - -1,4 - -10,6 - -1,1 + 21,0 - -1,4 + 3,0 + -1,7 - 3,5
Hs.159553 Chemokine-like receptor 1 CMKLR1 12q24.1 ++ 164,0 ++ -1,7 ++ 2,3 + -1,7 ++ 1,9 ++ 298,0 + -2,6 ++ -1,2 + -3,7 ++ 2,1
Hs.511794 chemokine (C-C motif) receptor 2 CCR2 3p21 ++ 429,0 + -7,0 + 2,0 + -4,3 + -1,7 + 86,0 + 1,1 + -1,1 + -1,7 + 1,2
Hs.198252 chemokine (C-X-C motif) receptor 3 CXCR3 xq13 + 48,0 + -2,3 + -1,3 + 1,3 + 1,2 + 53,0 + -1,2 ++ 1,6 + -1,2 + -1,9
Hs.421986 chemokine (C-X-C motif) receptor 4 CXCR4 2q21 ++ 877,0 ++ -2,1 ++ -1,1 ++ -1,2 ++ 2,0 ++ 906,0 ++ 1,5 ++ -2,3 ++ 1,1 ++ -2,6
Hs.1652 chemokine (C-C motif) receptor 7 CCR7 17q12-q21.2 + 134,0 - -18,4 + 9,8 + -2,0 + -1,5 + 28,0 + 1,0 - 1,0 + 2,6 + -6,5
Hs.89714 chemokine (C-X-C motif) ligand 5 CXCL5 4q12-q13 ++ 315,0 + -12,1 + 3,0 + -4,0 + -1,4 ++ 318,0 + -4,6 + -1,1 ++ -10,6 ++ 2,0
Hs.164021 chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2)CXCL6 4q21 + 51,0 + -3,5 ++ 3,2 ++ 1,1 ++ -1,3 ++ 22,0 ++ 1,5 ++ -1,3 ++ -1,3 ++ 2,3
Hs.271387 chemokine (C-C motif) ligand 8 CCL8 17q11.2 ++ 275,0 ++ -1,1 ++ 1,0 + -3,2 ++ 2,0 ++ 417,0 ++ -2,0 ++ 1,5 + -10,6 ++ 18,4
Hs.413924 chemokine (C-X-C motif) ligand 10 CXCL10 4q21 + 143,0 + -1,6 + 1,7 + -1,3 ++ 2,0 + 73,0 + 1,6 + 1,1 + -1,1 ++ 5,7
Hs.16530 chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)CCL18 17q11.2 ++ 333,0 ++ -2,5 ++ 3,7 + -2,6 ++ 1,7 ++ 306,0 ++ -2,0 ++ 1,0 ++ -2,8 ++ 3,2
Hs.458425 putative chemokine receptor GPR109B 12q24.31 ++ 138,0 ++ 4,9 + -8,0 ++ 4,3 ++ 1,2 + 50,0 ++ 3,2 + -5,3 + -2,0 ++ 4,9
0 Purinergic Receptors
Hs.41735 purinergic receptor P2X, ligand-gated ion channel, 1 P2RX1 17p13.3 ++ 160,0 + -2,1 ++ 1,7 + -1,6 ++ 1,6 ++ 174,0 ++ 1,1 + -1,5 + -3,0 ++ 1,4
Hs.321709 purinergic receptor P2X, ligand-gated ion channel, 4 P2RX4 12q24.32 ++ 523,0 ++ 1,9 ++ -2,3 ++ 1,4 ++ 2,5 ++ 515,0 ++ 2,3 ++ -2,0 ++ -1,1 ++ -2,1
Hs.528636 purinergic receptor P2X, ligand-gated ion channel, 7 P2RX7 12q24 ++ 241,0 ++ 2,0 + -8,0 ++ -1,9 ++ 2,6 ++ 187,0 ++ 1,7 ++ -2,3 ++ 1,1 + -6,1
Hs.113275 purinergic receptor P2X-like 1, orphan receptor P2RXL1 22q11.21 ++ 141,0 + -1,7 + 2,1 + -1,1 ++ 1,0 ++ 103,0 + 1,4 + -1,2 ++ -1,3 + 1,2
Hs.386296 purinergic receptor P2Y, G-protein coupled, 13 P2RY13 3q24 + 108,0 + -1,7 + 1,4 - -9,8 ++ 21,1 + 153,0 ++ 1,5 ++ -1,6 - -21,1 + 9,8
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related protein 1 (LRPAP1) with an upregulation in apoE3/3 but a downregulation in apoE4/4 
macrophages. This indicates a differential response of apoE4/4 compared to apoE3/3 
macrophages upon cholesterol loading. While apoE3/3 macrophages showed the expected 
regulation of LDL receptors with a downregulation during lipid loading to protect cells from an 
excess of cholesterol and an upregulation during lipid deloading, apoE4/4 macrophages 
showed the vice versa regulation. This could lead to cholesterol overloading of the cells 
leading to a higher risk of developing atherosclerosis. 
LPS receptor CD14, as well as toll-like receptor 2 (TLR2), which is involved in CD14 signal 
transduction were inversely regulated between the two genotypes during E-LDL deloading. In 
apoE3/3 macrophages they were upregulated while in apoE4/4 macrophages they were 
downregulated during E-LDL deloading. TLR4 which is also involved in CD14 receptor 
signalling was downregulated during E-LDL and Ox-LDL loading in apoE3/3 macrophages 
while it was upregulated in apoE4/4 macrophages. During Ox-LDL deloading TLR4 was 4 
fold upregulated in apoE3/3 macrophages but -1.5 fold downregulated in apoE4/4 
macrophages. 
The Fcg-receptors Ia, IIa, IIIa (CD64, CD32 and CD16) were inversely regulated during E-
LDL deloading with HDL3 between the apoE3 and the apoE4 genotype. They were increased 
in apoE3/3 macrophages while they were decreased in apoE4/4 macrophages during E-LDL 
deloading. CD64 and CD16 were also inversely regulated during E-LDL loading between the 
two genotypes. While they were decreased in apoE3/3 macrophages they were increased in 
apoE4/4 macrophages during E-LDL loading. This could indicate an enhanced phagocytosis 
activity of apoE4/4 macrophages which could lead to an increased uptake of E-LDL through 
phagocytosis. During Ox-LDL deloading CD16 was 13.9 fold increased in apoE3/3 
macrophages while it was -2.1 fold decreased in apoE4/4 macrophages. 
Scavenger receptor class B, member 2 (SCARB2) was inversely regulated during Ox-LDL 
loading as well as during E-LDL and Ox-LDL deloading between the apoE3 and the apoE4 
genotype. It was -2.3 fold downregulated during Ox-LDL loading in apoE3/3 macrophages 
while it was 2.0 fold upregulated in apoE4/4 macrophages. During E-LDL deloading it was -
2.8 fold downregulated and during Ox-LDL deloading 6.1 fold upregulated in apoE3/3 
macrophages. In apoE4/4 macrophages SCARB2 was 1.6 fold upregulated during E-LDL 
deloading and -2.0 fold downregulated during Ox-LDL deloading. 
Most of the integrins/complement receptors showed a differentially regulation between 
apoE3/3 and apoE4/4 macrophages during E-LDL deloading. In the apoE3/3 macrophages 
they were upregulated during E-LDL deloading while in the apoE4/4 macrophages they were 
downregulated. All the receptors can be found in table 12. 
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6. ApoE3/3 macrophages compared with macrophages obtained from patients with  
      ABCA1 deficiency (Tangier disease (TD))  
 
6.1. Cell surface expression of sphingo- and glycosphingolipids 
In a next set of experiments the surface expression of Cer, GSLs and GM1 ganglioside was 
compared between apoE3/3 macrophages and macrophages obtained from patients with 
ABCA1 deficiency (Tangier disease). The same protocol as in the previous experiments was 
used, with MCSF differentiation (day 1-7), E-LDL and Ox-LDL loading (day 4-6) and HDL3 
deloading (day 6-7) and cell surface expression of Cer, lactosylceramide (LacCer, CDw17), 
globotriaosylceramide (Gb3Cer, CD77), dodecasaccharideceramide (CD65s) and GM1 
ganglioside was analyzed by flow cytometry. Four different experiments were performed and 
means and standard deviations of the mean fluorescence intensities were calculated. 
Differences between apoE3/3 and Tangier macrophages that are significant in a student’s t-
test for independent samples at p<0.05 were indicated by an asterisk. 
During the differentiation phase with MCSF from day 1 to day 7 the surface expression of 
Cer, Gb3Cer and also GM1 ganglioside was lower in Tangier macrophages compared to 
apoE3/3 macrophages (Fig.61A,B;E,F;I,J) while the surface expression of LacCer and 
CD65s during MCSF differentiation was nearly the same in apoE3/3 and Tangier 
macrophages. (Fig.61C,D;G,H). During E-LDL loading of apoE3/3 and Tangier macrophages 
the surface expression of Cer, Gb3Cer and GM1 ganglioside was slightly induced compared 
to MCSF differentiated cells (Fig.61A,B;E,F;I,J) while CD65s showed no induction during E-
LDL loading (Fig.61G,H). However LacCer surface expression was reduced in Tangier 
compared to apoE3/3 macrophages during E-LDL loading (Fig.61C,D). During Ox-LDL 
loading cell surface expression of all measured cell surface markers Cer, CDw17, CD65s, 
CD77 and GM1 ganglioside was compared to MCSF differentiated cells only significantly 
induced in apoE3/3 but not in ABCA1 deficient (Tangier) macrophages (Fig.61A-J).  
During HDL3 deloading no significant changes between apoE3/3 and Tangier macrophages 
could be observed. 
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Figure 61: Surface expression of membrane ceramide, glycosphingolipids and GM1 
ganglioside of ApoE3/3 vs. Tangier macrophages 
Cell surface expression of ceramide (A,B), lactosylceramide (C,D), globotriaosylceramide (E,F), 
dodecasaccharideceramide (G,H), and ganglioside GM1 (I,J) of apoE3/3 homozygous macrophages 
vs. macrophages obtained from tangier patients measured by flow-cytometry. 
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6.2. Extracellular (surface) and intracellular expression-analysis of proteins involved  
          in cholesterol metabolism 
In order to find out differences in the expression of proteins involved in cholesterol 
metabolism between apoE3/3 macrophages and macrophages obtained from Tangier-
patients, extracellular (surface) and intracellular expression of apoE, apoC-I and CETP were 
measured by flow cytometry. Macrophages were analyzed during MCSF differentiation (day 
1-7), E-LDL and Ox-LDL loading (48h, day 4 to day 6) and HDL3 deloading (day 6 to day 7). 
Four independent experiments were performed and means and standard deviations of the 
mean flourescence intensities were calculated.  
 
6.2.1. ApoE 
ApoE surface expression was increased from day 1 to day 4 in apoE3/3 and in Tangier 
macrophages (Fig.62A,B). From day 4 to day 6 almost no change could be observed in the 
apoE3 genotype while there was an increase of apoE surface expression in “Tangier”-
macrophages (Fig.62A,B). From day 6 to day 7 in apoE3/3 and Tangier macrophages an 
increase could be observed which was higher in apoE3/3 macrophages (Fig.62A,B). During 
lipid loading apoE surface expression increased in apoE3/3 macrophages to a higher extent 
with E-LDL than with Ox-LDL loading compared to MCSF (Fig.62A). In Tangier macrophages 
apoE surface expression was only increased with E-LDL loading but not to the level of the 
apoE3 genotype and there was no change during Ox-LDL loading compared to MCSF 
(Fig.62B). During HDL3 deloading in apoE3/3 and Tangier macrophages a decrease of apoE 
surface expression could be observed compared to lipid loading (Fig.62A,B). 
Intracellular expression of apoE was lower in Tangier macrophages compared to apoE3/3 
macrophages at all states of incubation. It increased from day 1 to day 6 in apoE3/3 
macrophages to a higher level than in Tangier macrophages and decreased from day 6 to 
day 7 (Fig.59C). In Tangier macrophages apoE intracellular expression was only slightly 
increased from day 1 to day 4 and almost no change occured from day 4 to day 6 while it 
was increased from day 6 to day 7 (Fig.62D). During E-LDL loading of apoE3/3 
macrophages apoE intracellular expression was slightly increased while it was decreased 
during Ox-LDL loading (Fig.62C). In Tangier macrophages almost no change of intracellular 
apoE expression could be observed during lipid loading and the apoE expression was much 
lower compared with apoE3/3 macrophages (Fig.62D). During HDL3 deloading apoE 
intracellular expression was decreased in apoE3/3 macrophages while it was slightly 
increased in Tangier macrophages compared with lipid loading (Fig.62C,D). 
 
 
 
  Results   
 129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 62: Extracellular (surface) (A,B) and intracellular expression (C,D) of apoE in apoE3/3 (left 
column) and Tangier macrophages (right column) measured by flow cytometry. 
 
6.2.2. ApoC-I 
In apoE3/3 macrophages apoC-I surface expression was slightly increased during MCSF 
differentiation from day 1 to day 4, slightly decreased from day 4 to day 6 and increased from 
day 6 to day 7 (Fig.63A). ApoC-I surface expression in Tangier macrophages showed almost 
no regulation during MCSF differentiation from day 1 to day 6 but it was increased from day 6 
to day 7 (Fig.63B). During Ox-LDL loading a strong increase of apoC-I surface expression 
could be observed in apoE3/3 macrophages compared to MCSF while in Tangier 
macrophages the increase was lower (Fig.63A,B). E-LDL loading led in apoE3/3 and in 
Tangier macrophages to a slight increase of apoC-I surface expression (Fig.63A,B). Ox-LDL 
deloading with HDL3 of apoE3/3 macrophages didn’t change the surface expression of apoC-
I while E-LDL deloading led to an increase of apoC-I surface expression compared to lipid 
loading (Fig.63A). HDL3 deloading of Tangier macrophages led to an increase of apoC-I 
surface expression compared to E-LDL and Ox-LDL loading (Fig.63B). 
Intracellular expression of apoC-I during MCSF differentiation was similar in apoE3/3 and 
Tangier macrophages (Fig.63C,D). It increased from day 1 to day 4, didn’t change from day 
4 to day 6 and increased again from day 6 to day 7 (Fig.63C,D). During Ox-LDL loading an 
increase of apoC-I surface expression could be observed compared to MCSF in apoE3/3 as 
well as in Tangier macrophages to the same extent (Fig.63C,D). E-LDL loading showed a 
slight increase in apoE3/3 macrophages but a slight decrease in Tangier macrophages 
compared to MCSF (Fig.63C,D). HDL3 deloading didn´t change the intracellular expression of 
apoC-I in apoE3/3 macrophages while in Tangier macrophages during E-LDL deloading an 
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increase of apoC-I intracellular expression could be observed compared to lipid loading 
(Fig.63C,D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63: Extracellular (surface) (A,B) and intracellular expression (C,D) of apoC-I in apoE3/3 (left 
column) and Tangier macrophages (right column) measured by flow cytometry. 
 
6.2.3. CETP 
CETP surface expression was increased during MCSF differentiation from day 1 to day 7 to 
a higher level in apoE3/3 than in Tangier macrophages (Fig.64A,B). E-LDL loading increased 
CETP surface expression in apoE3/3 macrophages while there was no change of CETP 
surface expression in Tangier macrophages compared to MCSF (Fig.64A,B). Ox-LDL 
loading led in apoE3/3 and in Tangier macrophages to a decrease of CETP surface 
expression compared to MCSF (Fig.64A,B). E-LDL deloading with HDL3 led to a slight 
increase while Ox-LDL deloading led to a slight decrease of CETP surface expression in 
apoE3/3 macrophages compared to lipid loading (Fig.64A). HDL3 deloading of Tangier 
macrophages increased CETP surface expression compared to E-LDL and Ox-LDL loading 
(Fig.64B). 
Intracellular expression of CETP was increased during differentiation with MCSF from day 1 
to day 6 in apoE3/3 and in Tangier macrophages (Fig.64C,D). From day 6 to day 7 almost no 
change of CETP intracellular expression could be observed in apoE3/3 macrophages while 
an increase was observed in Tangier macrophages (Fig.64C,D). Lipid loading decreased 
intracellular CETP expression in both genotypes with a stronger decrease during Ox-LDL 
than during E-LDL loading (Fig.64C,D). E-LDL deloading of apoE3/3 macrophages increased 
while Ox-LDL deloading decreased CETP intracellular expression slightly compared to lipid 
loading (Fig.64C). In Tangier macrophages a strong increase during E-LDL deloading and a 
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strong decrease during Ox-LDL deloading could be observed compared to E-LDL and Ox-
LDL loading (Fig.64D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64: Extracellular (surface) (A,B) and intracellular expression (C,D) of CETP in apoE3/3 (left 
column) and Tangier macrophages (right column) measured by flow cytometry. 
 
6.3. Intracellular expression analysis of adipophilin 
Intracellular expression of adipophilin didn’t change from day 1 to day 4 of MCSF 
differentiation and increased from day 4 to day 7 in apoE3/3 and Tangier macrophages 
(Fig.65A,B). E-LDL loading increased adipophilin expression to a higher level in Tangier than 
in apoE3/3 macrophages (Fig.65A,B) compared to MCSF. Ox-LDL loading didn´t change 
adipophilin expression in apoE3/3 macrophages while it decreased adipophilin expression in 
Tangier macrophages (Fig.65A,B) compared to MCSF. E-LDL deloading with HDL3 
decreased adipophilin expression in apoE3/3 macrophages while it increased adipophilin 
expression in Tangier macrophages compared to E-LDL loading. Ox-LDL deloading with 
HDL3 increased adipophilin expression in apoE3/3 and in Tangier macrophages compared to 
Ox-LDL loading (Fig.65A,B). 
 
 
 
 
 
 
 
 
 
Figure 65: Intracellular expression of adipophilin in apoE3/3 (A) and Tangier macrophages (B)  
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7. ApoE3/3 macrophages compared with macrophages obtained from a patient with  
Hypertrigylceridemia (normal HDL, high VLDL and LDL) and coronary heart disease 
In contrast to macrophages obtained from Tangier patients which have low HDL and normal 
VLDL and LDL , macrophages obtained from a patient with hypertriglyceridemia (HTG) with 
normal HDL but high VLDL and LDL (like familial hyperlipidemia) were analyzed. 
Macrophages of the HTG patient were isolated by elutriation, differentiated with MCSF up to 
4 days, loaded with E-LDL (day 4-6) and deloaded with HDL3 (day 6 to day 7). The surface 
expression of Cer, GSLs and GM1 ganglioside was analyzed by flow cytometry. Further 
surface- and intracellular expression of proteins which are involved in cholesterol transport 
namely apoE, apoC-I and CETP, and also of adipophilin a marker for lipid loading was 
analyzed by flow cytometry. The results were compared to that obtained from apoE3/3 
macrophages which were considered as the healthy control group. 
 
7.1. Cell surface expression of sphingo- and glycosphingolipids 
The surface expression of membrane Cer, lactosylceramide (LacCer, CDw17), 
globotriaosylceramide (Gb3Cer, CD77), dodecasaccharideceramide (CD65s) and GM1 
ganglioside was analyzed by flow cytometry during differentiation with MCSF (day 1-7), E-
LDL loading (day 4-6) and HDL3 deloading (day 6-7). The experiment was performed of a 
patient with hypertriglyceridemia (HTG) and compared to the results obtained from 
macrophages of the apoE3/3 genotype. 
During differentiation with MCSF, macrophages of the patient with HTG, showed no change 
of Cer surface expression during day 1 to day 4 while it was increased from day 4 to day 6 
and decreased from day 6 to day 7. In apoE3/3 macrophages Cer surface expression 
increased during differentiation from day 1 to day 7 (Fig.66A). E-LDL loading led to an 
increase of Cer surface expression compared to MCSF in apoE3/3 macrophages but not in 
macrophages obtained from the patient with HTG (Fig.66A). During E-LDL deloading with 
HDL3, Cer surface expression increased compared to E-LDL loading in macrophages of the 
HTG while it was decreased in apoE3/3 macrophages (Fig.66A). LacCer surface expression 
was decreased during differentiation from day 1 to day 4, showed almost no change from 
day 4 to day 6 and increased from day 6 to day 7 in apoE3/3 and HTG macrophages 
(Fig.66B). E-LDL loading compared to MCSF differentiation led in apoE3/3 macrophages to a 
higher increase of LacCer surface expression compared with macrophages obtained from 
the HTG patient which showed only a slight increase of LacCer surface expression (Fig.66B). 
HDL3 deloading led to a decrease of LacCer surface expression in apoE3/3 macrophages 
compared to E-LDL loading while in HTG macrophages HDL3 deloading further increased 
LacCer surface expression (Fig.66B). Gb3Cer surface expression increased during MCSF 
differentiation from day 1 to day 7 to a higher level in apoE3/3 than in HTG macrophages 
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(Fig.66C). E-LDL loading led in both types of macrophages to an increase of Gb3Cer surface 
expression (Fig.66C). HDL3 deloading slightly increased Gb3Cer expression in apoE3/3 
macrophages while it didn´t change Gb3Cer surface expression of HTG macrophages 
(Fig.66C). A higher surface expression level of CD65s was observed in macrophages of the 
HTG patient compared with apoE3/3 macrophages. From day 1 to day 4 of differentiation, 
CD65s surface expression was decreased in HTG and apoE3/3 macrophages and from day 
4 to day 7 almost no further changes could be observed (Fig.66D). CD65s surface 
expression didn´t change during E-LDL loading while it was increased during HDL3 deloading 
in both types of macrophages (Fig.66D). GM1 ganglioside surface expression didn’t change 
during MCSF differentiation in macrophages of the HTG patient (Fig.66E), while in apoE3/3 
macrophages GM1 ganglioside surface expression increased during differentiation from day 
1 to day 7 (Fig.66E). E-LDL loading compared to MCSF led in apoE3/3 macrophages to an 
increase of GM1 ganglioside surface expression while in HTG macrophages no change 
could be observed (Fig.66E). HDL3 deloading led in both types of macrophages to an 
increase of GM1 ganglioside expression with the highest level in apoE3/3 macrophages 
(Fig.66E). 
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Figure 66: Surface expression of membrane ceramide (Cer), glycosphingolipids (GSLs) and 
GM1 ganglioside of macrophages obtained from macrophages of the apoE3/3 genotype and 
patient with hypertriglyceridemia (HTG)  
Surface expression of Ceramide (Cer) (A), lactosylceramide (LacCer,CDw17) (B), 
globotriaosylceramide (Gb3Cer, CD77) (C), dodecasaccharideceramide (CD65s) (D) and GM1 
ganglioside (E) was analyzed by flow cytometry. 
 
 
7.2. Extracellular (surface) and intracellular expression analysis of proteins involved  
          in cholesterol metabolism 
Further extracellular- and intracellular expression of proteins involved in cholesterol 
metabolism namely apoE, apoC-I and CETP was analyzed by flow cytometry. The 
experiment was performed like the previous described under 7.2.1. without Ox-LDL loading 
and deloading. 
 
7.2.1. ApoE 
During MCSF differentiation from day 6 to day 7 apoE surface expression was increased to a 
higher level in apoE3/3 compared to HTG macrophages (Fig.67A,B). E-LDL loading of 
apoE3/3 macrophages led to an increase of apoE surface expression compared to MCSF, 
while macrophages of the HTG revealed no change (Fig.67A,B). E-LDL deloading with HDL3 
decreased apoE surface expression of apoE3/3 macrophages while there was almost no 
change of apoE surface expression of HTG macrophages compared to E-LDL loading 
(Fig.67A,B). 
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ApoE intracellular expression increased during MCSF differentiation from day 1 to day 6 in 
apoE3/3 and HTG macrophages (Fig.67C,D). During day 6 to day 7 of differentiation apoE 
intracellular expression decreased in apoE3/3 macrophages while it further increased in HTG 
macrophages (Fig.67C,D). E-LDL loading compared to MCSF didn´t change apoE 
intracellular expression of apoE3/3 macrophages while it slightly increased apoE intracellular 
expression of HTG macrophages (Fig.67C,D). During E-LDL deloading with HDL3 apoE 
intracellular expression of apoE3/3 and HTG macrophages was decreased (Fig.67C,D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67: Extracellular (surface) (A) and intracellular expression (B) of apoE. 
Macrophages obtained from the apoE3/3 genotype and from a patient with hypertriglyceridemia (HTG)  
 
7.2.2. ApoC-I 
ApoC-I surface expression of apoE3/3 macrophages was increased from day 1 to day 4 of 
MCSF differentiation while in HTG macrophages it was decreased (Fig.68A,B). From day 4 
to day 6 of MCSF differentiation it was decreased and from day 6 to day 7 of MCSF 
differentiation it was increased in both types of macrophages (Fig.68A,B). E-LDL loading of 
apoE3/3 macrophages led to a slight increase of apoC-I surface expression while in 
macrophages of the HTG patient no change of apoC-I surface expression could be observed 
compared to MCSF (Fig.68A,B). During HDL3 deloading both types of macrophages showed 
an increase of apoC-I surface expression compared to E-LDL loading (Fig.68A,B). 
ApoC-I intracellular expression of apoE3/3 macrophages showed an increase during day 1 to 
day 4 of MCSF differentiation, a slight decrease during day 4 to day 6 and a slight increase 
during day 6 to day 7 of MCSF differentiation (Fig.68C). No apoC-I surface expression could 
be detected on HTG macrophages during day 1 to day 4 while it was increased during day 4 
to day 7 of MCSF differentiation. The apoC-I intracellular expression was slightly increased 
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during E-LDL loading in both types of macrophages compared to MCSF. HDL3 deloading led 
to no further changes of apoC-I intracellular expression (Fig.68B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68: Extracellular (surface) (A) and intracellular expression (B) of apoC-I. 
Macrophages obtained from the apoE3/3 genotype and a patient with hypertriglyceridemia (HTG)  
 
7.2.3. CETP 
CETP surface expression increased during differentiation from day 1 to day 4 in both types of 
macrophages (Fig.69A,B). During day 4 to day 7 of MCSF differentiation in apoE3/3 
macrophages CETP surface expression was further increased while in macrophages of HTG 
patient almost no further change of CETP surface expression could be observed (Fig.69A,B). 
E-LDL loading led in apoE3/3 macrophages to an increase of CETP surface expression 
compared to MCSF while in HTG macrophages a slight decrease could be observed 
(Fig.69A,B). HDL3 deloading slightly increased CETP surface expression of HTG and 
apoE3/3 macrophages compared to E-LDL loading (Fig.69A,B). 
CETP intracellular expression was increased during MCSF differentiation from day 1 to day 6 
to a higher level in apoE3/3 macrophages. From day 6 to day 7 CETP intracellular 
expression didn´t change in apoE3/3 macrophages while in HTG macrophages it was further 
increased. E-LDL loading led in apoE3/3 macrophages to a decrease of CETP intracellular 
expression while in HTG macrophages an increase of CETP intracellular expression 
compared to MCSF could be observed. HDL3 deloading led in apoE3/3 macrophages to a 
slight increase of CETP intracellular expression while in HTG macrophages a decrease of 
CETP intracellular expression could be observed compared to E-LDL loading (Fig.69B). 
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Figure 69: Extracellular (surface) (A) and intracellular expression (B) of CETP. 
Macrophages obtained from the apoE3/3 genotype and a patient with hypertriglyceridemia (HTG)  
 
7.3. Intracellular expression analysis of adipophilin 
During MCSF differentiation from day 1 to day 4 almost no change of adipophilin expression 
could be observed in both types of macrophages (Fig.70A,B). During day 4 to day 6 of MCSF 
differentiation adipophilin expression was increased in apoE3/3 macrophages while it was 
slightly decreased in HTG macrophages. During day 6 to day 7 of differentiation adipophilin 
expression was increased in both types of macrophages (Fig.70A,B). E-LDL loading led to 
an increase of adipophilin expression compared to MCSF differentiation to a higher extent in 
apoE3/3 than in HTG macrophages (Fig.70A,B). HDL3 deloading decreased adipophilin 
expression in apoE3/3 macrophages while it slightly increased it in HTG macrophages 
compared to E-LDL loading (Fig.70A,B). 
 
 
 
 
 
 
 
 
 
Figure 70: Intracellular expression of adipophilin. 
Macrophages obtained from the apoE3/3 genotype and a patient with hypertriglyceridemia (HTG) 
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8. Incubation of ApoE3/3 macrophages with PPARg and RXR agonists 
 
8.1. Analysis of CD36 and apoE expression after incubation with PPARg agonists 
In a next set of experiments the influence of different PPARg agonists on the surface 
expression of scavenger receptor CD36 (SRCD36) and on the surface and intracellular apoE 
expression was analyzed. SRCD36 was chosen because it is known that PPARg induces 
SRCD36 and therefore it seems to be a key component of lipid uptake and apoE is known to 
be a direct target of LXR and therefore PPARg sensitive. Monocytes were incubated from 
day 1 to day 4 with different glitazones solubilized in ethanol. The same amount of ethanol 
(Etoh) without glitazones was taken as a control. Three different experiments were 
performed and means of the mean fluorescence intensities and standard deviations were 
calculated. It could be observed that the surface expression of CD36 was upregulated during 
incubation with the different glitazones in comparison to Etoh as a control (Fig.71A). But no 
significant differences in the intensities between the different glitazones could be observed. 
However pioglitazone in a concentration of 5mM showed the greatest induction of CD36 
(Fig.71A). 
The apoE expression extracellular as well as intracellular was also induced during incubation 
with the different glitazones compared to Etoh as a control but no significant differences in 
their intensities could be detected (Fig.71B,C). 
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Figure 71: surface expression of CD36 (A) and  
expression of apoE extracellular (B) and 
intracellular (C) measured by flow cytometry  
after incubation with different PPARg-agonists 
(glitazones) and ethanol (Etoh) as a control. 
Ciglitazone (Cigl.), Troglitazone (Trogl.), 
Pioglitazone (Piogl.) 
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8.2. Expression-analysis of cell surface receptors involved in lipid uptake and  
       processing after incubation with RXR- and PPARg-agonists 
Further receptors involved in the monocyte innate immunity cluster and also other receptors 
involved in adhesion and signalling processes relevant for atherosclerosis were analyzed 
during incubation with RXR- and PPARg-agonists. Monocytes were differentiated from day 1 
to day 4 with MCSF. On day 4 they were incubated for 24h with the RXR agonists b-
Carotene (5 mM), cis-retinoic-acid (10 mM) and all-trans-retinoic-acid (10 mM) as well as with 
the PPARg-agonist rosiglitazone (30 mM). As a control MCSF differentiated cells respectively 
cells incubated with phosphatidylcholine (PC)-liposomes as the solvent for b-carotene or 
DMSO as the solvent for the other substances were taken. After 24h of incubation with the 
RXR- and PPARg-agonists, respectively cells were harvested and cell surface expression of 
receptors involved in lipid uptake and processing was analyzed by flow cytometry.  Results 
are shown in % change of MCSF as a control. 
As examples of receptors which are involved in lipid uptake, the scavenger receptor class B 
CD36 and the phagocytosis receptors Fcg-receptor III CD16 and Fcg-receptor II CD32 were 
analyzed (Fig.72A,B,C). Incubation with the RXR agonist beta-carotene showed a decrease 
of cell surface expression of all three receptors compared with PC-liposomes which were 
used as a solvent (Fig.72A,B,C). Cis-retinoic-acid decreased surface expression of CD36 
and CD32 compared to DMSO (Fig.72A,C). The surface expression of CD16 was slightly 
increased with cis-retinoic-acid compared to DMSO (Fig.72B). All-trans-retinoic-acid 
decreased the surface expression of CD36 and CD32 while there was no change of CD16 
surface expression compared to DMSO (Fig.72A,C,B). The PPARg-agonist rosiglitazone 
increased CD36 and CD16 expression but decreased surface expression of CD32 compared 
to DMSO (Fig.72A,C,B). Compared with MCSF only the incubation with rosiglitazone 
increased in the case of CD36 cell surface receptor expression while all the other stimuli 
revealed a decrease of cell surface receptor expression (Fig.72A,B,C). 
The LPS receptor CD14 and the toll like receptors (TLRs) 2 and 4 which are involved in 
CD14 signalling were also analyzed (Fig.72D,E,F). During beta-carotene stimulation CD14 
surface expression was increased while TLR 2 and 4 were decreased compared to 
incubation with PC-liposomes (Fig.72D,E,F). Cis-retinoic-acid led to a small decrease of 
CD14 surface expression and to a strong decrease of TLR 2 and 4 while all-trans-retinoic-
acid decreased CD14 as well as TLR 2 and 4 almost to the same extent (Fig.72D,E,F). The 
PPARg agonist rosiglitazone also decreased the surface expression of CD14 and the TLRs 2 
and 4 (Fig.72D,E,F).  
The adhesion molecules integrin-b2/CD18, integrin-aL/CD11a and integrin-aM/CD11b were 
also analyzed (Fig.72G,H,I). They play an important role in the adhesion of monocytes to the 
endothelium and following extravasation into the tissue with progression of atherosclerosis.  
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As the a subunit of the b2-integrin, CD11b forms a heterodimer complex with CD18 on the 
surface of granulocytes and monocyte/macrophages that is important in a variety of 
adherence-related activities and as a complement receptor which mediates the phagocytosis 
of opsonized particles. During incubation with beta-carotene CD18 and CD11b (complement 
receptor 3) were decreased while CD11a was slightly increased compared to incubation with 
PC-liposomes (Fig.72G,H,I). Incubation with cis-retinoic-acid and all-trans-retinoic-acid 
decreased cell surface expression of CD18, CD11a and CD11b compared to incubation with 
DMSO (Fig.72G,H,I). The PPARg-agonist rosiglitazone increased expression of CD18 while 
the surface expression of CD11a and CD11b was slightly decreased compared to DMSO 
(Fig.72G,H,I).  
The tetraspanin CD81, CD33 a member of the sialoadhesion family and CD95 the 
prototypical cell death receptor a member of TNF receptor family were decreased during 
incubation with beta-carotene compared to PC-liposomes (Fig.72J,K,L). Also the incubation 
with cis-retinoic-acid and all-trans retinoic acid decreased the surface expression of CD81, 
CD33 and CD95 compared to DMSO (Fig.72J,K,L). Rosiglitazone decreased CD81 and 
CD95 expression but had almost no influence on CD33 surface expression compared to 
DMSO (Fig.72J,K,L). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
beta carotene
PC liposomen
cis retinoic acid
DMSO
all trans retinoic acid
rosiglitazone
DMSO
A. Scavenger receptor class B CD36
0
5
10
15
20
25
30
35
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-18
-13
-8
-3
2
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-18
-13
-8
-3
2
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-25
-20
-15
-10
-5
0
5
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
B. Fcg-receptor III CD16
-25
-20
-15
-10
-5
0
5
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-25
-20
-15
-10
-5
0
 %
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-40
-30
-20
-10
0
10
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
C. Fcg-receptor II CD32
-40
-30
-20
-10
0
10
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-40
-30
-20
-10
0
10
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
 %
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
 %
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
  Results   
 141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
beta carotene
PC liposomen
cis retinoic acid
DMSO
all trans retinoic acid
rosiglitazone
DMSO
-45
-35
-25
-15
-5
%
ch
an
ge
 o
f M
C
SF
 c
on
tr
ol
-45
-35
-25
-15
-5
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-45
-35
-25
-15
-5
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
E. Toll like receptor 2 (TLR 2)
-55
-35
-15
5
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-55
-35
-15
5
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-55
-35
-15
5
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
D. LPS receptor CD14
F. Toll like receptor 4 (TLR 4)
-35
-30
-25
-20
-15
-10
-5
0
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-35
-30
-25
-20
-15
-10
-5
0
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-35
-30
-25
-20
-15
-10
-5
0
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
ch
an
ge
 o
f M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
ch
an
ge
 o
f M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
ch
an
ge
 o
f M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-48
-43
-38
-33
-28
-23
-18
-13
-8
-3
%
 c
ha
ng
e 
of
 M
C
SF
co
nt
ro
l
-48
-43
-38
-33
-28
-23
-18
-13
-8
-3
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-48
-43
-38
-33
-28
-23
-18
-13
-8
-3
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
I. Integrin aM CD11b
-27
-22
-17
-12
-7
-2
3
8
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-27
-22
-17
-12
-7
-2
3
8
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-27
-22
-17
-12
-7
-2
3
8
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
G. Integrin b2 CD18
H. Integrin aL CD11a
-38
-33
-28
-23
-18
-13
-8
-3
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-38
-33
-28
-23
-18
-13
-8
-3
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
-38
-33
-28
-23
-18
-13
-8
-3
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
co
nt
ro
l
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
co
nt
ro
l
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
co
nt
ro
l
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
%
 c
ha
ng
e 
of
 M
C
SF
 c
on
tr
ol
  Results   
 142 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 72: Surface expression analysis after incubation with the RXR agonists beta carotene, cis 
retinoic acid and all trans retinoic acid and the PPARg agonist rosiglitazone compared with the 
solvents PC liposomes and DMSO as a control. Results are shown in % of MCSF as control. 
CD36 (A), CD16 (B), CD32 (C), CD14 (D), TLR2 (E), TLR4 (F), CD18 (G), CD11a (H), CD11b (I), 
CD81 (J), CD33 (K), CD95 (L) 
 
 
8.3. Retinoids induce genes of lipid metabolism in human monocytes/macrophages 
Human monocytes and macrophages were stimulated in vitro with the retinoids b-carotene, 
9-cis retinoic acid and all-trans retinoic acid and gene expression was analyzed by Affymetrix 
U133A GeneChipsTM. As indicated in table 13, genes involved in cellular lipid metabolism 
were significantly induced by these retinoids. b-carotene had the lowest effects, whereas 9-
cis RA and ATRA where nearly equally potent in inducing genes of fatty acid metabolism, 
cholesterol metabolism, apolipoproteins and lipid-related transcription factors. Interestingly, 
both cell types, undifferentiated monocytes and in-vitro differentiated macrophages displayed 
a signifcant upregulation of mRNA levels of lipid genes even without prior cholesterol 
loading, which is a known potent stimulus of transcription for these genes including the ABC 
transporters ABCA1 and ABCG1, and apoE, which implies that retinoids have a strong 
impact on gene expression in human monocytes and macrophages. 
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Table 13: Changes of gene expression in human lipid metabolism by retinoids 
8.3.1. Verification of microarray results in human monocytes stimulated with retinoids 
To evaluate the results obtained with DNA microarrays with an independent and more 
sensitive technique, TaqMan realtime RT-PCR was performed for selected candidate genes 
in human monocytes incubated in the presence of b-carotene, 9-cis RA and ATRA (Fig.73). 
Among the genes of fatty acid metabolism, mRNAs of fatty acid desaturase 2 (FADS2), 
stearoyl-CoA desaturase, monoglyceride lipase (MGLL), and CD36 were clearly inducible by 
9-cis RA and ATRA, whereas b-carotene could not significantly upregulate mRNA levels of 
these genes (Fig.73a.). The level of gene induction was generally higher with 9-cis RA 
compared to ATRA. The insulin induced gene 1 (INSIG), which was slightly upregulated in 
DNA microarrays (table 13, 1.9 fold), was not induced in these experiments compared to 
control conditions. In the group of cholesterol metabolism genes, a strong upregulation of 
ABCA1, ABCG1, steroid-27 hydroxylase (CYP27A1) and liver X receptor a (LXRa) could be 
observed (Fig.73b.) with 9-cis RA and ATRA. Interestingly, CYP27A1 mRNA levels were 
considerably increased by b-carotene, which confirms the results from DNA microarrays. As 
shown in Fig.73c, the remarkable induction of mRNA expression of apolipoprotein genes 
after incubation with 9-cis RA and ATRA was confirmed by TaqMan RT-PCR. 
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Fatty acid metabolism
Hs.83190 Fatty acid synthase FASN 17q25 ++ 283 ++ 1,1 ++ 1,9 ++ 1,6 ++ 113 ++ 1,1 ++ 1,6 ++ 1,2
Hs.388164 fatty acid desaturase 2 FADS2 11q12-q13.1 ++ 446 ++ 1,2 ++ 2,0 ++ 1,4 ++ 337 + 1,0 ++ 1,7 ++ 1,1
Hs.119597 Stearoyl CoA desaturase SCD 10q23-q24 ++ 699 ++ 1,1 ++ 2,5 ++ 2,1 ++ 779 ++ -1,1 ++ 3,0 ++ 3,0
Hs.268012 Fatty-acid-Co A-ligase, long-chain 3 FACL3 2q34-q35 ++ 408 ++ 1,1 ++ 2,0 ++ 1,9 ++ 364 ++ 1,0 ++ 2,0 ++ 1,6
Hs.391561 fatty acid binding protein 4 FABP4 8q21 ++ 2219 ++ -1,1 ++ 1,0 ++ 1,0 ++ 268 + -1,3 ++ 2,3 ++ 1,6
Hs.409826 monoglyceride lipase MGLL 3q21.3 ++ 311 ++ 1,6 ++ 2,6 ++ 2,3 ++ 667 ++ 1,1 ++ -1,3 ++ -1,3
Hs.416385 insulin induced gene 1 INSIG1 7q36 ++ 1128 ++ 1,3 ++ 1,9 ++ 1,9 ++ 521 ++ 1,0 ++ 1,3 ++ 1,3
Hs.443120 CD36 CD36 7q11.2 ++ 839 ++ 1,3 ++ 1,6 ++ 1,6 ++ 467 ++ -1,1 ++ 2,5 ++ 1,9
Cholesterol metabolism
Hs.11899 HMG-CoA reductase HMGCR 5q13.3-q14 ++ 282 ++ 1,2 ++ 1,6 ++ 1,4 ++ 92 + -1,1 ++ 1,1 ++ 1,0
Hs.252457 mevalonate decarboxylase MVD 16q24.3 - 33 - 1,6 ++ 2,3 ++ 1,6 - 44 - 1,0 + 1,4 - 1,0
Hs.76038 Isopentenyl-diphosphate delta isomerase IDI1 10p15.3 ++ 412 ++ 1,0 ++ 1,9 ++ 1,3 ++ 199 ++ -1,1 ++ 1,1 ++ -1,1
Hs.11806 7-dehydrocholesterol reductase DHCR7 11q13.2-q13.5 ++ 166 ++ 1,1 ++ 1,6 ++ 1,2 + 128 + 1,1 ++ 1,7 + 1,3
Hs.213289 LDL-receptor LDLR 19p13.3 ++ 393 ++ 1,1 ++ 1,7 ++ 1,4 ++ 234 ++ -1,1 ++ 1,4 ++ 1,2
Hs.446331 Acyl-Co A: cholesterol acyltransferase SOAT1 1q25 ++ 119 ++ 1,5 ++ 1,1 ++ 1,3 ++ 157 ++ 1,2 ++ 1,4 ++ 1,3
Hs.82568 steroid 27-hydroxylase CYP27A1 2q33-qter ++ 234 ++ 2,6 ++ 4,6 ++ 3,5 ++ 1678 ++ 1,2 ++ 1,3 ++ 1,3
Hs.139851 Caveolin 2 CAV2 7q31.1 + 16 - 1,1 + -1,4 + -1,3 - 14 + 2,5 + 1,5 + 1,4
Hs.404930 Niemann-Pick disease, type C1 NPC1 18q11-q12 ++ 181 ++ 1,0 ++ 1,4 ++ 1,5 ++ 971 ++ -1,2 ++ -1,4 ++ -1,3
Hs.433222 Niemann-Pick disease, type C2 NPC2 14q24.3 ++ 2226 ++ 1,3 ++ 1,5 ++ 1,5 ++ 3119 ++ 1,1 ++ 1,0 ++ 1,1
Hs.147259 ATP-binding cassette transporter A1 ABCA1 9q31.1 ++ 186 ++ 1,1 ++ 3,5 ++ 4,0 ++ 371 ++ -1,1 ++ 2,5 ++ 2,3
Hs.369055 ATP-binding cassette transporter G1 ABCG1 21q22.3 ++ 37 ++ 1,2 ++ 5,3 ++ 4,6 ++ 120 ++ -1,1 ++ 4,6 ++ 4,6
Apolipoproteins
Hs.268571 apolipoprotein C-I  APOC1 19q13.2 ++ 778 ++ 1,1 ++ 2,8 ++ 2,6 ++ 2069 ++ 1,1 ++ 1,9 ++ 1,9
Hs.75615 apolipoprotein C-II   APOC2 19q13.2 - 129 - 1,1 + 1,6 + 1,6 + 428 + 1,2 + 2,3 + 2,6
Hs.110675 apolipoprotein C-IV APOC4 19q13.2 + 244 ++ 1,1 ++ 2,3 ++ 1,9 ++ 3226 ++ 1,1 ++ 1,1 ++ 1,2
Hs.169401 apolipoprotein E   APOE 19q13.2 ++ 238 ++ 1,4 ++ 2,8 ++ 3,5 ++ 3831 ++ -1,1 ++ 1,2 ++ 1,1
Transcription factors
Hs.426528 sterol regulatory element binding factor 1 SREBF1 17p11.2 + 152 + 1,0 ++ 2,3 ++ 2,0 + 131 ++ 1,1 ++ 2,1 ++ 1,9
Hs.108689 sterol regulatory element binding factor 2 SREBF2 22q13 + 133 ++ 1,2 ++ 1,6 ++ 1,4 ++ 187 + 1,0 + 1,1 ++ 1,1
Hs.361071 retinoic acid receptor, alpha RARA 17q21 + 44 - 1,0 + 1,6 ++ 1,5 + 61 + -1,1 ++ 1,4 + 1,5
Hs.387667 peroxisome proliferative activated receptor, gamma PPARG 3p25 ++ 86 ++ 1,6 ++ 1,9 ++ 1,7 ++ 118 ++ -1,1 ++ 1,3 ++ 1,5
Hs.438863 Liver X receptor, alpha NR1H3 11p11.2 ++ 122 ++ 1,6 ++ 4,9 ++ 4,3 ++ 581 ++ -1,1 ++ 1,7 ++ 1,7
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8.3.2.  Retinoids increase macrophage phospholipid and cholesterol efflux 
In order to analyze whether the increase in gene transcription of important regulators of 
intracellular cholesterol trafficking by retinoids causes functional consequences, lipid efflux of 
RAW264.7 macrophages was monitored. Therefore, cells were stimulated with 9-cis RA and 
ATRA for two different time points (24h and 48h) and the apoA-I specific phospholipid and 
cholesterol efflux was investigated. The analyzed retinoids significantly induced the efflux of 
both lipid species to apoA-I as acceptor particle (Fig.74). Remarkably, the retinoid-response 
of cholesterol efflux (Fig.74B.) was larger than the influence on phospholipid efflux 
(Fig.74A.). Furthermore, 9-cis RA was more potent in modulating specific efflux levels than 
ATRA. These results reveal that the increase in mRNA levels of lipid genes activated by 
retinoids parallels with a functional response of macrophages as related to cholesterol and 
phospholipid efflux. 
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on Figure 73: Retinoid-induced mRNA expression of 
genes involved in lipid metabolism 
(A) fatty acid desaturase 2 (FADS2), stearoyl-CoA 
desaturase (SCD), monoglyceride lipase (MGLL), 
CD36. (B) ATP-binding cassette transporters A1 
and G1 (ABCA1, ABCG1), steroid-27 hydroxylase 
(Cyp27A1), liver X receptor a (LXRa). (C) 
apolipoprotein C-I (apoC-I), apolipoprotein C-II 
(apoC-II), apolipoprotein C-IV (apoC-IV), 
apolipoprotein E (apoE).    
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Figure 74: Retinoids stimulate lipid efflux in macrophages. RAW264.7 macrophage cells were either 
incubated in the presence of vehicle (DMSO) or lipid agonists (5mM 9-cis RA or 5mM ATRA) for 24h or 
48h and apoA-I-specific phospholipids efflux (A) or apoA-I-specific cholesterol efflux (B) was 
monitored. 
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V. Discussion 
In the first part of the thesis, the differential effects of the atherogenic modified lipoproteins E-
LDL and mildly Ox-LDL and the antiatherogenic lipoprotein HDL3 on the cholesterol and 
sphingolipid metabolism and on raft microdomain constituents during in vitro foam cell 
formation of apoE3/3 human monocyte derived macrophages have been investigated. The 
differential composition as well as the differential uptake mechanisms of E-LDL and Ox-LDL 
could contribute to the specific effects of these lipoproteins concerning cholesterol and 
sphingolipid metabolism. E-LDL is internalized via CD36, Fcg-receptor and complement 
receptor dependent phagocytosis (149), while minimally oxidized LDL is known to be 
internalized mainly via the LDL receptor coated-pit pathway when exposed to macrophages 
(389). The degradation of esterified cholesterol by acid lipase treatment converts LDL to 
coreless liposome like E-LDL. That does not occur in Ox-LDL and is in accordance to in-vivo 
detection of large lipoprotein particles within the vessel wall (390;391). E-LDL in contrast to 
Ox-LDL, rapidly induces foam cell formation which is also present in vivo with extensive 
extracellular deposition of E-LDL already in the earliest stages of human atheriosclerotic 
lesions accompanying the onset of monocyte infiltration (152). The results obtained by mass 
spectrometry demonstrate that E-LDL induces total cellular cholesterol especially esterified 
cholesterol content due to the high free cholesterol content of E-LDL which leads inside the 
cell to rapid reesterification and foam cell formation. In contrast to E-LDL, Ox-LDL is poorly 
able to induce cytoplasmic cholesteryl ester accumulation since the oxidation processes lead 
to the formation of oxysterols from cholesterol and fatty acyl groups of core cholesteryl 
esters, rendering them resistant to lysosomal hydrolysis and trapping them within these 
organelles (161;392). Ox-LDL loading of macrophages leads to an upregulation of 
intracellular ceramide (Cer) content. Mass spectrometry analysis of the modified lipoproteins 
revealed that the Cer content of E-LDL and Ox-LDL is similar, indicating that cellular Cer 
elevation is not due to a higher Cer level in the oxidative modified lipoprotein itself. However 
it can not be excluded that macrophages have a higher capability to take up Cer from Ox-
LDL than from E-LDL. It has been shown previously that Ox-LDL induces the sphingomyelin 
(SM)-Cer pathway by stimulation of neutral and acid sphingomyelinase (SMase) (393) and 
that minimally Ox-LDL enhances Cer generation via induction of acid SMase (394) while in 
MCSF deprived macrophages Ox-LDL blocks Cer generation in part by inhibiting acid SMase 
(395). In this thesis an upregulation of relative mRNA expression of acid SMase, neutral 
SMase and neutral SMase activation associated factor during Ox-LDL but not during E-LDL 
loading could be demonstrated which could result in a rapid increase in Cer levels in which a 
large fraction of cellular SM is converted to Cer (396;397). Further the acitvity of acid SMase 
is mainly determined by its expression (398) and acid SMase translocates into and generates 
Cer within distinct plasma membrane sphingolipid-enriched microdomains (300). Sudden 
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increases in Cer levels due to the action of SMase upon the plasma membrane have 
important effects in bacterial pathogenesis, cholesterol homeostasis, and apoptosis (399-
403). Further a greater upregulation of relative mRNA expression of glucosylceramidase 
which degrades glucosylceramide to Cer could be detected during Ox-LDL loading compared 
with E-LDL. This suggests also a Cer elevation upon glucosylceramide degradation to a 
higher extent during Ox-LDL than during E-LDL loading. 
HDL3 deloading reverses the increase of cholesterol during E-LDL loading and the Cer 
increase resulting from Ox-LDL loading. This is due to the function of HDL3 as a cholesterol 
acceptor. However in contrast to a decrease in Cer, sphingosine levels increased during 
HDL3 deloading after Ox-LDL loading. Considering the formation of S1P from sphingosine, 
this diverse effect could be due to the differential effects of Cer and S1P concerning the Cer-
S1P rheostat regulating apoptosis and survival. 
In addition to an increase of cellular Cer content during Ox-LDL loading, an increase of cell 
surface Cer and from Cer derived glycosphingolipids (GSLs) and GM1 ganglioside could also 
be detected. The increased expression of GSLs on the cell surface during Ox-LDL loading 
could reflect either their increased net synthesis due to the increase in Cer content during 
Ox-LDL loading or an enhancement of their translocation from the Golgi to the plasma 
membrane. An inhibited degradation of the GSLs or their decreased endocytosis could also 
be responsible. The activities of the GSL degradation enzymes undergo a complex 
regulation by sphingolipid activator proteins (SAP-A to SAP-D and the GM2 activator) and it 
might be possible that these regulatory proteins may also be involved in regulating the net 
amount of GSL expression on the cell surface. 
Cer enriched Ox-LDL loaded macrophages compared to E-LDL loaded and MCSF 
differentiated macrophages bind more effectively apoE compared to apoA-I at 4°C. This 
increased binding of apoE during Ox-LDL loading of macrophages could be due to an 
enhanced surface expression of Cer and to the formation of Cer-enriched microdomains 
during Ox-LDL loading. This is supported by the recent observation that apoE prefers binding 
on Cer-enriched domains compared to SM-enriched domains exposed on emulsion particle 
surfaces (110) while further incorporation of SM into emulsion surfaces decreased binding of 
apoE and reduced apoE-mediated uptake (111). At 37°C binding and uptake of both, apoE 
and apoA-I was enhanced in Ox-LDL loaded macrophages. This effect could also be due to 
the higher plasma membrane Cer content in these cells and is in accordance with the higher 
expression of ABCA1 during Ox-LDL loading which could lead to enhanced cholesterol efflux 
with increased demand for the efflux mediating HDL constituent apoA-I.  
In accordance with the finding of increased apoE binding on Cer enriched microdomains in 
liposomes which decreases with SM enrichment is the formation of cholesterol/Cer rich rafts 
in Ox-LDL loaded macrophages which avidly bind apoE while E-LDL loaded macrophages 
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generate cholesterol/SM rich microdomains. Cer location within lipid rafts is an important 
factor in Cer action (399-401;404). Cer both stabilizes and associates strongly with lipid rafts 
(405;406). It can also induce the formation of unusually large raft domains (“platforms”) in 
plasma membranes (400) which can be detected by a monoclonal Cer antibody which has 
been used in the experiments (300). Raft composition could have marked effects upon raft 
structure, receptor clustering and function (407). In this regard certain previously observed 
physiological processes may be a result of raft composition. Recently it could be found that 
cholesterol and SM levels of the plasma membrane control g-secretase activity in amyloid 
precursor protein (APP) cleavage which results in amyloid b 40 (Ab40) and Ab42 respectively 
(408). Because of the fact that the accumulation of Ab is one of the main characteristics of 
Alzheimers´s disease (AD) and is associated with neurodegeneration it seems possible that 
differential raft formation could be associated with the development of AD. 
Differential effects on cell surface expression of the monocyte innate immunity receptor 
cluster resulting in different signaling pathways could also be ascribed to the differential 
formation of raft domains through Ox-LDL and E-LDL. Previously it could be shown that Cer 
induces the monocyte innate immunity receptor cluster including Fcg-receptors (FcgRs) and 
LRP1 important for lipid uptake, complement constituents for immune regulation and the LPS 
receptor CD14 (30). According to this receptor cluster it could be demonstrated in this thesis 
that these receptors are differentially regulated during E-LDL and Ox-LDL loading. The 
FcgRs CD32 and CD64 increase during E-LDL loading but decrease during Ox-LDL loading 
compared to M-CSF, indicating an involvement of the phagosomal compartment during E-
LDL uptake and a stimulation of type I phagocytosis during E-LDL loading. Fcg-RII/CD32 
shows a raft association in Cer enriched Ox-LDL loaded cells which is in accordance to the 
fact that cell surface Cer precedes and controls Fcg-RII/CD32 clustering in rafts (302). It was 
also shown that CD32 is a constituent of detergent resistant membranes (DRMs) in human 
platelets and neutrophils (215;216) and the lupus-associated FcgRIIb polymorphism 
FcgRIIbT232 excludes CD32 from sphingolipid rafts rendering CD32 unable to fulfill its 
proposed function of inhibiting activatory receptors (409) resulting in an enhancement of 
inflammatory processes and an exacerbation of the disease. 
Scavenger receptor (SR) class B CD36 increases during E-LDL and Ox-LDL loading while 
LRP1/CD91 and SR cysteine rich/CD163 increase during E-LDL but decrease during Ox-
LDL loading. SRs with charge and motif recognition are well known to be involved in uptake 
of modified lipoproteins in particular ac- and Ox-LDL. Especially CD36 as the major class B 
SR is considered to be relevant for E-LDL induced foam cell formation (36) and the uptake of 
E-LDL appears to be mediated in part by CD36 (149). The induction of CD36 surface 
expression during E-LDL and Ox-LDL loading as an autoamplifying internalization loop for 
enhanced lipid uptake indicate an involvement of CD36 in the uptake of both modified 
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lipoproteins. The stronger upregulation of CD36 during Ox-LDL loading could be due to an 
activation of PPARg with oxysterols derived from Ox-LDL. CD91 and CD163 increase during 
E-LDL loading which is probably due to a participation of these receptors in the phagocytic 
uptake of E-LDL. The importance of CD163 for phagocytosis was shown previously by 
Buechler et al. who demonstrated an upregulation of CD163 in phagocytic macrophages but 
not in dendritic cells (410). The upregulation of CD11a, CD11b and CD18 (complement 
receptor 3) during E-LDL loading but not during Ox-LDL loading indicates an induction of 
complement as well as type II pagocytosis during E-LDL but not during Ox-LDL loading. The 
enhanced complement activity of E-LDL has been previously described by Klouche et. al. 
(154) while Ox-LDL shows only minor complement activation (411). Cer inhibits IgG-
dependent phagocytosis in human pylymorphonuclear leukocytes (412) and phagocytosis is 
enhanced through inhibition of de novo Cer synthesis (413). This implicates an inhibitory 
effect of Cer in phagocytosis which could explain the decrease of phagocytotic receptors in 
Cer enriched Ox-LDL loaded macrophages. Upregulation of integrins on the cell surface lead 
to enhanced phagocytosis, adhesion and migration of monocytes with increased risk of 
developing atherosclerosis. Enhanced presence of CD11b at the cell surface may reflect an 
unspecific cellular activation (414). The integrin associated protein CD47 is also increased 
during E-LDL but decreased during Ox-LDL loading. Decay acceleration factor CD55 is 
increased during E-LDL and Ox-LDL loading. The LPS receptor CD14 a GPI-linked raft 
associated receptor was decreased during E-LDL and Ox-LDL loading. It has been 
demonstrated that minimally modified Ox-LDL bind to CD14 and lead to cytoskeletal 
rearrangements and pro-inflammatory gene expression (415). Because of the similar 
regulation of CD14 with Ox-LDL and E-LDL, probably the same effect could be assumed for 
E-LDL. The downregulation of CD14 during lipid loading could be due to a compensatory 
effect to protect the cell against pro-inflammatory stimuli. This differential regulation of the 
surface expression of the monocyte innate immunity receptor cluster during E-LDL and Ox-
LDL loading and deloading could lead to the conclusion that differential formation of rafts with 
the different atherogenic lipoproteins are accompanied by certain receptors resulting in 
specific signal transduction events for E-LDL and Ox-LDL loading and deloading. Further 
influences on the cholesterol and sphingolipid trafficking could be a result of different raft 
domains accompanied by different receptor clustering and could cause disturbances in 
cholesterol homeostasis. In this thesis it could be shown that ATP cassete transporter 
ABCA1, a lipid transporter which is responsible for cholesterol efflux from cells is differentially 
regulated with E-LDL and Ox-LDL loading. Ox-LDL induces protein and mRNA expression of 
ABCA1, to a higher extent than E-LDL. This could be due to an activation of LXR, a 
subfamily of nuclear receptors through oxysterols as components of Ox-LDL which in turn 
activate ABCA1. A possible explanation for the increased ABCA1 protein content by Ox-LDL 
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could also be due to the enhanced Cer content of Ox-LDL loaded cells which could lead 
either to enhanced synthesis or delayed degradation of ABCA1 resulting in a specific cellular 
regulation of ABCA1 content and ABCA1 mediated cholesterol efflux. In this regard it could 
be shown previously that Cer enhances cholesterol efflux to apoA-I by increasing cell surface 
presence of ABCA1 (416) which could also happen in Cer enriched Ox-LDL loaded cells in 
contrast to E-LDL loaded cells. The upregulation of ABCA1 during lipid loading is reversed 
with HDL3 deloading of the cells leading to a depriviation of cholesterol and Cer and in turn to 
a downregulation of ABCA1. HDL which function as a cholesterol scavenger serve as 
depository for apoA-I, apoE and apoC-I. ApoE protein expression shows an upregulation 
during lipid loading compared to MCSF differentiation and a further upregulation during HDL3 
deloading which is probably reflecting the apoE content of HDL3 itself. ApoE surface and 
intracellular expression measured by flow cytometry is higher during E-LDL than during Ox-
LDL loading. However HDL3 deloading leads to a decrease of apoE surface and intracellular 
expression. Recently it could be shown that apoE respectively apoE-rich lipoproteins like 
VLDL contribute to antigen presentation of lipid antigens by high affinity binding of 
endogenous or exogenous antigens mainly Cer derived GSLs (117). The uptake of these 
lipid antigens takes place via LRP1 by antigen presenting cells and after processing they are 
presented to lipid antigen-reactive T-cells on the cell surface by CD1. Therefore induction of 
apoE by E-LDL could also lead to a promotion of inflammatory processes which is reversed 
with HDL3. 
In contrast to apoE, apoC-I surface and intracellular expression measured by flow cytometry 
as well as apoC-I protein expression shows a higher increase during Ox-LDL than during E-
LDL loading. This could be a compensatory effect of the cell because apoC-I activates 
lecithin cholesterol acyl transferase (LCAT) (75) which catalyze the esterification of free 
cholesterol in plasma and cholesteryl ester enrichment of HDL and apoC-I is also described 
as an inhibitor of phospholipase A2 (PLA2) (79) which amplifies atherogenic processes by 
liberating potent pro-inflammatory lipid mediators and by generating pro-atherogenic LDL 
(80). On the other side apoC-I inhibits lipoprotein lipase an enzyme involved in lipoprotein 
processing (78) which leads to high plasma TG levels and low HDL levels which are 
considered as pro-atherogenic factors (417).  
Surface and intracellular expression of cholesterol ester transfer protein (CETP), a member 
of the lipopolysaccharide binding protein (LBP) gene family increases during MCSF 
differentiation which was reported previously (131). With E-LDL loading surface CETP 
increases and with Ox-LDL loading it decreases compared to MCSF and the intracellular 
expression of CETP decreases with E-LDL and to a higher extent with Ox-LDL compared to 
MCSF. This is a contradictory result to the known functions of CETP which would suggest an 
increase of CETP with cholesteryl ester accumulation and further an induction of CETP like 
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ABCA1 via LXR induced by oxysterols as components of Ox-LDL. A possible explanation for 
this fact could be a compensatory effect of CETP in response to the upregulation of ABCA1 
upon Ox-LDL loading. 
Analyzing the impact of apoE polymorphism and Tangier disease on cholesterol, sphingolipid 
and GSL metabolism, it could be demonstrated that monocytes of the apoE3/3 and apoE4/4 
genotype develop both foam cell morphology and accumulate lipids but show differences in 
the cellular lipid profile upon E-LDL and Ox-LDL loading. While analysis with mass 
spectrometry reveals no changes of the esterified and unesterified cholesterol content 
between the two genotypes, phosphatidylserine (PS) and lysophosphatidylcholine (LPC) 
content is decreased and phosphatidylcholine (PC) content is increased in apoE4/4 
compared to apoE3/3 macrophages during lipid loading. 
 
 
 
 
 
 
 
 
 
Fig. 75: The Phosphatidylcholine/ Phosphatidylserine/ Phosphatidylethanolamine Rheostat 
 
The decrease of PS content in apoE4/4 macrophages could be due to a downregulation of 
gene expression of the PS generating enzymes PS-synthases I and II in the apoE4 genotype 
and to the additional Arg-X-Arg (RXR) endoplasmatic reticulum (ER) retention domain in the 
apoE4/4 genotype leading to a prolonged retention of PS in the ER associated with impaired 
ER to Golgi trafficking and translocation to the plasma membrane. In contrast to PS the PC 
content is increased in apoE4/4 compared to apoE3/3 macrophages which could be 
explained by upregulation of PE-N-Methyltransferase gene expression in apoE4/4 
macrophages during lipid loading but not by increased PE content which shows no 
differences between the two genotypes. The decrease in LPC during Ox-LDL loading in 
apoE4/4 compared with apoE3/3 macrophages could be explained by an upregulation of 
gene expression of the LPC processing enzymes phospholipase A2, group IVC and VII and 
lysophospholipid acyltransferase in apoE3/3 but not in apoE4/4 macrophages. Another 
explanation for LPC increase could be the additional RXR domain in the apoE4/4 genotype 
leading to retention of PC in the ER and impaired LPC synthesis. The differences in lipid 
content of apoE3/3 and apoE4/4 macrophages affect the PC/PS/PE rheostat (Fig.75). The 
lower PS content in apoE4/4 macrophages could lead to decreased apoptosis while the 
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higher PC content could lead to an increase in non-apoptotic signals in apoE4/4 
macrophages. In summary the PC/PS/PE rheostat switches apoE4/4 macrophages 
compared to apoE3/3 cells to the “nonapoptotic” side during lipid loading. This may allow the 
conclusion that foam cells of the apoE4 genotype could execute proinflammatory effects for a 
prolonged time and thereby promotes lesion progression as compared to apoE3/3 
macrophages which could exert controlled apoptosis. 
SM and Cer content is decreased upon Ox-LDL loading in apoE4/4 compared to apoE3/3 
macrophages and the sphingosine content is decreased during HDL3 deloading of apoE4/4 
compared to apoE3/3 macrophages. The lower amount of SM during Ox-LDL loading of 
apoE4/4 compared with apoE3/3 macrophages could lead to a lower content of Cer, which is 
derived from either SM or degradation of glycosyl-Cer species, and could lead to decreased 
synthesis of glucosylceramide and GSLs. This could be a possible explanation for the 
reduced surface expression of Cer and GSLs upon Ox-LDL loading in apoE4/4 macrophages 
found in this thesis by flow cytometry analysis compared with apoE3/3 macrophages. 
Taqman RT-PCR analysis of sphingomyelin synthases 1 and 2, involved in SM synthesis 
and also of serine palmitoyltransferases 1 and 2, involved in Cer synthesis shows a higher 
relative mRNA expression during lipid loading of apoE4/4 compared with apoE3/3 
macrophages which could be a compensatory effect of the apoE4/4 macrophages to balance 
the lower SM and Cer content. Enhanced degradation of Cer indicated by increased mRNA 
expression of acid ceramidase during lipid loading could also be a reason for decreased 
surface expression of Cer and Cer derived GSLs. Other reasons for the decreased surface 
expression of Cer in apoE4/4 macrophages could be defects in the trafficking pathways of 
Cer and GSLs from the ER to Golgi and following translocation to the plasma membrane due 
to the additional RXR-retention domain in the apoE4/4 genotype. A compensatory effect to 
defects in this transport pathway and the resulting low amount of Cer and GSL surface 
expression could lead to increased mRNA expression of Cer generating enzymes during lipid 
loading of apoE4/4 compared to apoE3/3 macrophages. 
Decreased surface expression of Cer and GSLs during lipid loading of apoE4/4 and Tangier 
macrophages compared to apoE3/3 macrophages could indicate differential capacities of 
activation, apoptosis and survival with consequences in signal transduction. This could 
contribute as a risk factor for inflammatory response during atherogenesis in apoE4/4 and 
Tangier macrophages. Also macrophages of a patient with hyperlipidemia and coronary 
heart disease shows decreased surface expression of Cer and GSLs during E-LDL loading 
compared with apoE3/3 macrophages. This may allow the conclusion that a defect in 
lipoprotein metabolism could be associated with a lower expression of GSLs. 
ApoE containing lipoproteins are involved in the modulation of amyloid precursor protein 
(APP) transport and processing by interfering with Kunitz-domain-mediated binding of APP to 
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the extracellular domain of LRP. Therefore apoE could be regarded as an opsonin for APP 
binding to LRP receptors (192). Proteolytic cleavage of APP by the action of beta- and 
gamma secretases leads to amyloid-b (Ab) peptide which is considered as the hallmark of 
Alzheimer disease (AD) (194). Recently it has been found that SM levels are predominantly 
downregulated by Ab42, due to activation of the SM degrading enzyme neutral SMase. By 
contrast, Ab40 downregulates cholesterol de novo synthesis due to inhibition of 
hydroxymethylglutaryl-CoA reductase (HMGR) activity (408). Considering this regulatory 
principle apoE could also play a role in modulating SM and cholesterol levels via APP 
processing. 
The decrease of apoE and apoC-I mRNA expression of apoE4/4 compared with apoE3/3 
macrophages is associated with decreased secretion of apoE and apoC-I into the culture 
medium. This could be due to the described lower apoE concentrations and enhanced 
degradation of apoE because of an additional RXR retention domain in apoE4/4 monocytes 
compared to apoE3/3 monocytes (256) and is in accordance with a previous publication of 
our institute of Stöhr et al. (25). Another explanation for the decrease of apoE and apoC-I in 
the medium could be a redirection of apoE and apoC-I from the secretory to the degradation 
pathway in apoE4/4 macrophages. Impaired recycling of apoE4 could interfere with 
intracellular cholesterol transport and contribute to the pathophysiological lipoprotein profile 
observed in apoE4 homozygotes (254). Macrophage specific expression of human apoE 
reduces atherosclerosis in hypercholesterolemic apoE null mice, supporting a possible 
function of macrophage-produced apoE within atherosclerotic plaques in promoting 
cholesterol efflux. It has been shown that apoE effectively stimulates cholesterol efflux from 
macrophages (114;250;252). Compared with apoE3, apoE4 is less efficient  in promoting 
cholesterol efflux in fibroblasts and astrocytes (252;253), indicating that apoE isoforms 
differentially affect the mobilization of cellular cholesterol.  
ApoC-I intracellular expression analyzed by flow cytometry revealed a higher level in 
apoE4/4 macrophages during all states of incubation which could be considered as a 
genotype specific regulatory effect leading to an atherogenic lipid profile in the apoE4/4 
genotype due to the inhibitory effects of apoC-I on lipoprotein lipase. 
In ABCA1 deficient (Tangier) macrophages the greatest difference could be observed in the 
intracellular expression of apoE which shows a lower expression level in Tangier 
macrophages compared to apoE3/3 macrophages during all states of incubation. This could 
be associated with the lower levels of HDL in Tangier macrophages and a disturbance in 
cholesterol metabolism and cholesterol efflux leading to a higher risk factor of atherosclerosis 
or splenomegaly. Further apoC-I surface expression shows a lower expression during Ox-
LDL loading in Tangier macrophages while HDL3 deloading in Tangier macrophages leads to 
a strong increase of apoC-I surface expression compared to apoE3/3 macrophages and also 
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intracellular expression of apoC-I increases strongly during HDL3 deloading after E-LDL 
loading compared to apoE3/3 macrophages. These effects might be due to the failure of 
ABCA1 as a lipid efflux mediator in ABCA1 deficient Tangier macrophages and could result 
in an atherosclerotic lipid profile in addition to the inhibitory effects of apoC-I on lipoprotein 
lipase. The expression of CETP fails to illustrate a differential regulation between the 
apoE3/3, apoE4/4 and tangier macrophages. 
Intracellular expression of adipophilin, a sensitive marker of lipid accumulation, increases 
stronger during E-LDL loading in apoE3/3 than in apoE4/4 macrophages and decreases 
during HDL3 deloading in both genotypes. Tangier macrophages show a higher increase of 
adipophilin during E-LDL loading and a further increase of adipophilin expression during 
HDL3 deloading. Possibly, differences in lipid sensitivity, cellular lipid distribution or lipid 
droplet structure account for this observation. Further the ABCA1 defect in Tangier 
macrophages lead to a defect in lipid efflux with the consequence that probably the lipid 
marker protein adipophilin further increases during HDL3 deloading compared with the 
apoE3/3 macrophages which show a decrease of adipophilin expression during HDL3 
deloading. 
However, despite the importance of apoE4 as a risk factor of atherosclerosis and 
Alzheimer´s disease (255), the cellular mechanisms, which are responsible for the 
differences between apoE3 and apoE4, are yet unclear.   
Opsonization of lipoproteins, especially of E-LDL with b-Amyloid 42 (Ab42), a protein 
involved in the pathogenesis of Alzheimer disease (AD), lead to increased surface 
expression of Cer, LacCer, Gb3Cer and GM1 ganglioside compared to non-opsonized E-
LDL. Probably the phagocytosis-related pathways which are responsible for E-LDL uptake 
were facilitated by opsonizing agents such as Ab42  and lead to increased E-LDL uptake 
with the result of increased surface expression of Cer and GSLs. Recently it could be 
demonstrated that Ab42 leads to a downregulation of SM levels due to the activation of 
neutral SMase which degrades SM to Cer (408). Therefore the incubation with E-LDL Ab42 
complex could result in an increased amount of Cer and Cer derived GSLs indicative for 
abnormal processing of GSLs in the pathogenesis of Alzheimer´s disease. Additionally the 
complex of E-LDL and Ab42 bind more efficiently to the monocyte subpopulation MNP2 
(CD14 high; CD16 high) which have high capacity for phagocytosis. This binding affinity to 
MNP2 has also been shown for E-LDL alone (149). 
PPARg agonists as drugs important for atherosclerosis associated with the metabolic 
syndrome and especially insulin resistance are key components of lipid uptake by inducing 
the SR-B CD36 that mediates Ox-LDL uptake in macrophages. This effect may be 
compensated by increased expression of ABCA1 and apoE in macrophages (244). The 
increase of ABCA1 and apoE could further induce cholesterol efflux and attenuate 
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atherosclerosis which may allow the conclusion that PPARg agonists have protective effects 
preventing atherosclerosis by regulating apoE expression in macrophages. Analyzing 
different glitazones as agonists for PPARg by flow cytometry an induction of SR-B CD36 
surface expression and also of apoE surface and intracellular expression could be detected 
which is in accordance to the functions of PPARg. The influence of the PPARg agonist 
rosiglitazone as well as the RXR agonists beta carotene, 9-cis retinoic acid (9-cis RA) and all 
trans retinoic acid (ATRA) have been analyzed on receptors of the monocyte innate immunity 
receptor cluster. The PPARg agonist rosiglitazone increases cell surface expression of SR-B 
CD36. However the RXR/RAR agonists beta carotene, 9-cis RA and ATRA decrease SR-B 
CD36 surface expression compared to control while a RAR-mediated induction of SR-B 
CD36 transcription has been shown in THP-1 cells (418). The Fcg-receptors CD16, CD32 as 
well as CD11b/CD18 (complement receptor 3) are decreased with beta carotene, 9-cis RA 
and ATRA indicating reduced phagocytic acitivity with retinoids resulting in reduced uptake of 
atherogenic lipoproteins with reduced foam cell formation capacity and positive effects for 
atherosclerotic processes. The glycosylphosphatidylinositol-anchored receptor CD14 which 
plays a major role in the inflammatory response of monocytes to lipopolysasscharide is 
decreased during incubation with retinoic acids. Thus the generation of potentially 
proinflammatory signalling mechanisms could be elicited by retinoids in monocytes.  
In addition to the differential expression of receptors involved in lipid uptake and processing 
the upregulation of genes important for lipid uptake, namely ABCA1, ABCG1, CYP27A1 and 
LXRa by 9-cis RA and ATRA could be demonstrated by microarray and Taqman RT-PCR 
analysis (249). Previous reports have shown that ABCA1 and LXRa can be induced at the 
mRNA and protein level by incubation of murine macrophages and THP-1 cells with ATRA 
(419;420) confirming these results. Although Wagsater et al. (419) reported that the amount 
of ABCG1 mRNA was not changed by treatment with ATRA, these results clearly 
demonstrate that 9-cis RA and ATRA are potent inducers of ABCG1 transcription in primary 
human monocytes. The CYP27A1 gene, which is critically important for the mitochondrial 
conversion of cholesterol to 27-hydroxycholesterol in monocytes and macrophages, is highly 
induced by all analyzed retinoids including b-carotene. Since LXRa is also upregulated by 
retinoids this could imply that indirect oxysterol-dependent activation of these genes via 
LXRa and 27-hydroxycholesterol as newly synthesized ligand could be elicited by retinoids. 
However, recent data suggest that at least for the ABCA1 gene, direct binding of RAR/RXR 
heterodimers to the DR4 element in the promoter is the most important signaling pathway 
predominating over LXR-dependent mechanisms (420).  
A major side effect of retinoids including ATRA, which is used as therapeutic agent for the 
treatment of several forms of cancer (421) is the development of hypertriglyceridemia. In our 
results we could observe a common induction of fatty acid metabolism genes (fatty acid 
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synthase, fatty acid desaturase 2, monoglyceride lipase), apolipoprotein genes (apoC-I, 
apoC-II, ApoC-IV, and apoE) and the master regulator of fatty acid gene transcription sterol 
regulatory element binding protein 1c (SREBP1c), which is in agreement with previous 
results, demonstrating that hepatic apoC-III transcription is mediated via the RXR-specific 
agonist LG1069 (422). In this line, Costet et al. (420) have also noticed a slight increase in 
SREBP1c transcription in mouse macrophages stimulated with ATRA. Furthermore, 
upregulation of Acyl-coenzyme A: cholesterol acyltransferase 1 (ACAT1) by ATRA in THP-1 
cells may cause storage of cholesteryl esters in lipid droplets (423). These findings 
collectively have encouraged the hypothesis that retinoids and RAR/RXR-mediated gene 
induction may promote foam cell formation and inflammation and thereby favour the 
development of atherosclerosis. However, the findings that genes important for lipid efflux 
such as ABCA1, ABCG1, CYP27A1, LXRa, and apoE are very effectively upregulated by 
retinoids point out that the net effect of stimulation with these compounds may not result in 
an augmented uptake and storage of lipids in monocytes and macrophages. This is also 
supported by cellular lipid efflux. Macrophages incubated in the presence of 9-cis RA and 
ATRA showed a strong induction of both phospholipid and cholesterol efflux to apoA-I as an 
acceptor counterbalancing potential esterification and storage mechanisms. 
In conclusion, retinoids are potent inducers of genes related to human lipid metabolism and 
especially of genes involved in reverse cholesterol transport associated with increased 
macrophage lipid efflux. Based on these findings, the development of selective retinoic 
receptor agonists promoting the upregulation of antiatherogenic genes without influencing 
the levels of genes involved in triglyeride metabolism may be a useful tool for the treatment 
or prevention of atherosclerosis. 
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VI. Summary  
 
A hallmark in atherosclerosis is the generation of lipid loaded macrophage foam cells. In this 
thesis the effects of the different atherogenic lipoproteins, enzymatically modified LDL (E-
LDL) and mildly oxidized LDL (Ox-LDL) on cellular cholesterol, sphingolipid and 
glycosphingolipid (GSL) metabolism, raft microdomain generation and cell surface receptor 
expression during in vitro foam cell formation and HDL3 dependent deloading of human 
monocyte-derived macrophages (MDM) were analyzed. Total cell analysis of lipid loaded and 
deloaded MDM, using lipidomics, genomics and proteomics based on mass spectrometry, 
Affymetrix microarray analysis, Taqman RT-PCR, flow cytometry, image microscopy and 
western blot analysis, was applied to unravel key mechanisms underlying the regulation of 
cellular lipid influx, raft formation, lipid efflux and storage as well as surface expression of 
receptors involved in lipid uptake and processing. 
In the first part of this thesis apoE3/3 homozygous MDM were analyzed. Using mass 
spectrometry it could be demonstrated that E-LDL loading predominantly increased cellular 
cholesterol content, while Ox-LDL loading preferentially increased cellular ceramide (Cer) 
content. This may be due to a stronger upregulation of acid and neutral sphingomyelinase 
(SMPD1, SMPD2), neutral sphingomyelinase activation associated factor (NSMAF) as well 
as upregulation of glucosylceramidase during Ox-LDL loading compared with E-LDL loading 
and not by differences in ceramide synthesis as found by quantitative TaqMan RT-PCR. Ox-
LDL in comparison to E-LDL also led to a higher cell surface expression of Cer and the Cer 
derived GSLs lactosylceramide (LacCer, CDw17), dodecasaccharideceramide (CD65s), 
globotriaosylceramide (Gb3Cer, CD77) as well as GM1-ganglioside as determined by flow 
cytometry. ApoE with its high affinity for Cer in contrast to apoA-I was mainly bound and 
internalized by Cer enriched Ox-LDL loaded cells. Ox-LDL preferentially induced 
cholesterol/Cer rich-membrane microdomains while E-LDL loading induced 
cholesterol/sphingomyelin microdomains as confirmed in situ by confocal microscopy and by 
mass spectrometry of isolated detergent resistant membranes.  
Microarray and flow cytometry analysis of the monocyte innate immunity receptor cluster 
revealed an induction of the complement system and of Fcg-receptors with E-LDL but not 
with Ox-LDL loading. This indicates that E-LDL in contrast to Ox-LDL, which preferentially 
upregulate CD36, induces type-I and type-II phagocytosis. Further Ox-LDL induced mRNA 
and protein expression of ABCA1 to a higher extent than E-LDL. ApoE protein expression 
and expression analyzed by flow cytometry was higher during E-LDL loading while apoC-I 
expression was higher during Ox-LDL loading compared to MCSF differentiation.  
It is concluded that core-depleted E-LDL and surface oxidized Ox-LDL particles originating 
from the same LDL pool exert differential effects on cholesterol and sphingolipid metabolism 
as well as on cell surface receptor expression associated with the formation of different raft 
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microdomains and thereby may trigger different macrophage effector functions during 
atherogenesis.  
In the second part of the thesis apoE3/3 homozygous MDM were compared with MDM of the 
apoE4/4 genotype and ABCA1 deficient (Tangier) macrophages using the same incubation 
protocol with E-LDL and Ox-LDL loading and HDL3 deloading, to search for genotype specific 
differences in lipid and GSL metabolism. Mass spectrometry revealed a lower 
phosphatidylserine (PS) but higher phosphatidylcholine (PC) content in apoE4/4 
macrophages during lipid loading compared to apoE3/3 macrophages. This could be 
explained by downregulation of phosphatidylserine synthase gene expression and 
upregulation of phosphatidylethanolamine-methyltransferase gene expression respectively 
during lipid loading in apoE4/4 macrophages as found by microarray analysis. GSL surface 
expression during Ox-LDL loading was higher in apoE3/3 compared with apoE4/4 and 
ABCA1 deficient macrophages. Quantitative TaqMan-RT-PCR during Ox-LDL loading 
demonstrated no upregulation of acid SMase and a higher upregulation of acid ceramidase 
in apoE4/4 compared to apoE3/3 macrophages which could be the reason for the lower GSL 
surface expression of apoE4/4 macrophages associated with impaired lipid trafficking to the 
plasma membrane. E-LDL loaded apoE3/3 macrophages demonstrated also a higher GSL 
surface expression compared with macrophages of a patient with hyperlipidemia and 
coronary heart disease. The apolipoproteins apoE, apoC-I and CETP which are involved in 
cholesterol and lipid metabolism were also analyzed in apoE3/3, apoE4/4 and ABCA1 
deficient macrophages using the same incubation scheme with E-LDL and Ox-LDL loading 
and HDL3 deloading. mRNA expression as well as the protein amount of secreted apoE and 
apoC-I was higher in apoE3/3 than in apoE4/4 macrophages. Additionally surface and 
intracellular expression of these proteins was different between the two different genotypes 
and ABCA1 deficient macrophages. The differences between the two genotypes apoE3 and 
apoE4 could be due to a third Arg-x-Arg (RXR) endoplasmatic reticulum (ER) retention 
domain in the apoE4 genotype leading to enhanced degradation of apoE4 in the ER 
associated with impaired ER to Golgi trafficking and translocation to the plasma membrane. 
The effect of lipoprotein opsonisation with amyloidb42 a protein involved in the pathogenesis 
of Alzheimer´s disease on the surface expression of GSLs was also analyzed. It could be 
shown that opsonisation of E-LDL lead to an enhanced surface expression of Cer and GSLs 
in apoE3/3 macrophages indicative for abnormal processing of GSLs in the pathogenesis of 
Alzheimer´s disease. In summary total cell analysis using lipidomics, genomics and 
proteomics based on mass spectrometry, Affymetrix microarray analysis, Taqman RT-PCR, 
flow cytometry, image microscopy and western blot analysis is a valuable and reasonable 
tool to unravel key mechanisms underlying the regulation of cellular lipid influx, raft formation, 
lipid efflux and storage as well as surface expression of specific receptors and sphingolipids.
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